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Abstract 
Mutations in different gene loci that lead to the encoding of the unstable and expanded 
glutamine-encoding cytosine-adenine-guanine (CAG) repeats results in the group of diseases 
known as the polyglutamine diseases. The most common forms are Huntington disease (HD) 
and spinocerebellar ataxia (SCA) types 1, 2, 3 and 7. These are autosomal dominant 
neurodegenerative diseases responsible for severe movement disorders with primary atrophy 
of the striatum in HD and the cerebellum/pons in SCAs before spreading to several brain 
regions. HD and SCAs are purely genetic disorders. HD and SCAs are thought to share 
common pathophysiological pathways with a major emphasis on metabolic dysfunction. 
Metabolic dysfunction in these diseases coupled with their monogenic attribute make them 
important models to study and understand the pathophysiological processes of 
neurodegeneration especially for therapeutic interventions seeking to amend metabolic 
dysfunction. Furthermore, the availability of genetic testing and their predominantly adult 
onset opens a window for therapeutic intervention before their onset. However, current 
clinical scales – Unified Huntington Disease Rating Scale (UHDRS) for HD and the Scale for 
the Rating and Assessment of Ataxia (SARA) or the Composite Cerebellar Functional 
Severity Score (CCFS) for SCAs – have relatively low effect sizes, which implies the 
recruitment of large numbers of patients in therapeutic trials, and cannot be used to evaluate 
individuals at the presymptomatic stage. This prompts the need for biomarkers that are 
sensitive to macroscopic and microscopic changes that may occur prior to disease onset. 
Magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques present non-invasive 
approaches to extract pertinent information that otherwise would not be possible with clinical 
scales. In this work, we present a combination of different MRI and MRS techniques to 
identify robust biomarkers in HD and SCA since it is unlikely for a single biomarker to have 
the power to be used alone in clinical trials. We also present therapeutic approaches that hold 
promise in HD.  
In HD, we identified abnormal brain metabolic profile using 31P MRS coupled with visual 
stimulation. During visual stimulation, controls showed an increase in the inorganic 
phosphate/phosphocreatine ratio whilst there was no change in HD patients. This profile 
remained abnormal in the patients after one-month of follow-up. However, one-month 
anaplerotic therapy using triheptanoin improved brain metabolic profile in 10 HD patients. 
Two separate blinded randomized placebo controlled studies are ongoing to further test the 
 xix 
anaplerotic properties of triheptanoin, as well as a regulator of mitochondrial energy 
homeostasis, resveratrol, in 100 HD patients each for a year. To understand the underlying 
cause of the abnormal brain energy profile in HD, we used 31P magnetization transfer in 
another study to measure the rate of the creatine-kinase (CK) in HD patients and controls. We 
identified a reduced CK rate in HD, which could explain the abnormal brain energy profile. 
Furthermore, applying 1H MRS in HD allowed to identify other metabolites that showed 
alterations in HD. In order to better explain the abnormal profile in HD and identify robust 
biomarkers reflecting dynamic energy metabolism, a study is ongoing in a larger cohort of 
HD patients and presymptomatic carriers. This study combines multimodal MRI and MRS 
techniques including magnetization transfer, diffusion weighted spectroscopy and resting state 
functional MRI.  
Additionally, using 1H MRS in a bicentric study, we showed that the lack of reproducibility of 
MRS results could be resolved when the same sequence and analytical procedures are used. 
We applied this validated protocol in SCAs and we identified alterations in several 
metabolites including decreased neuronal markers – total N-acetylaspartate and glutamate –, 
increased glial marker – myo-inositol –, and increased energetic marker – total creatine.  
Analysis of follow-up SCA data showed similar metabolic alterations. Clinical scores 
worsened and atrophy of the cerebellum and the pons significantly increased over two years. 
However, atrophy showed very large effect sizes compared to clinical scores. A novel 
tractography method accounting for different fiber populations in each voxel, called fixel-
based analysis, showed changes in white matter fibers in all SCA groups compared to controls 
with reduced fiber density and fiber cross-section. In addition, we applied a multimodal 
biomarkers approach, aiming at the integration and visualization of multivariate datasets (i.e.  
volumetry, MRS, metabolomics and lipidomic) to best explain the pathology in SCAs.  
 
Keywords: Biomarkers, Huntington disease, spinocerebellar ataxia, magnetic resonance 
spectroscopy, magnetic resonance imaging, disease modeling, 31P MRS, 1H MRS, 
magnetization transfer, diffusion weighted spectroscopy, resting state fMRI, diffusion tensor 
imaging, fixel based analysis. 
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Résumé 
Les maladies par expansion de polyglutamines sont des maladies neurodégénératives 
d’origine génétique dues à l’expansion du trinucléotide cytosine-adénine-guanine CAG 
codant pour une expansion d’homopolymère de glutamine dans les protéines mutées. Les 
formes les plus courantes sont la maladie de Huntington (MH) et les ataxies 
spinocérébelleuses (SCA) types 1, 2, 3 et 7. Ce sont des maladies neurodégénératives 
autosomiques dominantes, responsables de troubles moteurs graves avec une atrophie initiale 
du striatum dans la MH et du cervelet/pont dans les SCAs avant de s’étendre à plusieurs 
régions du cerveau. La MH et les SCAs sont des maladies purement génétiques et partagent 
des voies physiopathologiques communes, notamment en terme de dysfonction métabolique. 
Le dysfonctionnement métabolique et le caractère monogénique de ces maladies en font des 
modèles importants à étudier dans le but de comprendre les processus physiopathologiques de 
la neurodégénérescence, notamment pour les interventions thérapeutiques visant les 
dysfonctions métaboliques. En outre, la disponibilité des tests génétiques et le fait que la 
maladie débute le plus souvent à l’âge adulte offrent la possibilité d’une intervention 
thérapeutique avant l’apparition de symptômes. Toutefois, les échelles cliniques – Unified 
Huntington Disease Rating Scale (UHDRS) dans la MH et les échelles d’évaluation de 
l’Ataxie (SARA et CCFS) dans les SCA – ont une taille d'effet relativement faible, ce qui 
implique le recrutement d'un grand nombre de patients dans les essais thérapeutiques, ne sont 
pas assez sensibles et ne peuvent être utilisées pour évaluer les personnes au stade 
présymptomatique de la maladie. D’où la nécessité de trouver des biomarqueurs sensibles aux 
changements macroscopiques et microscopiques qui peuvent survenir avant l’apparition de la 
maladie. L’imagerie par résonance magnétique (IRM) et les techniques de spectroscopie 
(SRM) sont des approches non invasives permettant de recueillir des informations pertinentes, 
impossibles à obtenir avec les échelles cliniques. Dans ce travail, nous présentons une 
combinaison de différentes techniques IRM et SRM  afin d’identifier des biomarqueurs 
robustes dans la MH et les SCA puisqu’il est peu probable qu’un biomarqueur unique puisse 
être utilisé seul dans les essais cliniques. Nous présentons également des approches 
thérapeutiques prometteuses dans la MH.  
 
Dans la MH, l’utilisation du 31P SRM couplé à la stimulation visuelle nous a permis 
d’identifier un profil métabolique anormal au niveau du cerveau. Pendant la stimulation 
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visuelle, les témoins ont montré une augmentation du ratio entre phosphate inorganique et 
phosphocréatine alors que le ratio était inchangé chez les patients MH. Ce profil est resté 
anormal dans les patients qui ont été suivis pendant un intervalle d’un mois. A l’inverse, une 
thérapie anaplérotique à base de triheptanoïne administrée pendant un mois a corrigé le profil 
métabolique cérébral chez 10 patients MH. Deux études distinctes, randomisées, contrôlées, 
en double aveugle sont en cours afin de tester les propriétés anaplérotiques de la 
triheptanoïne, ainsi qu’un régulateur de l’homéostasie énergétique mitochondriales, le du 
resvératrol, chez 100 patients MH chacune. Pour comprendre la cause sous-jacente du profil 
énergétique cérébral anormal dans la MH, nous avons utilisé une technique de transfert de 
magnétisation afin de mesurer le taux de créatine kinase chez les patients MH et les témoins. 
Nous avons identifié une plus faible activité de la CK chez les patients MH qui pourrait 
expliquer leur profil énergétique cérébral. D’autre part, l’utilisation de la technique SRM du 
proton nous a permis d'identifier d'autres altérations métabolites chez les patients MH. Afin 
d'identifier des biomarqueurs dynamiques du métabolisme énergétique cérébrale,  une étude 
est en cours chez un plus grand nombre de patients MH et d’individus présymptomatiques. 
Cette étude combine les techniques multimodales IRM et SRM, y compris le transfert de 
magnétisation, la spectroscopie pondérée en diffusion et l’IRM fonctionnelle à l'état de repos. 
 
En utilisant la technique de SRM du proton dans une étude menée dans deux sites distincts, 
nous avons montré que le manque de reproductibilité des résultats de SRM pouvait être résolu 
lorsqu’on utilisait la même séquence et les mêmes procédures analytiques. Nous avons 
appliqué ce protocole validé dans les SCAs et nous avons identifié des altérations dans 
plusieurs métabolites, y compris la diminution de marqueurs neuronaux – N-acétylaspartate 
total et du glutamate –, l’augmentation d’un marqueur glial  – myo-inositol – ainsi que 
l’augmentation d’un marqueur énergétique - créatine totale. Ces altérations métaboliques 
étaient stables sur deux ans chez les patients SCA. Les scores cliniques se sont aggravés et 
l’atrophie du cervelet et du pont s’est majorée sur deux ans. Toutefois, l'atrophie a montré des 
tailles d’effet bien plus importante que les scores cliniques. Une nouvelle méthode de 
tractographie qui tient compte des différentes populations de fibres au sein de chaque voxel, 
appelée «fixel-based analysis», a montré une altération des fibres de la substance blanche 
dans tous les groupes SCA par rapport aux témoins, avec une réduction de la densité des 
fibres et de leur section transversale. Par ailleurs, nous avons appliqué une approche 
biomarqueurs multimodale, qui vise à l'intégration et à la visualisation d'ensemble de données 
 xxii 
multivariées (volumétrie, SRM, métabolomiques et lipidomiques), afin de mieux expliquer la 
physiopathologie des SCA. 
 
Mots-clés: Biomarqueurs, maladie de Huntington, ataxie spinocérébelleuses, spectroscopie de 
résonance magnétique, imagerie par résonance magnétique, modélisation de la maladie, 31P 
SRM, 1H SRM, transfert de magnétisation, spectroscopie à diffusion ponctuelle, imagerie par 
tenseur de diffusion, fixel based analysis. 
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Introduction 
Polyglutamine diseases are a group of neurodegenerative disorders that result from mutations 
in different gene loci that contain the glutamine encoding cytosine-adenine-guanine (CAG) 
triplet repeats that leads to expansion and instability of the gene and affected proteins. There 
are different forms of polyglutamine disorders and they include Huntington disease (HD), 
several spinocerebellar ataxia (SCA), dentatorubral pallidoluysian atrophy (DRLPLA) and 
spinal bulbar muscular atrophy (SBMA).  
This work focuses on HD and SCA types 1, 2, 3 and 7 as they remain the most common 
forms of polyglutamine diseases.  They are autosomal dominant diseases that present with 
severe movement disorders in the form of chorea in HD and ataxia in SCAs. They are 
monogenic diseases with the possibility of genetic testing and hence serve as important 
models to study neurodegeneration unlike other neurodegenerative disorders such as 
Parkinson and Alzheimer. They are late onset, which opens a window for therapeutic 
intervention before symptoms develop. They also share common pathophysiological 
pathways with a major emphasis on metabolic dysfunction. The two main potential 
therapeutic interventions include targeting the polyglutamine protein to reduce their 
production or modify them, and metabolic interventions to reverse metabolic dysfunction. 
The problem of testing these therapies lies in the limitations of the clinical scales used to 
evaluate the disease progression. The major clinical scales are the Unified Huntington Rating 
Scale (UHDRS) to evaluate HD and the Scale for the Rating and Assessment of Ataxia 
(SARA) and the Composite Cerebellar Functional Severity Score (CCFS) to evaluate SCAs. 
However, in therapeutic trials of very rare disorders like SCAs, the low effect sizes of these 
clinical scales would likely require a large number of patients making these trials hardly 
feasible. Clinical scores are not able either to detect macro- and microstructural changes such 
as atrophy and metabolic alterations that may occur before, during and after symptoms onset. 
Another important caveat of clinical scales is that, by definition, they cannot be used to 
evaluate premanifest individuals. Hence, there is a need for biomarkers with effect sizes 
greater than clinical scores that can be used on small sample sizes of patients with HD or 
SCA.  
The objectives of this work are to identify robust biomarkers of HD and SCA using non-
invasive magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques and to 
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assess the anaplerotic properties of potential therapeutic agents in improving metabolic 
dysfunction in HD. These biomarkers can then be used in models to explain disease 
progression. Currently, there has been a rise in the number of modalities used to characterize 
a given disease. These modalities include, but are not limited to, clinical, imaging, molecular 
biology, physiological, and biochemical methods. Since each modality differs in the type and 
number of variables they generate, conventional statistical tools are incapable of integrating 
these multimodal data into models while preserving the unique properties of each modality. 
Therefore, we applied new statistical tools based on multiblock analyses that allowed the 
integration and visualization of these multivariate datasets. The selection of a few meaningful 
variables can also enable their combination into composites scores, which are likely to 
provide both a better reflection of the disease process pathology and larger effect sizes than 
any biomarker alone. 
The manuscript has therefore been organized into 7 parts as follows: 
Chapter 1 is a brief overview of the pathophysiology of HD and SCA types 1, 2, 3 and 7. 
This chapter also introduces different MRI and MRS techniques that can be used to study 
these disorders. Finally, this chapter presents the objectives of the thesis. 
Chapter 2 presents the application of a 31P MRS technique in biomarker identification study 
in HD and its use in a proof-of-concept anaplerotic study in HD. Likewise, I will present the 
follow-up of this anaplerotic study with the inclusion of diffusion tensor imaging (DTI) and 
boundary shift integral (BSI) approaches. 
Chapter 3 presents a study that resulted from the study in chapter 2. In this chapter, I present 
a method that aims at elucidating the biochemical basis of altered 31P profiles in HD. I also 
applied techniques allowing the analysis of an expanded neurochemical profile in HD 
patients. The next step involves the combination of metabolic, structural, and functional 
techniques in order to study the dynamics of brain energy metabolism in HD patients and 
presymptomatic individuals.  
Chapter 4 is a methodological study to test the reproducibility of a modified 1H MRS 
sequence in order to standardize acquisition and quantification protocols between study sites 
in view of multi-centric studies.  
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Chapter 5 reports the application of the methods in chapter 4 to elucidate the metabolic 
dysfunction in the brain of SCA patients. 
Chapter 6 presents the use of diffusion imaging and volumetric analysis in biomarker 
identification in SCA.  
Chapter 7 presents a statistical approach that improves multimodal data integration for 
disease modeling. 
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Polyglutamine disorders 
The pathological expansion of CAG repeats in different gene loci gives rise to the different 
neurodegenerative disease known as polyglutamine disorders. They are all autosomal 
dominant disorders with the exception of the X-linked SBMA (Orr & Zoghbi, 2007). The 
genes involved are nonetheless unrelated as each disease has a different target protein that is 
defective. Still, they share common neurodegenerative pathway (Shao & Diamond, 2007; Fan 
et al., 2014). Even though the defective proteins are widespread in the body, it is not yet 
known why there is selective cellular damage such as in the striatum of HD and the vermis 
and pons in SCAs.  
On average, the occurrence of more than 35 CAG repeats lead to the disease though the actual 
numbers vary depending on the disease (Paulson et al., 2000; Shao & Diamond, 2007). This 
expansion has an inverse correlation with the age of clinical manifestations, a phenomenon 
known as anticipation (Friedman, 2011). Therefore successive generations tend to have 
increased expansion of the CAG repeat, which in turn leads to earlier onset of the disease 
which is more severe than the previous generation. The progressive worsening of the disease 
is a common feature that continues for about 10 - 20 years.  
The exact causes of polyglutamine disorders are not clearly understood but several 
mechanisms have been implicated as strong influencers on their pathophysiology. These 
mechanisms are summarized in Figure 1. These mechanisms will be further elaborated for HD 
and SCA types 1, 2, 3 and 7 which are the focus of this project. 
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Figure 1: Pathogenesis of polyglutamine disorders. (a) The mutant protein (b) can be 
proteolytically processed (c) to form toxic fragments (d) that can form aggregates in the 
cytoplasm. (e) Breakdown down of these aggregates into toxic products can be shuttled into 
the nucleus (f) to form intermediate species (h) and nuclear aggregates (g) that can indirectly 
result in the sequestration of vital proteins. (i) The mutant protein aggregates can damage 
important cellular components such as the mitochondria (Weber et al., 2014). 
 
1.1 Huntington disease 
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder that bears its 
name from the describing physician, George Huntington (Lanska, 2000). HD is a pure genetic 
disorder with complete penetrance.  Even though there are juvenile forms, it is mostly a late-
onset disease with symptoms appearing in affected individuals between the ages of 30 and 50 
years. Anticipation is very important in HD (Figure 2) and more than 36 CAG repeats lead to 
the disease with incomplete penetrance between 36 and 39 CAG repeats (Kremer et al., 1994). 
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Evaluations of the prevalence of HD shows marked heterogeneity across different regions. 
The prevalence rate per 100,000 of the population is estimated at 0.40 (0.36-0.44) in Asia, 
2.17 (1.95-2.41) in Central and Eastern Europe, 7.33 (6.94-7.74) in North America, 5.63 
(5.61-6.25) in Oceania, 6.68 (6.40-6.97) in the United Kingdom, and 3.60 (3.50-3.69) in 
Western Europe (Rawlins et al., 2016). 
 
Figure 2: CAG-repeat length correlates with the age of symptoms onset in HD. The lines 
represent age at neurological onset (red) and duration of disease from onset to death (blue). 
Source (Finkbeiner, 2011). 
 
1.1.1 Genetics and mitochondrial dysfunction in HD 
Several decades after its initial description in 1872, advancement in molecular biology 
allowed the mapping of the disease to chromosome 4p16.3 (Gusella et al., 1983). The disease 
was then linked to the unstable CAG expansion in the IT15 gene (The Huntington's Disease 
Collaborative Research Group, 1993), also known as the huntingtin gene (HTT) which codes 
for the huntingtin protein (Htt). The discovery of HTT paved the way for extensive genetic 
studies to be performed on this disease. Htt is found throughout the body with the highest 
concentrations in the brain. Though its exact function is not completely understood, it has 
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been associated with normal function of the brain and development (Schulte & Littleton, 
2011; Elias et al., 2014; Saudou & Humbert, 2016). Wild type Htt is involved in gene 
expression as it interacts with several transcription factors including CBP, SP1, TBP, p53, 
p300, Sin3a, and REST/NRSF. It interacts directly with β-tubulin in microtubules to facilitate 
vesicle transport and cytoskeletal anchoring. Furthermore, by binding directly to mitochondria 
and also indirectly regulating transcriptional co-activators such as PGC-1α, it is implicated in 
the regulation of metabolism (Shao & Diamond, 2007; Mochel & Haller, 2011; Fan et al., 
2014).  
Mutations in the HTT result in the production of mutant Htt (mHtt) and this leads to the 
disruption in the normal function of Htt as well as its nuclear and cytoplasmic distributions. 
Most of the impact is on metabolism in HD (Figure 3). Interactions with mHtt affects gene 
transcription through the depletion of important factors such as CBP (Jiang et al., 2006) or the 
down-regulation of important co-factors such as PGC-1α (Cui et al., 2006) necessary for 
mitochondrial biogenesis. Moreover, HD pathogenesis may also be influenced by impairment 
to intracellular and vesicular shuttling of organelles and other cellular content. Conditional 
knockout mice expressing less than 50% endogenous Htt showed decreased mitochondrial 
movement along neuritis and this was even observed in asymptomatic HD mouse neurons 
(Trushina et al., 2004). The importance of mitochondria cannot be over-emphasized. Apart 
from serving as the principal energy source, they are also involved in maintaining 
homeostasis by regulating intracellular calcium (Ca2+); an important step to normal process of 
oxidative phosphorylation. An important enzyme complex that creates a critical link between 
the Krebs cycle and the respiratory chain is succinate dehydrogenase or mitochondrial 
complex II. Its activity is greatly disrupted by mHtt and leads to energy defects in HD and 
may play a critical role in the degeneration of striatal neurons in HD (Damiano et al., 2013). 
Likewise, reduced glucose metabolism has been found in the brain of HD patients even before 
symptoms onset (Grafton et al., 1992; Antonini et al., 1996). In addition, HD patients and 
presymptomatic carriers show sings of weight loss even when they are on high caloric diet 
(Djousse et al., 2002; Mochel et al., 2007). Metabolic dysfunction might not be limited to the 
brain only. Reduced branched chain amino acids (BCAA) – valine, leucine and isoleucine – 
were found in the plasma of patients at the early stage of HD despite high caloric intake 
(Mochel et al., 2007). Reduction in the BCAA might signify lack of substrates to fuel the 
Krebs cycle. Therefore impairment to the movement of mitochondria, disruption in Ca2+ 
regulation, reduction in Krebs cycle substrates and decreased mitochondrial biogenesis 
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through downregulation of transcription factors likely contribute to mitochondrial dysfunction 
in HD. This further implies inability to replenish damaged mitochondria in certain regions, 
perturbation in meeting energy demands, calcium overload, increase in reactive oxygen 
species, release of cytochrome c and apoptosis (Lee & Wei, 2000; Nicholls, 2009).  
 
Figure 3: Mechanisms that contribute to metabolic/mitochondrial dysfunction in HD. 
mHtt may lead to lack of substrates to fuel the Krebs cycle, impair Ca2+ buffering, disrupt 
vesicular transport and mitochondrial movement, and downregulate important transcription 
factors needed for mitochondrial biogenesis. Source (Mochel et al., 2007). 
 
1.1.2 Pathogenesis and symptoms of HD 
Severe atrophy of the caudate and putamen are significant neuropathological signs of HD 
(Vonsattel et al., 1985). The mHtt causes medium-sized spiny neurons in the striatum that 
contain γ-amino butyric acid (GABA) to undergo selective degeneration (Vonsattel & 
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DiFiglia, 1998). Cortical atrophy has also been reported (Hedreen et al., 1991). Progressive 
degeneration of neurons in the striatum and other regions of the brain present several 
symptoms that can be classified as motor, cognitive or psychiatric symptoms.  
Cognitive symptoms: There are discrepancies in reporting cognitive symptoms in most 
studies and may be attributed to the subtle cognitive changes at the early stage of HD which 
might be overlooked for the more prominent motor symptoms (Chaganti et al., 2017). 
Cognitive decline normally precedes long-term memory loss and it might impact executive 
functions involved in day-to-day activities such as organizing, planning, checking, or adapting 
alternatives, and delays the acquisition of new motor skills (Walker, 2007). Visuospatial 
ability and judgment are impaired as the disease progresses further and global dementia is 
observed (Lauterbach et al., 1998). 
Motor symptoms: Degeneration of the medium spiny neurons in the striatum are vital to the 
involuntary movements characteristic to HD – chorea; involuntary dance-like movement – 
and may be attributed to loss of the projection neurons (Mitchell et al., 1999), which make up 
the bulk of striatal neurons. Motor symptoms start with small involuntary movements that for 
example might resemble twitching of the eyelids and other muscles. As the disease progresses 
the subtle movements give way to more pronounce involuntary jerky movements. In addition, 
there is the inability to maintain voluntary muscle contraction at a constant level and 
incapacity to apply steady pressure during handshake. Gross motor coordination skills, 
including gait and postural maintenance, and fine motor skills, such as finger-tapping rhythm 
and rate, also deteriorate as the disease progresses. While comprehension is affected, the rate 
of speech deterioration is faster (Walker, 2007). Dystonia and myoclonus are other forms of 
movement disorders that may occur. 
Psychiatric symptoms: Principal psychiatric symptoms are related to mood disorders. Chronic 
depression, irritability, impulsiveness and aggression, are variable and sometimes precede 
motor onset by years (Gusella & MacDonald, 2006). Patients tend to show personality 
changes, schizophrenia, anxiety, impulse control and sexual disorders (Lauterbach et al., 
1998). Affected individuals contemplating suicide are higher in HD than other diseases such 
as stroke and Parkinson. Moreover, suicidal tendencies are observed as early as the 
presymptomatic stage and it increases following genetic testing (Almqvist et al., 1999). 
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Other symptoms: Aside the neuropsychological symptoms of HD, there are other non-
neurological symptoms as well. One of such is the loss of weight even when affected 
individuals are on high caloric diet (Djousse et al., 2002; Mochel et al., 2007).  
 
1.2 Spinocerebellar ataxia  
SCAs are a group of disorders with progressive and irreversible neurodegeneration that results 
in cerebellar ataxia leading to unsteady gait and movement coordination. They are clinically 
heterogeneous with many different subtypes whose numbering corresponds to the order of the 
identified gene (Manto, 2005). Some SCAs are more severe than others but generally 10-15 
years after symptoms onset, most patients are wheelchair bound (Fan et al., 2014). Extensive 
cerebellar atrophy, particularly of the Purkinje cells, is common to SCAs. Involvement of the 
brainstem, spinal cord and peripheral nerves is another common feature. Severe ataxia is a 
predominant symptom in all SCAs, variably associated with pyramidal signs, parkinsonism, 
cognitive impairment and/or peripheral neuropathy. Though they share common features, 
others are very unique to each SCA type, such as retinal degeneration in SCA7 (Paulson, 
2009).  
The polyglutamine forms of SCA (SCAs 1, 2, 3, 6, 7 and 17) are autosomal dominant and just 
like HD, they have varying CAG repeat thresholds depending on the affected gene (Manto, 
2005; Rüb et al., 2013). In addition, they are mostly late onset even though juvenile forms 
exist when the transmission is by an affected father. Furthermore, similar to HD, the age of 
onset is correlated to the number of CAG repeats (Figure 4). This work focuses on SCAs 1, 2, 
3 and 7. The prevalence of the autosomal dominant polyglutamine SCAs is about 1 - 4 per 
100,000 of the population with variable frequency of occurrence depending on the region or 
ethnic group (Durr, 2010; Fan et al., 2014). 
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Figure 4: CAG repeat length correlates with the age of symptoms onset in SCAs 
(Stevanin et al., 2000). 
 
1.2.1 Spinocerebellar ataxia type 1 (SCA1) 
The dominantly inherited neurodegenerative SCA1 is caused by CAG expansion in the 
ataxin-1 gene (ATXN1) that is located on chromosome 6p23 (Orr et al., 1993) and which 
codes for the ataxin-1 protein. CAG repeats of more than 39 in ATXN1 is reported for SCA1 
(Rüb et al., 2013).  
Wild type ataxin-1 has been linked to RNA processing and shuttling of RNA between the 
nucleus and the cytoplasm (Irwin et al., 2005). It also mediates transcriptional repression by 
interacting with transcriptional co-repressor SMRT (silencing mediator of retinoid and thyroid 
hormone receptors) (Tsai et al., 2004). Likewise, it influences transcription by interacting 
with other transcription co-repressors such as PQBP-1 and Capicua (Okazawa et al., 2002; 
Lam et al., 2006) and the transcription factor critical for cerebellar development – RORα 
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(Serra et al., 2006). Disturbing this interaction through mutation in ataxin-1 is thought to 
contribute to the pathogenesis of SCA1. A study in transgenic mouse models of SCA1 
showed that genes responsible for early Purkinje cells development were reduced in response 
to mutant ataxin-1 (Serra et al., 2006). Another study showed that mutant ataxin-1 interacts 
with PQBP-1 to further enhance the reduction of phosphorylated RNA polymerase II large 
subunit and repress transcription (Okazawa et al., 2002).  A cerebellar transcriptomic study on 
two transgenic mouse models of SCA1 – one developed ataxia with Purkinje cell death 
(ATXN1[82Q]) whilst the other developed ataxia with no death of Purkinje cells 
(ATXN1[30Q]D776) – showed that two groups of co-expressed genes were highly correlated 
with the disease. Co-expressed genes with Cic-binding sites were downregulated whilst those 
devoid of Cic-binding sites within their upstream regions were upregulated in relation to the 
disease (Ingram et al., 2016). Further analysis of the ATXN1[30Q]D776 mice revealed highly 
expressed levels of the neuropeptide gene cholecystokinin. Deletion of this gene led to 
ATXN1[30Q]D776 mice developing symptoms similar to ATXN1[30Q]D776 mice with 
Purkinje cell death. This may imply that the cholecystokinin confers some form of 
neuroprotection and may be a potential therapeutic target (Ingram et al., 2016).  Furthermore, 
other mechanisms independent of the polyglutamine tract are involved in the disease process. 
Haploinsufficiency in Pumilio1, an RNA-binding protein that binds ataxin-1 mRNA and 
regulates its stability, resulted in an increase in ataxin-1 levels and exacerbated the symptoms 
in SCA1 knock-in mice (Gennarino et al., 2015). 
Studies into the neuropathology of SCA1 have revealed neuronal intranuclear inclusion 
bodies in SCA1 (Figure 5ab). This may directly or indirectly relate to the marked atrophy of 
the brainstem and cerebellum (Figure 5c). There is also the depletion of Purkinje cells in the 
cerebellum and loss of neurons in the pontine nuclei and inferior olivary nucleus (Yamada et 
al., 2008; Rüb et al., 2013).  
Different SCA1 patients have variable phenotypes and anticipation depending on the size of 
the CAG repeats (Paulson, 2009). Pyramidal impairment and oculomotor palsy are observed 
at the early stages. At the later stages amyotrophic lateral sclerosis-like disorders and sensory 
disturbance are observed (Yamada et al., 2008; Durr, 2010). Likewise, there is variable 
expression of dysphagia, extrapyramidal motor symptoms and executive dysfunctions in 
addition to cerebellar ataxia, dysarthria and cerebellar oculomotor signs (Rüb et al., 2013). 
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Figure 5: Neuropathological observations in SCA1. Neuronal intranuclear inclusion bodies 
are found in the affected (a) inferior olive and (b) pontine nuclei. (d) The inferior olives are 
degenerated in SCA1 compared to (c) healthy controls. (f) Degeneration of the brainstem and 
cerebellum are observed in SCA1 with flattened brainstem and widened fissures in the 
cerebellum compared to (e) healthy controls (Rüb et al., 2013). 
 
1.2.2 Spinocerebellar ataxia type 2 (SCA2) 
Mutations in the chromosome 12q24.1 has been linked to SCA2 (Pulst et al., 1996). This 
locus is for the ataxin-2 gene (ATXN2) which codes the ataxin-2 protein. Normal CAG 
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repeats can range from 13 - 32 repeats whilst expanded pathogenic repeats in ATXN2 are 
often between 33 - 77 CAG repeats (Stevanin et al., 2000; Rüb et al., 2013; Fan et al., 2014). 
However, repeats of 32 - 34 normally presents reduced penetrance (Paulson, 2009).  
Ataxin-2 is ubiquitously expressed just like Htt. Its subcellular localization to the rough 
endoplasmic reticulum suggests its role in modulating endocytosis. It is also located in the 
plasma membrane and may aid in the internalization and signaling of receptor tyrosine 
kinases. Ataxin-2 in the nucleus is also implicated in fine-tuning mRNA translation and decay 
by binding to transcription factors and related proteins (Rüb et al., 2013).  In addition, ataxin-
2 is linked to cell specification, apoptosis and receptor-mediated signaling, formation of actin 
filaments, and secretion (Orr & Zoghbi, 2007). Mutant ataxin-2 reduces neuronal excitability 
by binding to intracellular calcium release channel and altering calcium signaling. It also 
renders Purkinje cells sensitive to glutamate-induced apoptosis (Liu et al., 2009).  
Neuropathological findings are similar to SCA1 with the depletion of Purkinje cells and 
atrophy of the cerebellum and brainstem (Figure 6). The basal ganglia, thalamus and cerebral 
cortex may show mild degeneration in some patients (Yamada et al., 2008; Rüb et al., 2013). 
In contrast to the other SCAs, intranuclear inclusions are not of importance in SCA2.  
Clinically, individuals with small CAG repeats tend to present postural tremor. Medium 
repeat is often associated with progressive cerebellar ataxia, decreased reflexes and slow eye 
movement. In addition to cerebellar ataxia, large repeats often present chorea and dementia. 
Furthermore, patients with very large repeats may have myoclonus, dystonia, cardiac failure, 
and retinal degeneration (Durr, 2010). 
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Figure 6: Neuropathological observations in SCA2. The inferior olives are degenerated in 
(b) SCA2 compared to (a) healthy controls and (c) the brainstem is particularly atrophied in 
SCA2 compared to healthy controls (Rüb et al., 2013). 
 
1.2.3 Spinocerebellar ataxia type 3 (SCA3) 
SCA3, also known as the Machado-Joseph Disease, is the most commonly inherited SCA 
(Paulson, 2007). Normal CAG repeats are in the range of 12 - 43 whilst expanded repeats are 
52 - 77 (Stevanin et al., 2000; Paulson, 2009; Rüb et al., 2013). The lack of overlap in the 
sizes of normal and pathogenic repeats suggests there is no range for reduced penetrance 
unlike in SCA2. The CAG expansion is found on chromosome 14q24.3-q32.2 (Kawaguchi et 
al., 1994; Paulson, 2007) which contains the ataxin-3 gene (ATXN3).   
A thorough review of ataxin-3 protein has shown that it is localized to the cytoplasm, nucleus 
and mitochondria of peripheral and neuronal tissues. In addition, its normal function has been 
linked to the ubiquitin-proteasome activity that checks short-lived and misfolded proteins and 
degrade them (Costa Mdo & Paulson, 2012). It may also possess neuroprotective properties, 
aid in cellular response to heat stress, interact with shuttle proteins, influence aging process, 
regulate transcription by binding to transcriptional factors (Costa Mdo & Paulson, 2012). The 
c 
a 
b 
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mutant protein alters the ubiquitin-proteasome activity and hence reduces the degradation of 
short-lived and misfolded proteins. This leads to the accumulation of proteins including 
aggregates of mutant ataxin-3 in affected tissues. Furthermore, the mutant protein leads has 
low neuroprotective features, impaired transcriptional regulation and shuttling of materials 
(Costa Mdo & Paulson, 2012). Impaired intracellular calcium signaling has also been linked 
to mutant ataxin-3 (Chen et al., 2008). 
Cerebellum, brainstem, basal ganglia and other brain regions have been reported to show 
atrophy in SCA3 (Figure 7) (Paulson, 2007). There is widespread neuronal loss in the 
Purkinje cell layers. The dopaminergic, cholinergic, noradrenergic and GABAergic 
neurotransmitter systems also show neuronal loss (Rüb et al., 2013). Neuronal intranuclei 
inclusions are also present in affected tissues (Paulson, 2007; Yamada et al., 2008; Rüb et al., 
2013).  SCA3 mutation carriers have perturbed glucose utilization in cerebellum, brainstem 
and cerebral cortex even before symptoms onset (Soong & Liu, 1998). 
Clinical presentations are dependent on the size of the CAG repeat with larger repeats leading 
to more severe and early onset SCA3 (Paulson, 2007). SCA3 is characterized by progressive 
cerebellar ataxia, muscle atrophy, dystonia, and spasticity. Very small repeats lead to the rare 
very late onset SCA3 that can have parkinsonian symptoms. Eye-lid retraction and infrequent 
blinking are peculiar features of SCA3. Patients can also have speech impairment and 
difficulty in swallowing (Paulson, 2007; Durr, 2010; Rüb et al., 2013). 
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Figure 7: Neuropathological observations in SCA3. Neuronal intranuclear inclusion bodies 
in the (a) substantia nigra and (b) pontine nuclei in SCA3. Degeneration of the inferior olives 
in (d) SCA3 compared to (c) healthy controls. (f) SCA3 brain shows atrophy of the brainstem 
compared to (e) healthy controls (Rüb et al., 2013). 
 
1.2.4 Spinocerebellar ataxia type 7 (SCA7) 
Among the dominantly inherited SCAs, SCA7 is uniquely differentiable as the only SCA with 
retina involvement that may lead to blindness. It is caused by expanded CAG repeats in the 
short arm of chromosome 3p12–13 where the ataxin-7 gene (ATXN7) gene is located (David 
et al., 1997). Whilst CAG repeats of more than 37 are considered pathologic, some 
a b 
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individuals can have over 300 repeats, and hence SCA7 has the most unstable CAG repeats 
(Stevanin et al., 2000; Paulson, 2009; Rüb et al., 2013). Anticipation is therefore 
exceptionally severe in SCA7, since the very large expansions can cause early onset disease 
in newborns (Paulson, 2009). 
Ataxin-7 is ubiquitously expressed and localized in the cytoplasm and nucleus of neuronal 
and non-neuronal tissues (Cancel et al., 2000). Some studies have suggested that like other 
SCAs, it plays a role in transcriptional regulation by functioning as part of transcriptional 
repressor complexes (Palhan et al., 2005; Strom et al., 2005). In addition, it is associated with 
histone deubiquitination and mRNA export from the nucleus (Rüb et al., 2013). CAG 
expansion in ataxin-7 interferes with the normal transcription complexes such as the STAGA 
transcription coactivator complex. This complex interacts with the cone-rod homeobox 
(CRX) transactivator that is responsible for the normal function of photoreceptor genes (La 
Spada et al., 2001). Mutant ataxin-7 impairs the function of glial which may in turn induce 
degeneration in Purkinje cells (Orr & Zoghbi, 2007). The N-terminal of the mutant protein 
contains a stretch of polyalanine that is elongated in birth defects and oculopharyngeal 
muscular dystrophy (Rüb et al., 2013) and hence may play a role in the retinal degeneration 
observed in SCA7. A study on a SCA7 transgenic mouse model created by inserting 92 
polyglutamine cDNA flanked by loxP at the start site of translation in the murine PrP gene in 
a bacterial artificial chromosome (BAC), led to cerebellar degeneration and loss of 
Bergamann glia (Furrer et al., 2011). Removal of the 92 polyglutamine ataxin-7 by crossing 
the transgenic mice with driver lines expressing Cre-recombinase in the Purkinje cells and 
inferior olive protected against cerebellar atrophy and Bergamann glia pathology. Meanwhile, 
when the transgenic mice were crossed with driver lines expressing Cre-recombinase in the 
Bergamann glia, the pathological features were not prevented (Furrer et al., 2011) and thus 
signify the importance of glia in SCA7 pathology. To understand the mechanism by which 
mutant ataxin-7 influences retinal degeneration and neurological dysfunction, transgenic mice 
(SCA7-D266N) with second-site mutation to prevent caspase-7 proteolysis were generated 
(Guyenet et al., 2015). It was reported that by inhibiting caspase-7 cleavage of the mutant 
ataxin-7, toxicity and aggregation of ataxin-7 were diminished and the mice lived twice as 
long with reduced retinal degeneration and neurological dysfunction compared to SCA7 mice 
(Guyenet et al., 2015). Hence proteolytic cleavage is critical to SCA7 pathology.   
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Retinal degeneration is unique to SCA7 with characteristic photoreceptors degeneration and 
damage to the retinal pigment epithelium (Durr, 2010; Rüb et al., 2013). Histopathological 
examinations have revealed atrophy of the optic pathways, loss of bipolar cells and ganglion 
cells, degeneration in the cerebellum, brainstem and pyramidal pathway (Yamada et al., 
2008). Like the other SCAs, degeneration of the inferior olive is another common occurrence 
in the SCA7 (Figure 8). 
 
Figure 8: Neuropathological observations in SCA7. Intranuclei inclusion bodies are found 
in the (a) facial nuclei and (b) hypoglossal nuclei. (d) The inferior olives are degenerated in 
SCA7 compared to (c) healthy controls. (f) SCA7 pons are atrophied with loss of traversing 
pontocerebellar fibers and reduced medial cerebellar peduncle (Rüb et al., 2013). 
a b 
c d 
f e 
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Affected individuals tend to have decreased visual (83%) and auditory (24%) acuity (Durr, 
2010). Affected individuals also present progressive cerebellar ataxia, dysarthria, dysphagia, 
slow saccades, somatosensory deficits and neuropsychological deficits (Yamada et al., 2008; 
Durr, 2010; Rüb et al., 2013). Patients with very large CAG repeats are also prone to cardiac 
failure (Durr, 2010). 
 
1.3 Diagnosis and treatment of polyglutamine diseases 
Diagnosis becomes easy when there is a family history of the disease. Persons at risk of HD 
and SCA might opt to perform genetic testing in order to make critical life decisions such as 
marriage, career and procreation. At risk individuals with no known family history of the 
disease might be caught off guard when the symptoms start appearing later on in life and 
when they have already started a family. The chance for children to inherit the disease with 
increased early onset is increased by 50% when the disease is inherited from the father 
(Myers, 2004).  Other individuals might opt out of genetic testing due to the lack of treatment 
for the disease and the emotional burden that accompanies positive results. Anxiety, stress 
and suicidal tendencies are common with positive test results (Walker, 2007). Extensive 
genetic counseling could however help at risk individuals overcome the burden with the test. 
Genetic testing in at risk individuals may open a therapeutic window for potential therapies 
that could treat the disease (Figure 9).  
 
Figure 9: Genetic testing may offer an opportunity to take advantage of the therapeutic 
window before symptoms onset. Modified from (Lo, 2010). 
Time after disease initiation
Optimal treatment 
window
Clinical symptoms
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Currently, supportive management and symptomatic treatments are given to individuals with 
HD or SCA. There are treatments for some of symptoms manifested by the disease but there 
is still the lack of effective treatment for the disease itself. Physiotherapy must be advocated 
(Ilg et al., 2014; Synofzik & Ilg, 2014), and speech therapy to patients with dysarthria. Anti-
choreic and mostly neuroleptic drugs have also been used to treat involuntary movements as 
well as anxiety and irritability (Walker, 2007; Videnovic, 2013). Such symptomatic treatment 
and supportive management are helpful and shall be initiated soon when symptoms develop. 
In the search for disease modifying therapies, most of the studies have been focused on HD. 
This may be because HD is more common, but since it shares common pathophysiology with 
SCAs, drugs that are found to be beneficial in HD can become potential candidates for SCAs. 
Several treatments for HD have been explored but some showed no benefit at all, while in 
others the risks outweighed the benefits (Lauterbach et al., 1998; Walker, 2007). These 
standard clinical trials however take several years to perform and many patients are needed in 
order to see sufficient therapeutic effect (Tabrizi et al., 2012). Since these diseases are rare, 
enrolling large numbers of patients may not be feasible.  
Potential treatments for polyglutamine disorders may either fall under targeting the 
polyglutamine protein such as gene therapy to reduce to reduce or modify the mutated protein 
(Labbadia et al., 2012; Olson et al., 2012) or reversing cellular defects such as compensation 
of key downstream cellular alterations through anaplerotic therapy (Mochel et al., 2010). In 
order to be able to test potential therapies that seek to amend metabolic dysfunction, methods 
with high effect sizes are needed to identify robust biomarkers of metabolism. As such, 
MRI/MRS techniques are the go to methods for exploring HD and SCA biomarkers.  
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Magnetic resonance (MR) approaches to biomarker identification 
1.4.1 Principles of MR 
Several macroscopic and microscopic changes occur prior to and after symptoms onset. These 
changes are easily assessable with MR modalities. MR uses non-ionizing radiation to generate 
three-dimensional (3D) high-resolution images with high spatial and temporal resolution 
unlike position emission tomography or ultrasound. In addition, structural, physiological and 
metabolic information can be measured using MR techniques (Sosnovik & Weissleder, 2007). 
Due to its effectiveness and ease of use, the past decades have seen an exponential rise in its 
development (Edelman, 2014). 
The human body is made up of different atoms, the most abundant of which is hydrogen 
atoms (protons, 1H) due to the body being composed of almost 75% water (H2O). These 
protons are in constant motion as they spin around their axis generating an electromagnetic 
field and therefore they act as magnets that possess North and South poles (dipole). Naturally, 
these spins are randomly oriented and hence they cancel each other out and not net 
magnetization is observed. However, due to their spin and charge, they will align and rotate or 
precess at a given frequency (resonance or Larmor frequency) along the magnetic field of a 
large external magnet (B0) (Hunt & Thomas, 2008; Plewes & Kucharczyk, 2012; Vijayalaxmi 
et al., 2015). While all magnetic substances align in one direction in the presence of an 
external magnetic field, protons may either align parallel to the B0 (spin-up) or opposite to the 
B0 (spin-down) (Edelman & Warach, 1993), which represent the lower energy state and 
higher energy state respectively. At this point the net magnetization is very low and not 
readily observed. However, when a radiofrequency (RF) energy generated from additional 
oscillating magnetic field (B1) is applied perpendicular to the B0, the spin-up protons absorb 
the energy and move into the higher energy state (Bloch, 1946). This energy is released when 
the spins return to their original state and this induces current in a receiver coil or antenna 
placed near the measured region. The current induced is the magnetic resonance signal. 
During the absorption of the RF energy, the net precession is pushed away from the B0 
(Figure 10) depending on the amplitude and duration of the RF pulse (B1) and the angle 
between the precessing spins and the B0 field is known as flip angle. With time the net 
magnetization (M0) along the B0 begins to recover or relax as the absorbed energy is being 
released. M0 increases gradually until a steady state is reached and this recovery process is 
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known as relaxation. The time taken to recover 63% of its equilibrium value is known as the 
longitudinal relaxation time (T1) (Plewes & Kucharczyk, 2012). Another important relaxation 
time that is influenced by the interaction between the spins is the T2 relaxation time. The 
applied RF rotates the M0 into the transverse plane (XY plane). The magnetization that is 
observed in the transverse plane (Mxy) reflects how much M0 has been pushed and the degree 
at which the spins are in phase (Hunt & Thomas, 2008). The precession of the spins in the XY 
plane induces local currents in receiver coils. A strong signal is generated when the spins are 
in phase and also when a large flip angle is used, preferably at 90o. When the RF is turned off, 
the interaction of the spins with each other causes them to spin out of phase which leads to a 
decline in Mxy (Figure 10). The process of dephasing or fading of the transverse signal is 
known as free induction decay and the time it takes for Mxy to completely dephase is called 
the transverse relaxation time (T2). Relaxation times are specific to each tissue type thus 
producing contrast between different tissue types.  
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Figure 10: Dipole moment and free induction decay. (a) The spins are randomly oriented 
and hence generate no net magnetization. (b) They align and rotate at a unique frequency 
along an external magnetic field to generate a net magnetization (M0). (c) A RF pulse of same 
frequency flips the M0 in the transverse plane and the portion of the M0 in this plane is the 
Mxy. (d) When the RF is stopped, the spin-spin interaction causes them to precess out of phase 
leading to (e) a decrease in the Mxy whilst the magnetization along the B0 (Mz) is recovered. 
(f) Mxy decreases faster than the recovery of Mz (Hunt & Thomas, 2008). (g) Real (Sx) and 
imaginary (Sy) parts of FID that correspond to x and y components of the rotating 
magnetization vector M0 (Jiru, 2008). 
g 
0 
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1.4.2 Evaluating atrophy and axonal damage  
Brain volumetry 
Advances in MR hardware has enabled the rapid acquisition of data with great resolution and 
high signal to noise ratio (SNR). Images are formed by spatial localization of signal 
intensities. T1 and T2 relaxation times influence the type of image that can be acquired (Figure 
11). For atrophy characterization, it is imperative to have enough contrast between different 
tissues types that allow separation of white matter (WM), gray matter (GM) and cerebrospinal 
fluid (CSF) in order to determine their respective volumes in regions of interest (ROI). T1-
weighted images are thus preferred as they provide such contrast.  
 
Figure 11: Relaxation times introduce endogenous contrast between tissue types. Long 
T1 and T2 generate a T1-weighted image with darker CSF (b) and a short T1 and T2 generates a 
T2-weighted image with brighter CSF (c). A combination of varying T1 and T2 generates 
proton density image (Plewes & Kucharczyk, 2012). 
T1 recovery     T2 decay 
b 
a 
c d 
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Segmentation can be achieved either by manually delineating ROIs or using automatic 
segmentation tools such as SPM (Ashburner & Friston, 2005), Freesurfer (Fischl et al., 2002) 
or FSL (Smith et al., 2002). Each of these has their strengths and weaknesses (Heinen et al., 
2016). Importantly, they reduce segmentation time significantly and are the method of choice 
when large sets of data are to be analyzed. Preferably, the volumes of the ROIs should be 
normalized to the total intracranial volume to remove the bias introduced by different skull 
sizes.  
Another promising approach is the boundary shift integral (BSI) which can be used to 
determine whole brain atrophy and atrophy of specific regions such as the caudate 
(Freeborough & Fox, 1997; Hobbs et al., 2009). The added advantage of BSI is that instead of 
looking at the whole volume of ROIs, it measures the change in the boundary between the 
tissue and CSF and determines how much it has changed over time. The boundary change 
might be very minimal and hence whole volume analysis might not be sensitive to the change 
whereas BSI can easily identify these changes. Therefore, BSI is more sensitive to atrophy 
than whole volume analysis. It uses probabilistic segmentations to estimate the change 
between serial MRI scans at different time points. The process is semi-automatic and hence 
manual corrections can be performed to improve the estimation process. It has been applied in 
in large cohorts of early stage HD patients and presymptomatic individuals and showed a 
marked atrophy of the striatum that is present at the presymptomatic stage and worsens as the 
disease progresses (Figure 12) (Tabrizi et al., 2011). The limitation is that the software is not 
generally available.   
 
Figure 12: Brain boundary shift integral application in HD. The image shows regions of 
atrophy (red) in presymptomatic individuals (PreHD) and early stage HD patients. Source 
(Tabrizi et al., 2011). 
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Diffusion-weighted imaging 
Diffusion imaging provides an avenue to probe white matter integrity without the need for 
invasive biopsy and histological analysis.  
Diffusion is the random movement of molecules in thermal equilibrium. In diffusion imaging, 
the principal focus is on the movement of water in tissues. Diffusion in the brain is affected 
by the tissue properties. In the CSF for example, diffusion is not restricted and hence can be 
equal in all directions and this is known as isotropic diffusion. In axons however, especially in 
the WM, the myelin restricts movement perpendicular to the axons and favors parallel 
diffusion, a phenomenon termed anisotropic diffusion. The anisotropy helps to understand the 
tissue structure and alterations in relation to pathology. Previously, in order to measure the 
anisotropy, knowledge of the axonal orientation was needed and thus was limited to fixed 
samples (O'Donnell & Westin, 2011). Applications to complex structures such as the brain 
fibers were made possible through the introduction of the diffusion tensor (DTI) model 
(Basser et al., 1994a, 1994b; Pierpaoli & Basser, 1996).  
In order to measure diffusion in the brain, a first gradient pulses is used to change the phase of 
the water molecules whilst a second gradient pulse is applied after a short period of time to 
refocus the phase. Therefore, in the absence of diffusion, no signal is lost and the image 
appears brighter, whilst in the presence of diffusion, the refocusing pulse is not able to rewind 
the phase-shift from the first gradient and hence leads to signal loss and the image appears 
darker (Mori & Zhang, 2006). Unlike volumetric images, it is impossible to extract diffusion 
orientation from a single intensity value (Mori & Zhang, 2006). Hence, a minimum of 6 
diffusion images with one non-diffusion encoded image is needed to estimate the DTI model. 
A 3 x 3 matrix is used to represent the diffusion model of the anisotropy. Decomposition of 
this matrix generates the three eigenvalues (λ1, λ2, λ3) with their corresponding eigenvectors. 
The principal eigenvalue (λ1) corresponds to the principal diffusion along the axons (axial 
diffusivity) whilst the average of the remaining eigenvalues represents diffusion perpendicular 
to the axons and known as radial diffusivity. The anisotropy of the axons is represented in a 
metric called the fractional anisotropy (FA) that is scaled from 0 (isotropic) to 1 (anisotropic) 
(Pierpaoli & Basser, 1996). 
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Interpretation of diffusion metrics remains complicated. Generally, however, reduced FA is 
thought to reflect loss of white matter integrity with a possible damage to the myelin or a 
disruption in the organization of the fibers (Samartzis et al., 2014). Increased RD has also 
been linked to alterations in the axonal diameter (Concha et al., 2010), which may in turn 
reflect demyelination. Despite its use in several pathologies (Alexander et al., 2007), DTI has 
many limitations that could complicate the interpretation of results. First of all, DTI metrics 
are sensitive to noise from the hardware and patient movements so that the noise might 
contribute to poorly estimated eigenvalues. Furthermore, DTI metrics are not capable of 
resolving fiber populations in regions with crossing-fibers (Wiegell et al., 2000; Tuch et al., 
2002) and hence changes in the metrics cannot be attributed to specific structural changes. To 
resolve this, high order diffusion models for fiber tracking or tractography have been 
proposed (Tuch et al., 2002). Tractography technique with the non-negativity constrained 
spherical deconvolution (CSD) approach that has low fiber orientation error rate and high 
fiber detection rates is the most suitable for fiber tracking (Tournier et al., 2007; Wilkins et 
al., 2015). It allows the estimation of different fiber populations within a given voxel and 
attributes changes to specific structural changes.   
 
1.4.3 Determination of brain metabolic alterations with MRS 
Metabolic dysfunction and weight loss is a commonly shared pathophysiological mechanism 
in HD and SCAs (Weber et al., 2014). Estimating the degree to which neurochemical are 
perturbed due to a pathology provides an important source of information on metabolic 
biomarkers.  A detailed review of the physics behind MRS can be found in (de Graaf, 2007). 
Some few additional steps separate MRS from MRI. As a reminder, the signal that is induced 
in the coil is spatially localized to generate MRI images. However, in MRS, this signal is 
mathematically transformed using Fourier Transform (FT) to separate the frequency 
components and determine the intensity or proportion of each metabolite. Metabolites are 
easily separated from each other due to a condition referred to as chemical shift. The 
interactions of the spins create small variations in the B0 and therefore protons in different 
molecules resonate at slightly different frequencies from their Larmor frequency. The 
variations are expressed in parts per million and are dependent on the position of the atom in 
the molecule and the neighboring spins.  
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MRS is often performed in a demarcated region of interest known as a spectroscopic volume 
of interest (VOI). The static magnetic field (B0) does not have a truly homogenous magnetic 
field along all points. Hence, one of the most important steps in MRS is to map the B0 field 
variations and correct them with gradient coils in the VOI. The process of producing 
homogenous magnetic fields in the VOI is known as a shimming. FASTMAP shimming is an 
automatic method of shimming with minimal time constraints that generates highly resolved 
spectral linewidth with excellent shim values (Gruetter & Tkac, 2000). Another important 
step is the calibration of the RF pulse to determine the exact amplitude needed to excite the 
nucleus and generate spectra with good SNR. 
MRS can be performed on any nucleus with a magnetic moment (Table 1)(de Graaf, 2007). 
The most abundant with high sensitivity is 1H. In vivo studies have focused on 1H, 31P 
(phosphorus) and 13C (carbon) nuclei.  
 
Table 1: Properties of nuclei that can be used in MRS (de Graaf, 2007). 
 
He: helium; Li: lithium, N: Nitrogen, O: oxygen, F: fluorine, Na: sodium, K: potassium, Xe: 
xenon. 
1H MRS detects a wide range of metabolites including N-acetylaspartate (NAA), glutamate 
(Glu), choline (Cho) and creatine (Cr). Water is very abundant in the body and hence its 
signal overshadows those of other metabolites whose concentrations are about 24 times 
smaller than water. Active water suppression is therefore needed in order to observe the 
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spectra from metabolites. This can be coupled with outer volume suppression pulses (OVS) in 
order to attenuate the signal from outside the VOI and suppress signal from lipids. In addition, 
the VOI can be placed away from the scalp and fat-enriched bone marrow to limit the 
contribution of lipids and improve the shimming. In the acquisition of the spectra, one 
important factor to consider is the echo time (TE). TE is the time between the initial 90
o 
excitation of the nuclei with the RF and the sampling of the signal induced in the coil. Short 
TE is optimum for 
1H MRS as it allows metabolites with short and long T2 to be measured. In 
contrast, long TE experiments allow the detection of the major metabolites that have long T2 
including NAA, Cho and Cr.  
Asides measuring static concentrations, diffusion weighted spectroscopy (DWS) can be 
performed by coupling diffusion sensitizing gradients to MRS to allow the extraction of cell 
specific information. Practically, MRI measures such as DTI and functional imaging are 
indirect indicators of biological events in the brain. Direct physiological monitoring of cell-
specific activities is achieved when the diffusion properties of metabolites are determined. 
Compartment specific information directly relates to the cell types, glial or neuronal, that are 
implicated in neurodegenerative disorders (Ronen & Valette, 2015). 
31P MRS is used to measure the metabolites that are directly related to brain bioenergetics. It 
is used to determine the concentration of phosphorus-containing metabolites such as ATP, Pi 
and PCr. Due to the relatively high abundance of 31P good quality spectra can be acquired 
over a short period of time. Furthermore, by utilizing their endogenous magnetization 
properties, reaction rates or fluxes of metabolic processes can be evaluated such as the rate of 
creatine-kinase (CK) that modulates the exchange of high-energy phosphate group between 
PCr and ATP in the following equilibrium reaction (Figure 13) (de Graaf, 2007). This process 
is called magnetization transfer (MT). The most common form of MT utilizes RF with 
specific bandwidth to selectively saturate resonances such as that of γ-ATP. The exchange 
between γ-ATP and PCr will cause an indirect reduction of the PCr peak and the degree of 
attenuation will determine the rate of CK. In order to prevent RF bleed over, which is the 
direct effect of the saturation pulse on the PCr signal, a symmetric saturation is performed on 
the opposite side of PCr and this is used to correct for RF bleed over. Understanding the rate 
of CK can shed light on the mechanisms underlying altered static measures of energetic 
metabolites such as Cr and PCr. 
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Figure 13: Equation of equilibrium reaction of the exchange of high-energy phosphate 
group between ATP and PCr (de Graaf, 2007).  
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Objectives 
The objective of this project was to combine several neuroimaging modalities to identify 
biomarkers in HD and SCAs. Specifically, this project aimed at: 
- Using 31P MRS to validate Pi/PCr ratio as functional biomarker of brain energy 
metabolism in HD. 
- Evaluating the efficacy of an anaplerotic therapy in HD using Pi/PCr ratio as a 
functional biomarker. 
- Evaluating the underlying cause of altered energy metabolism in HD by evaluating the 
rate of the CK. 
- Identifying additional dynamic biomarkers of metabolism in HD. 
- Standardizing the acquisition and quantification process for 1H MRS in SCAs. 
- Determining the metabolic and structural changes associated with SCAs. 
- Integrating the multimodal data of SCAs into a model to explain the pathology. 
The thesis is thus organized based on the methodologies that answer the specific aims of the 
project. 
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Study 1: Validation of a functional biomarker and its use to evaluate an 
anaplerotic therapy in HD.  
2.1 Introduction and objectives  
Metabolic dysfunction is an important contributor to the pathophysiology of HD. A previous 
study in HD patients showed that 31P MRS was able to detect bioenergetic alterations in the 
muscle of HD patients during exercise (Mochel et al., 2010). The study also reported that 
patients who had muscle acidosis and reduced Cr recovery saw a normalization in their pH 
and Cr recovery time after one week of anaplerotic therapy with triheptanoin. In order to 
perform therapeutic interventions seeking to amend metabolic dysfunction especially in the 
brain, there was the need to identify biomarkers of brain energy metabolism. A 31P MRS 
study in 15 HD patients and 15 age- and sex-matched controls reported alterations in the 
Pi/PCr ratio in patients during visual stimulation (Mochel et al., 2012) and suggested to use 
such ratio as a functional biomarker of brain energy metabolism.   
Therefore, this study (ClinicalTrials.gov Identifier: NCT01696708) sponsored by the Institut 
national de la santé et de la recherche médicale (Inserm) was designed to i) reproduce and 
validate the use of Pi/PCr ratio as a functional biomarker of brain energy metabolism; ii) and 
evaluate the therapeutic effect of triheptanoin in the brain of HD patients. 
 
2.2 Materials and methods 
31P MRS coupled with visual stimulation was performed on a 3-Tesla (3T) Siemens 
Magnetom Trio (Siemens Medical Solutions, Erlangen, Germany) scanner in the visual cortex 
of 13 healthy controls and 9 patients at the early stage of HD. UHDRS was used for 
neurological assessment of patients. Using the pulse acquire sequence, FIDs were collected 
with a transmit/receive surface coil (RAPID Biomedical GmbH, Rimpar, Germany) for 4 
minutes whilst subjects closed their eyes (rest), 8 minutes during visual stimulation 
(activation), and 8 minutes after visual stimulation (recovery) with subject’s eyes closed. 
Patients were rescanned after a month to determine if their metabolic profile changed with 
time. The data were analyzed with the java-based graphical user interface for the magnetic 
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resonance user interface (jMRUI) with the AMARES quantification method. The Pi/PCr 
ratios of controls were then compared to the patients. 
Five of the patients used for the validation phase were recruited with 5 new patients to 
evaluate the anaplerotic properties of triheptanoin, a carbon-7 (C7) fatty acid, on the brain 
metabolic profile of HD patients. The patients had 31P MRS performed on them before and 
after one month of treatment. 
 
2.3 Principal results 
We obtained good quality data from the visual cortex and the quantification method was 
efficient to detect all the metabolites (Figure 14). We observed similar findings as reported 
previously (Mochel et al., 2012) with a significant increase in Pi/PCr ratio in controls during 
visual stimulation. In contrast, patients showed no change in the Pi/PCr ratio during visual 
stimulation and this profile remained stable over one month period. This can be attributed to 
the underlying metabolic dysfunction in HD. Patients who were recruited to evaluate the 
efficacy of triheptanoin also showed no increase in the Pi/PCr ratio before treatment. After 
one month of treatment however, their profile was improved with an increase in Pi/PCr ratio 
during visual stimulation. 
In another unrelated paper (Annex A, ClinicalTrials.gov Identifier: NCT02014883), we 
showed that this functional 31P biomarker can be used in other disorders related to primary 
metabolic dysfunction. The glucose transporter 1 (GLUT1) is an integral membrane protein 
responsible for the transport of glucose across plasma membrane (Olson & Pessin, 1996). 
Glucose is an important energy source for ATP synthesis through glycolysis. The higher 
energy demand of the brain means that a continuous delivery of glucose from the blood is 
essential for normal brain function. Mutations in GLUT1 in brain capillaries cause the 
impairment of glucose transport across the blood-brain-barrier and lead to cerebral energy 
deficiency in the rare autosomal dominant GLUT1 deficiency syndrome (GLUT1-DS) (De 
Vivo et al., 1991). GLUT1-DS is characterized by seizures, permanent and paroxysmal 
movement disorders, and delayed development (Gras et al., 2014). Ketogenic diets used to 
treat this syndrome require very high fat contents that make them hard to tolerate for patients 
on the long term. Ketogenic diets are made up of even-chain fatty acids that are precursors of 
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acetyl-CoA only, whilst odd-chain fatty acids like triheptanoin are precursors of both acetyl-
CoA and propionyl-CoA, a key substrate for the Krebs cycle (Roe et al., 2002; Mochel, 
2017). 
In this study (Annex A), we showed that triheptanoin was able to replenish the substrates 
needed to fuel the Krebs cycle, which led to a dramatic improvement (90%) of patient’s 
movement disorders (Mochel et al., 2016). We also showed that 31P MRS was able to capture 
the brain energy profile of GLUT1 deficient patients at baseline. Importantly, the 31P MRS 
profile normalized with triheptanoin along with clinical improvement. Therefore, this study 
showed that our 31P MRS protocol can be a good clinical predictor of brain energy 
homeostasis.  
 
 
Figure 14: Representative spectra and the coil and region of interest for the 
31
P 
experiment. The surface coil was adjusted to the center of the visual cortex with the aid of a 
water-filled tube (white sphere on the image of the head) beneath the coil. Good quality 
spectra were obtained and the AMARES quantification method allowed the detection of the 
metabolites with no residue after the model fitting. PME: phosphomonoester, PDE: 
phosphodiester, NADH:  nicotinamide adenine dinucleotide. 
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Triheptanoin improves brain energy
metabolism in patients with Huntington
disease
ABSTRACT
Objective: Based on our previous work in Huntington disease (HD) showing improved energy
metabolism in muscle by providing substrates to the Krebs cycle, we wished to obtain a proof-
of-concept of the therapeutic benefit of triheptanoin using a functional biomarker of brain energy
metabolism validated in HD.
Methods: We performed an open-label study using 31P brain magnetic resonance spectroscopy
(MRS) to measure the levels of phosphocreatine (PCr) and inorganic phosphate (Pi) before (rest),
during (activation), and after (recovery) a visual stimulus. We performed 31P brain MRS in 10
patients at an early stage of HD and 13 controls. Patients with HD were then treated for 1 month
with triheptanoin after which they returned for follow-up including 31P brain MRS scan.
Results: At baseline, we confirmed an increase in Pi/PCr ratio during brain activation in controls—
reflecting increased adenosine triphosphate synthesis—followed by a return to baseline levels
during recovery (p5 0.013). In patients with HD, we validated the existence of an abnormal brain
energy profile as previously reported. After 1 month, this profile remained abnormal in patients
with HD who did not receive treatment. Conversely, the MRS profile was improved in patients
with HD treated with triheptanoin for 1 month with the restoration of an increased Pi/PCr ratio
during visual stimulation (p 5 0.005).
Conclusion: This study suggests that triheptanoin is able to correct the bioenergetic profile in the
brain of patients with HD at an early stage of the disease.
Classification of evidence: This study provides Class III evidence that, for patients with HD, treat-
ment with triheptanoin for 1 month restores an increased MRS Pi/PCr ratio during visual
stimulation. Neurology® 2015;84:490–495
GLOSSARY
ANOVA 5 analysis of variance; ATP 5 adenosine triphosphate; BCAA 5 branched-chain amino acid; CoA 5 coenzyme A;
fMRS 5 functional magnetic resonance spectroscopy; HD 5 Huntington disease;MRS5magnetic resonance spectroscopy;
PCr 5 phosphocreatine; Pi 5 inorganic phosphate; UHDRS 5 Unified Huntington’s Disease Rating Scale.
Huntington disease (HD) is characterized by autosomal dominant inheritance and motor,
behavioral, and psychiatric symptoms.1 There is strong evidence for hypometabolism in the
brain of patients with HD. For example, glucose consumption is reduced, especially in the basal
ganglia, even in presymptomatic mutation carriers.2–4 Studies in animal models have revealed
decreased adenosine triphosphate (ATP) concentrations in the brain of HD mouse models.5
There are also nonneurologic symptoms at the early stage of the disease, such as weight loss
despite enhanced caloric intake, which suggest a hypercatabolism in HD.6 Reduced concen-
trations of branched-chain amino acids (BCAAs)—valine, leucine, and isoleucine—have been
found in plasma samples of patients with HD as early as in presymptomatic carriers even when
they were on a high-caloric diet.6 We hypothesized that decreased circulating levels of BCAAs
reflect their mitochondrial oxidation in order to provide 2 key intermediates for the Krebs cycle:
acetyl coenzyme A (acetyl-CoA) and succinyl-CoA.6 Consequently, therapies aiming at
From Inserm U 1127 (I.M.A., D.R., R.V., A.D., F.M.), CNRS UMR 7225, Sorbonne Universités, UPMC University Paris 06, UMR S 1127,
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NeuroImaging Research (R.V.), Institut du Cerveau et de la Moelle épinière, Paris, France.
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providing substrates to the Krebs cycle may be
of special interest in HD.We previously showed
that dietary anaplerotic therapy—replenishing
the pool of metabolic intermediates in the
Krebs cycle—was able to improve peripheral
energy metabolism in HD using 31P magnetic
resonance spectroscopy (MRS) in muscle.7
Recently, we have identified the inorganic phos-
phate (Pi)/phosphocreatine (PCr) ratio as an
outcome measure of brain metabolic dysfunc-
tion in patients with HD.8 We therefore aimed
at obtaining a proof-of-concept of the effect of
anaplerotic therapies on brain energy metabo-
lism in HD using our 31P functional MRS
(fMRS) biomarker.
METHODS MRS data were acquired on a 3T whole-body
Siemens Magnetom Trio (Siemens Medical Solutions, Erlangen,
Germany). Motor dysfunction was evaluated with the total
motor score of the Unified Huntington’s Disease Rating Scale
(UHDRS) with a maximal-worth score of 124. Eligibility
criteria included patients 18 years and older with UHDRS score
between 5 and 50, and who had the ability to undergo magnetic
resonance scanning. The research was performed at the Pitié-
Salpêtrière University Hospital.
The study was designed to answer 2 primary research ques-
tions: (1) Can the initial findings of abnormal Pi/PCr ratio be re-
produced in the same patient population and how stable is the
profile over a 1-month interval? and (2) Is triheptanoin able to
correct the abnormal bioenergetic profile in the brain of patients
with HD at an early stage of the disease?
This study therefore falls under Class III evidence because of
the absence of a concurrent control group.
Standard protocol approvals, registrations, and patient
consents. Participants were enrolled in an observational
(NCT01696708) and an interventional (NCT01882062) clini-
cal protocol promoted by INSERM and approved by the local
ethical committee. All participants were older than 18 years and
signed a written informed consent before participating in the
studies.
Recruitment of participants. Observational phase: Validation
of functional biomarker. Thirteen healthy individuals (mean age
456 15 years) and 9 patients with HD (mean age 416 12 years)
at an early stage of the disease with a mean UHDRS motor score of
10 6 3 (table 1) were recruited within 3 months to validate the
functional biomarker: Pi/PCr ratio. Patients with HD had 2 MRS
scans at a month interval to assess the stability of the 31P profile.
Interventional phase: Evaluation of the anaplerotic therapy.
Ten patients (5 females and 5 males) at the early stage of HDwith a
mean age of 46 6 10 years (range 22–61 years) and a mean
UHDRS motor score of 14 6 6 (range 5–27) (table 2) were
recruited within 2 months for the TRIHEP2 Study. Five of these
patients (P1–P5) were recruited from the observational study. The
dietitian determined the caloric intake of all patients and adapted
their daily menus so that their diet remained isocaloric despite the
addition of triheptanoin. At baseline, patients were evaluated for
their UHDRS scores and MRS was performed to assess their brain
energy profile. Each participant was then required to ingest 1 g/kg
body weight of triheptanoin oil per day, divided in 3 to 4 intakes
per day during meals. All patients came for follow-up after 1 month
of triheptanoin therapy and underwent neurologic examination
with UHDRS scoring and scanning with MRS profile. Blood
samples were collected after an overnight fast for standard analyses,
as well as plasma C3-carnitine concentrations that reflect the proper
metabolism of triheptanoin7 (table 2).
31P fMRS. The 31P fMRS protocol has been previously
described.8 We targeted the visual cortex for the 31P fMRS
because it has higher energy metabolism, is easily stimulated,
and is close to the scalp allowing an increased sensitivity to small
surface coils. In addition, occipital volume loss has been reported
in patients with HD.9–11 T1-weighted 1H images of the head were
acquired to position our voxel. A 6-cm 31P transmit/receive
surface coil (RAPID Biomedical GmbH, Rimpar, Germany)
was used to collect free induction decays for 4 minutes at rest,
8 minutes during visual activation with 6-Hz red/black
checkerboard flashes, and 8 minutes after stimulation. Subjects
were able to focus on the flashes with a nonmagnetic mirror
mounted above their eyes while all lights in the room were
turned off.
Metabolite quantification. The spectra were analyzed in the
time domain using AMARES in jMRUI, a Java-based
graphical user interface for the magnetic resonance user
interface. The spectra were preprocessed to include removal of
dummy scans at the beginning of acquisition, zero-order and
first-order phase correction, and apodization. AMARES allows
the inclusion of prior knowledge about relations between
peaks and was used to obtain metabolite concentrations.8 The
ratio of Pi/PCr was calculated to determine the brain response to
cortical activation.
Statistics. Paired t tests were used to compare UHDRS scores
and plasma C3-carnitine before and after treatment with
triheptanoin. Last observation carried forward imputation
approach was used on the 2 UHDRS missing data. For the Pi/
PCr ratio, repeated-measures analysis of variance (ANOVA) were
used to test the global hypothesis that all time points—rest,
activation, and recovery—are equal. If significant with an a of
0.05, paired t tests were used to make pairwise time comparisons
with an a of 0.05 and Bonferroni multiple-testing corrections.
Pearson correlation coefficients were computed to evaluate the
relationship between Pi/PCr ratio and UHDRS scores and CAG
repeats length with Bonferroni correction. Probability values
,0.05 were considered significant.
RESULTS Tolerance and metabolism of triheptanoin.
Triheptanoin was well tolerated in all patients with
HD except one patient who had episodes of diarrhea.
This was due to the ingestion of triheptanoin
only once or twice a day, usually as shots instead of
mixing it with food as recommended. At posttreat-
ment, we observed an increased plasma C3-
carnitine (p 5 0.002) reflecting the proper
metabolism of triheptanoin (table 2).
Motor functions. For 2 patients, UHDRS scores could
not be evaluated after treatment because of a twisted
ankle and a broken arm. Nonetheless, paired t test
with last observation carried forward imputation
approach showed a decrease in the UHDRS motor
score of patients with HD treated for 1 month with
triheptanoin (p 5 0.012) (table 2).
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31P fMRS in validation of functional biomarker. In con-
trols, repeated-measures ANOVAs were significant for
Pi/PCr (p 5 0.029). We observed an increase in Pi/
PCr ratio during activation, which was followed by a
significant decrease during recovery using the
Bonferroni-corrected paired t tests (p 5 0.013).
Conversely, no change in Pi/PCr ratio was detected
during activation in patients with HD. In addition,
the brain MRS profile of patients with HD remained
abnormal after 1 month (figure 1), as well as their
UHDRS score (table 1). We found no correlation
between the UHDRS or the CAG repeat length and
the changes in Pi/PCr ratio during brain activation.
31P fMRS in evaluating anaplerotic therapy. At baseline,
31P fMRS studies were repeated and reconfirmed
an abnormal brain energy profile in patients with
HD, i.e., the absence of an increased Pi/PCr ratio dur-
ing visual stimulation. After 1 month of triheptanoin
therapy, the profile was greatly improved and repeated-
measures ANOVAs were significant for Pi/PCr ratio
(p 5 0.035). We observed an increase in Pi/PCr ratio
during visual stimulation and a decrease during
recovery using the Bonferroni-corrected paired t tests
(p 5 0.005) (figure 2). We found no correlation
between the UHDRS or the CAG repeat length and
the changes in Pi/PCr ratio during brain activation.
Table 2 Characteristics of patients with Huntington disease from the interventional phase of the study
ID Sex Age at exam, y BMI, kg/m2 CAG P CAG N
UHDRS score Plasma C3-carnitine, mmol/L
Pretreatment Posttreatment Pretreatment Posttreatment
P1 F 51 22 41 17 5 ND 0.21 2.73
P2 M 49 24 42 19 27 ND 0.50 3.81
P3 F 42 21 46 ND 13 11 0.38 1.45
P4 F 61 21 42 16 18 9 0.36 0.48
P5 M 22 23 55 16 15 14 0.48 1.51
P6 M 52 24 44 19 5 4 0.68 2.67
P7 F 45 20 41 18 10 7 0.39 1.36
P8 F 52 18 43 23 14 11 0.35 4.09
P9 M 39 26 44 15 13 8 0.30 3.39
P10 M 46 29 45 29 16 13 0.56 0.47
Abbreviations: BMI 5 body mass index; exam 5 examination; ID 5 identification; UHDRS 5 Unified Huntington’s Disease Rating Scale.
P1 to P5 were recruited from the observational phase of the study. The CAG repeat lengths reported are the pathologic repeat sizes (CAG P) and the
normal allele sizes (CAG N). ND represents CAG repeat lengths that could not be evaluated and the UHDRS scores that could not be evaluated at
posttreatment for 2 patients with acute motor problems. Last observation carried forward (LOCF) imputation approach was used on the missing data. The
p values for UHDRS scores (paired t test with LOCF imputation approach for UHDRS [p5 0.012]) and levels of plasma C3-carnitine (paired t test on plasma
C3-carnitine [p 5 0.002]) were obtained using paired t test to compare pre- and posttreatment.
Table 1 Characteristics of patients with Huntington disease from the observational phase of the study
ID Sex Age at exam, y CAG P CAG N BMI, kg/m2 UHDRS visit 1 UHDRS visit 2
P1 F 42 46 17 21 13 13
P2 M 21 55 19 23 11 11
P3 M 52 44 ND 24 6 5
P4 F 45 41 16 20 13 8
P5 M 39 44 16 26 14 14
P6 F 52 39 ND 44 13 14
P7 M 59 40 ND 23 6 6
P8 M 31 48 16 22 10 9
P9 F 29 44 ND 19 7 7
Abbreviations: BMI 5 body mass index; exam 5 examination; ID 5 identification; UHDRS 5 Unified Huntington’s Disease
Rating Scale.
The CAG repeat lengths reported are the pathologic repeat sizes (CAG P) and the normal allele sizes (CAG N). ND
represents CAG repeat lengths that could not be evaluated. A paired t test was used to compare visit 1 and visit 2 (paired t
test on UHDRS scores [p 5 0.282]).
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DISCUSSION This study assesses the benefit of an
anaplerotic therapy on brain energy metabolism in
HD. We observed an abnormal energy response to
brain activation before treatment that was improved
after 1 month under triheptanoin therapy.
In the search for treatment-related biomarkers
with high sensitivity to metabolic changes in the brain
of patients with HD, an initial study using 31P fMRS
showed an 11% increase in Pi/PCr ratio in controls
during activation, followed by a return to baseline
levels during recovery while no such difference was
found in patients.8 The Pi/PCr ratio has been linked
to mitochondrial activation, and metabolic deficiency
has been found to lead to an unusual change in Pi/
PCr in response to work.12 The ratio is directly related
to the ADP levels, which regulate mitochondrial oxi-
dative metabolism. Pi/PCr ratio thus provides an
index of mitochondrial oxidative regulation.13 We
have successfully reproduced the initial findings in
newly recruited healthy individuals as well as in pa-
tients with HD. In addition, we observed that the
abnormal profile of patients with HD is stable over
time, which buttresses the fact that, without thera-
peutic intervention, metabolic dysfunction in patients
with HD does not improve. This study also empha-
sizes the robustness of 31P fMRS to capture brain
energy profiles. However, the small number of pa-
tients recruited here constitutes a limitation to this
study. In addition, reproducibility of MRS protocols
has been an issue and thus 31P MRS should be vali-
dated in a multicentric study just as it has been done
recently for 1H MRS.14 To better understand the
dynamics of ATP, Pi, and PCr in the brain, metabolic
Figure 2 Pi/PCr dynamics after 1 month of triheptanoin therapy
At visit 1 (pretreatment), 31P functional magnetic resonance spectroscopy studies confirmed
an abnormal brain energy profile in patients with Huntington disease, as previously shown.
After 1 month of triheptanoin therapy, the profile was corrected and we observed an
increase in Pi/PCr ratio during visual stimulation with a decrease during recovery (p 5
0.005). Error bars represent SEM of within-subject differences using the method of Morey30
to apply a correction factor to the SEM of the standardized data.31 PCr 5 phosphocreatine;
Pi 5 inorganic phosphate.
Figure 1 Pi/PCr ratios in controls and patients
An increase in Pi/PCr ratio was observed in controls during activation, followed by a decrease during recovery (p 5 0.013).
Patients with Huntington disease showed an abnormal profile characterized by the absence of changes in Pi/PCr ratio
during brain activation. This abnormal profile remained stable over 1 month. Error bars represent SEM of within-subject
differences using the method of Morey30 to apply a correction factor to the SEM of the standardized data.31 PCr 5 phos-
phocreatine; Pi 5 inorganic phosphate.
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imaging tools such as 31P magnetization transfer tech-
niques may be utilized to measure the dynamics of
creatine kinase and ATP synthase in the brain of
patients with HD.15
When triheptanoin (C7 fatty acid) oil is ingested, it
is hydrolyzed to 1 glycerol molecule and 3 molecules of
heptanoate (C7) that are metabolized by the liver.16
The catabolism of heptanoate produces acetyl-CoA
and propionyl-CoA, which fuel the Krebs cycle.17 Hep-
tanoate is more effective in fueling the Krebs cycle than
even-chain fatty acids such as octanoate, which are
metabolized to acetyl-CoA only.17 The effectiveness of
heptanoate over even-chain fatty acids is therefore
attributable to the importance of propionyl-CoA in
serving as a substrate for gluconeogenesis in the liver
and kidneys and as an anaplerotic substrate to fill the
Krebs cycle in all tissues.16 In addition, oxidation of
heptanoate in the liver leads to the export of C5 ketone
bodies, which can be metabolized in peripheral tissues
or in the brain to produce acetyl-CoA and propionyl-
CoA.16 Likewise, the anaplerotic property of trihepta-
noin has been used in several preclinical and clinical
trials. Besides its effect on peripheral energy metabo-
lism, especially fatty acid b-oxidation,18 triheptanoin
has been shown to exert anticonvulsant effects in mouse
models of epilepsy19,20 and affect neurotransmitter con-
centrations in patients with pyruvate carboxylase
deficiency.21
In HD, the therapeutic effect of triheptanoin
may be mediated by its ability to provide Krebs
cycle intermediates. Indeed, we showed that the
reduced levels of BCAAs in the plasma of patients
with HD likely reflect a critical need in the brain
for Krebs cycle substrates provided by peripheral
organ metabolism.6 Furthermore, ketone bodies
have the ability to cross the blood-brain barrier20
and can be used as alternative substrates to glucose
in the brain.22 Therefore, the C5 ketone bodies
derived from triheptanoin may compensate for glu-
cose hypometabolism in the brain of patients with
HD.23 Ketone bodies have also been shown to sig-
nificantly increase brain bioenergetic substrates
such as ATP and PCr.24,25 Thus, improving mito-
chondrial metabolism using triheptanoin may lead
to the mobilization of high-energy phosphates in
the brain as suggested by our findings of increased
Pi/PCr ratios after treatment with triheptanoin.
Finally, triheptanoin may affect the glutamate-
glutamine cycling that is altered in HD26 through
the provision of Krebs cycle intermediates such as
a-ketoglutarate, which undergo transamination for
the synthesis of glutamate.27 Newly developed tech-
niques that have the potential to establish brain map
of glutamate levels, such as chemical exchange sat-
uration transfer,28 may be able to further elucidate
the mechanisms of action of triheptanoin on the
brain of patients with HD.
Our proof-of-concept study strongly suggests that
triheptanoin is able to improve the brain metabolic
profile of patients with HD at an early stage of the
disease. Although it has to be interpreted with caution
because of a possible placebo effect in this open-label
study, we also observed an improvement of motor
functions in patients with HD after 1 month of
anaplerotic therapy. Besides the short-term effect of
triheptanoin on brain energy metabolism, its effect
on surrogate markers such as caudate atrophy or
motor functions, which have been reported as prom-
inent in a multicentric HD study,29 needs now to be
evaluated. Overall, this study shows the significance
of functional or metabolic biomarkers such as the
Pi/PCr ratio in establishing proof-of-concepts for
candidate drugs, especially when they target brain
metabolism.
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2.6 Perspective 
The promising results from the proof-of-concept anaplerotic therapy with triheptanoin has led 
to the start of two new studies to test in a randomized, blinded, placebo-controlled trials, the 
efficacy of triheptanoin (TRIHEP3) and resveratrol (REVHD) on regulating brain metabolic 
functions in HD. The studies are designed as follows (Figure 15) 
 
Figure 15: Design of the multi-centric studies to test the efficacy of two therapeutic 
agents in improving metabolic dysfunction and slowing caudate atrophy in HD. 
 
2.6.1 TRIHEP3 
TRIHEP3 is a randomized, double-blind, controlled and bi-centric study between France and 
the Netherlands, sponsored by Inserm (ClinicalTrials.gov Identifier: NCT02453061). The 
study started in 2015 and plans to recruit 100 early stage HD patients (5 ≤ UHDRS ≤ 40). The 
project is structured such that patients receive 1g/kg of body weight per day of either 
triheptanoin (n = 50) or a placebo (n = 50) for six months. After six months, all patients will 
receive triheptanoin in the open-label-phase of the study for an additional six months. 
Triheptanoin (UX007; Ultragenyx Pharmaceuticals Inc; Novato; USA) is a medium odd-chain 
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triglyceride containing three 7-carbon fatty acids. Its metabolism yields appropriate substrates 
for both fatty acid metabolism and anaplerosis. A trained dietician determines the daily 
calorie intake for each patient and adjusts his or her daily menu to ensure both proper 
treatment administration and an isocaloric diet. The patients are asked to ingest a treatment 
dose (triheptanoin or placebo) representing around 30% of their usual daily calorie intake. 
The primary objectives are to evaluate the efficacy of triheptanoin in: 
i. Increasing the short-term energy response in the metabolic profile of the brain of early 
affected HD patients. 
ii. Slowing atrophy in the caudate of early affected HD patients as measured with 
volumetric magnetic resonance imaging. 
The secondary objectives are to: 
• Assess the impact of triheptanoin on brain diffusion metrics 
• Assess the clinical benefit of triheptanoin on motor function in HD. 
• Assess the clinical benefit of triheptanoin on cognitive function and psychiatric 
symptoms in HD. 
• Confirm long-term clinical and biological tolerance of triheptanoin in HD. 
• Find correlations between neuroimaging volumetric parameters, brain energy profiles 
and clinical scores, before and after treatment.  
Patients are evaluated at baseline and every three months for a year. The UHDRS and Total 
Functional Capacity (TFC) scores are used for the clinical assessment of patients. 
Neuropsychological tests include symbol digit modality (visuomotor integration), trail making 
parts A and B (attention, processing speed and mental flexibility), forward and backward digit 
span (short-term and working memory), stroop (attention and capacity for inhibition), 
sustained attention to response task (attention and inhibitory processes of attention control) 
and a self-report questionnaire (SF36) to obtain self-ratings of physical and emotional health. 
Psychiatric evaluations with Problem Behaviors Assessment for HD Short Version (PBA-S) 
allows the assessment of the severity and frequency of different behavioral symptoms in HD. 
Dietary consultations with the dietician help participants to incorporate triheptanoin or the 
placebo into their daily food. Biochemical assessments are performed on plasma and urine 
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samples to test for plasma acylcarnitines, plasma C5-ketone bodies and urine organic acids – 
which give information on the metabolism of triheptanoin. 
31P MRS is used to assess the metabolic profile of patients at baseline and during treatment 
with triheptanoin or placebo using the Pi/PCr ratio biomarker. The MRI protocol consists of a 
3D T1-weighted anatomical sequence (1 mm isotropic, TR = 2300 ms, TE = 2.98 ms, field of 
view (FOV) = 240 x 256). The brain image is analyzed using the whole brain and caudate 
boundary shift integral (BSI) approach (Freeborough & Fox, 1997; Hobbs et al., 2009) to 
determine rate of atrophy over time. Finally, DTI and tractography are performed on 
diffusion-weighted data (b value = 1500 s/mm2, TR = 14400 ms, TE = 93 ms, slice thickness = 
2 mm isotropic, matrix = 128 x 128, flip angle = 90o) acquired in 30 directions.  
Currently, the first phase of the study (n= 50 patients) has been completed in both centers and 
the study is now on the second phase (n= 50 patients). The data are still blinded and statistical 
analysis are awaiting the end of the study. 
 
2.6.2 REVHD 
Resveratrol is a non-toxic polyphenol present in certain foods (grape, blackberry, red wine, 
peanuts) showing anti-inflammatory and anti-oxidant properties. Studies in mice showed that 
resveratrol enhances mitochondrial number and function at the peripheral level, as well as 
mouse aerobic skills (Lagouge et al., 2006). Many preclinical studies have also demonstrated 
a neuroprotective effect of resveratrol in HD (Quincozes-Santos & Gottfried, 2011). But until 
now, the use of resveratrol in therapeutic trials in humans has been limited due to a short half-
life in plasma resulting in a poor bioavailability. In this study, a newly formulated resveratrol, 
which has prolonged absorption and no risk of toxicity, is given in capsules that contain 20 
mg of purified resveratrol, with a maximum given daily dose of 80 mg. 
REVHD is a French multi-centric randomized, double-blind, controlled study, sponsored by 
the Assistance Publique des Hôpitaux de Paris (APHP, ClinicalTrials.gov Identifier: 
NCT02336633), that plans to recruit 102 early affected HD patients. Patients receive either 
resveratrol at 80 mg (n = 51), or placebo (n = 51) for 12 months. 
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The primary objective of REVHD is to evaluate the ability of resveratrol to slow down 
disease progression in early affected HD patients reflected by a decrease in the rate of caudate 
atrophy. 
The secondary objectives are to: 
• Assess the impact of resveratrol on brain energy metabolism. 
• Assess the impact of resveratrol on brain diffusion metrics. 
• Assess the clinical benefit of resveratrol on motor function in HD. 
• Assess the clinical benefit of resveratrol on cognitive function and psychiatric 
symptoms in HD. 
• Confirm the clinical and biological tolerance of resveratrol in HD. 
• Determine correlations between the neuroimaging volumetric parameters, brain energy 
profile and clinical scores, before and after treatment. 
The total participation period for each patient is 13 months (12 months of treatment and 1 
month follow-up). All neuroimaging is performed in Paris at the Institut du cerveau et de la 
moelle (ICM) whilst other tests including neuropsychological, clinical and biochemical tests 
are performed in the co-investigator site (Angers, Bordeaux, Marseille, Montpellier, Paris) 
nearest to the patient. After a pre-screening phase participants visit their co-investigator site 
for inclusion (V1). Immediately afterwards, the second visit (V2) is made to ICM in Paris for 
neuroimaging before receiving either resveratrol or placebo. Patients receive their treatment 
(placebo or resveratrol at 80 mg/day, i.e. two 20 mg capsules in the morning and in the 
evening) for three months. Every three months, patients return to their nearby hospital in 
order to have neurological (UHDRS, TFC) and clinical examination. Neuropsychiatric and 
cognitive evaluations consist of Starkstein apathy scale (relating to apathy), hospital anxiety 
and depression scale (depression and anxiety symptoms), frontal systems behavior inventory 
(behavior associated with damage to frontal systems of the brain), forward and backward digit 
span, stroop, trail making parts A and B, SF36, and symbol digit modality. A nurse performs 
fasting blood sampling 30 minutes after pill intake at visits 3 (V3) and 5 (V5) and before pill 
intake at visit 4 (V4) in order to get information on the metabolism of resveratrol. After a year 
of treatment, patients return to ICM for neuroimaging, as described for TRIHEP3 – i.e. 31P 
MRS, 3D T1-weighted anatomical sequence and diffusion weighted imaging. 
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Currently, more than 70 patients have been enrolled in REVHD. The data are still blinded and 
statistical analysis are awaiting the end of the study. 
 
2.6.3 Key role of MRI-MRS evaluations in both studies 
MR is used as the primary outcome measures of both studies.  I did set-up the protocol on the 
newly installed Siemens Magnetom Prisma (Siemens Medical Solutions, Erlangen, Germany) 
scanner at ICM (TRIHEP3 and REVHD) and on the Philips scanner in Leiden (TRIHEP3). 
This entailed performing phantom and volunteer tests to ensure that similar sequences, 
acquisition approaches and visual stimulations were being applied at both centers.  
I perform the image and spectra acquisitions in Paris whilst dedicated doctoral students are 
responsible for data acquisition in Leiden. One of the main challenges to MR data is poor 
shimming. I therefore perform quality control on all the MRS datasets to ensure that we 
reported values are reliable. I also ensure that all data are well preprocessed to include zero 
and first order phase correction as well as shot-to-shot frequency correction.  
In order to eliminate bias, I am the only one responsible for whole brain and caudate BSI 
analysis of volumetric data from both study sites. I have also setup an analytical pipeline for 
the analysis of diffusion weighted data. 
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Study 2a: Understanding the biochemical basis of altered bioenergetics in 
HD using 
31
P MT 
3.1.1 Introduction and objectives  
We showed in study 1 that metabolic dysfunction persists in HD patients in the absence of 
therapeutic intervention. The altered Pi/PCr ratio could be attributed to underlying enzymatic 
disturbances. Indeed, creatine kinase (CK) is responsible for the equilibrium reactions 
involving the donation of high-energy phosphate group from one phosphate-containing 
molecule to the other such as from PCr to adenosine diphosphate (ADP) to form ATP (Figure 
13). As an energy transport system between site of ATP synthesis and ATP utilization (de 
Graaf, 2007), we hypothesized that decreased CK activity may explain the altered Pi/PCr ratio 
observed in study 1. 
In this study, sponsored by Inserm (ClinicalTrials.gov Identifier: NCT01696708), we chose to 
focus on the CK rate that regulates PCr and ATP interaction. We did not look at Pi and ATP 
flux since the small Pi peak is prone to noise in MT experiments making quantification and 
interpretation of results difficult at 3T.  
 
3.1.2 Materials and methods 
Ten early stage HD patients (UHDRS 15 ± 11) and 10 age and sex-matched controls were 
recruited for the study. The rate of CK was measured using 31P MT (pulse-acquire, TR 15s). 
A 25 x 25 x 25 mm3 voxel placed in the visual cortex and covering most of the calcarine was 
used for shimming. Frequency calibration was performed for each subject in order to 
determine the voltage needed to achieve maximum signal. Saturation of the γATP resonance 
was performed using 8 cycles of B1-insensitive train to obliterate signal (BISTRO) (Luo et 
al., 2001) pulse (duration 3.5 s). Phantom and volunteer tests were first performed to calibrate 
the flip angle at which complete saturation of γATP resonance is achieved with minimal to no 
direct effect on the PCr resonance. The transmit-receive frequency was set at -50 Hz, a region 
of noise, to avoid contamination of resonances by the direct current artifact. A symmetric 
saturation was performed at the opposite side of the PCr resonance to correct for RF bleed 
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over. Data were collected for 8 min each at rest, activation and recovery. The rate of PCr was 
then calculated assuming T1= 2.4 s using the formula:  
!!" = !
1
!!
!× !
!!
!!
− 1  
Where Ms and Mo are the steady-state magnetization with and without saturation of γATP 
respectively.  
 
3.1.3 Results 
We achieved complete attenuation of the γATP signal with the BISTRO pulse with no effect 
on the PCr resonance (Figure 16). 
 
Figure 16: 
31
P MT spectra from the visual cortex. (A) Saturation applied on the γATP 
achieves complete attenuation of the signal. (B) Symmetric saturation does not have an effect 
on the PCr resonance; hence any decrease in the PCr signal reflects the chemical exchange 
between PCr and γATP through the CK reaction. PME: phosphomonoester, PDE: 
phosphodiester. 
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The symbolic error propagation calculation in MATLAB was used to estimate the error in our 
CK calculations. The rate of CK was observed to be similar in controls and patients at rest. 
During visual stimulation, however, the rate of CK showed a 5% increase in controls (k = 
0.326 ± 0.041 s-1) compared to patients (k = 0.296 ± 0.027 s-1) (p = 0.07) (Figure 18) but did 
not reach significance. This however could suggest an abnormal energy metabolism in the 
visual cortex during functional activation in patients at early stage of HD. Although not 
significant, possibly due to the small sample size, this reduced CK rate could explain the lack 
of increase in Pi/PCr ratio during visual activation that we observed previously. However, this 
study should be validated in a larger cohort of patients and presymptomatic individuals. 
 
Figure 17: Rate of CK measured with 
31
P MT in the visual cortex of patients and 
controls. No change was observed at rest but a trend of 5% increase in CK was observed in 
controls during visual stimulation (p = 0.07). 
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Study 2b: Proton spectroscopy in the visual cortex and striatum of HD 
3.2.1 Introduction and objectives  
The previous studies focused on the phosphate containing-molecules that are limited in the 
number of metabolites that can be reported. Several studies have used 1H MRS to identify 
neurochemical alterations in different parts of brain (Clarke et al., 1998; Ruocco et al., 2007; 
van den Bogaard et al., 2011). Whilst metabolite ratios were reported in some studies, it is 
unreliable and interpretation of ratios are complicated since changes cannot be attributed to 
particular metabolites. Even though the visual cortex is also affected in HD, most MRS 
studies have focused on the striatum. 
One of the major challenges of MRS studies is results reproducibility. This often leads to 
studies reporting different results from the same brain region. Having a standardized protocol 
with similar acquisition and analytical procedure could bridge this gap.  
In this study sponsored by Inserm (ClinicalTrials.gov Identifier: NCT01696708), we sought 
to use a validated 1H MRS sequence (described in Chapter 4) to identify more metabolites in 
the striatum and visual cortex of patients at the early stage of HD. 
  
3.2.2 Materials and methods  
This study was performed on the subjects recruited in study 2a. The 1H MRS protocol 
consisted of a validated semi-LASER protocol (TR = 5000 ms, TE = 28 ms, averages = 64, 
vector size = 2048, acquisition time = 6 min). A 34 x 19 x 23 mm3 VOI and a 25 x 25 x 25 
mm3 VOI were placed in the striatum and visual cortex respectively. Calibrations were 
performed in each VOI to include FASTMAP shimming and RF power calibration for the 90o 
excitation pulse. Water suppression and outer volume suppression were performed for each 
VOI to attenuate signal from the more abundant water and quell signals from lipids and 
regions outside the VOI respectively. We corrected for CSF contributions as well as partial 
volume fractions during quantification with LCModel. In addition to 1H MRS, we compared 
the volumes of WM, GM and CSF in each VOI. 
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3.2.3 Principal results 
Significantly higher total creatine (tCr) was observed in the visual cortex of patients whilst a 
decrease in Glu concentration was observed in the striatum. Moreover, in patients, the GM 
was significantly decreased whilst CSF was significantly increased. No change in WM was 
observed. 
 
3.2.4 Submitted paper for publication 
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ABSTRACT 
Purpose: The striatum is a well-known region affected in Huntington disease (HD). 
However, other regions including the visual cortex are implicated. We previously identified 
an abnormal energy response in the visual cortex of patients at an early stage of HD using 
31
P 
magnetic resonance spectroscopy (MRS). We therefore sought to further characterize these 
metabolic alterations with 
1
H MRS using a well-validated semi-LASER sequence that 
minimizes J-modulation.  
Materials and methods: Ten early affected patients (UHDRS, total motor score = 13.6 ± 
10.8) and ten healthy volunteers of similar characteristics were recruited for the study. We 
performed 
1
H MRS in the striatum – the region that is primary affected in HD – and the visual 
cortex. 
Results: This allowed a reliable quantification of 10 metabolites in the visual cortex and 8 in 
the striatum, compared to 3-5 metabolites in prior 
1
H MRS studies performed in HD. We 
identified higher total creatine (p = 0.030) in the visual cortex and decreased glutamate (p = 
0.001) in the striatum of HD patients compared to controls. Lower abundant neurometabolites 
(glutamine, GABA, lactate, glutathione, ascorbate or aspartate) showed similar concentrations 
in both groups.  
Conclusion: Our study identifies early energy changes in the visual cortex of HD patients 
related to creatine metabolism. Decreased striatal glutamate could reflect early neuronal 
dysfunction or impaired glutamatergic neurotransmission.  
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INTRODUCTION 
Huntington disease (HD) is a polyglutamine disorder caused by expansion in the glutamine-
encoding cysteine-adenine-guanine (CAG) repeats
1
 and striatal atrophy is a prominent 
characteristic of the disease.
2
 Other brain regions including the thalamus, cerebral cortex, 
cerebellum
3,4 
and visual cortex
5
 are also involved in the pathological process as the disease 
progresses. Positron emission tomography studies have shown metabolic alterations in the 
striatum
6
 whilst 
31
P MRS studies have revealed abnormal energy response in the visual cortex 
of HD patients at an early stage of the disease.
7,8
 With the availability of genetic testing for 
HD, there exists a therapeutic window that can be taken advantage of before symptoms onset. 
However, biomarkers are critically needed to evaluate presymptomatic individuals and make 
use of this therapeutic window
5
 since the Unified Huntington Disease Rating Scale 
(UHDRS),
10
 the most commonly used measure to assess disease severity, is unable to 
evaluate pathological processes prior to motor symptoms onset. In the search for biomarkers, 
1
H MRS has been used to study neurometabolism in HD at different field strengths.
11-15
 
Metabolic alterations start indeed in the very early stages of the disease,
16
 and represent 
important targets for neuroprotective therapies.
8
  
Previous studies with 
1
H MRS in HD were carried out at field strengths between 0.5 T and 7 
T (Table 1), with several studies performed on 3 T systems that are becoming common in 
hospitals.
12,13,15,17
 In general, these studies have focused on the most prominent metabolites in 
the 
1
H spectrum – total NAA (tNAA), total creatine (tCr), total choline (tCho), and to a lesser 
extent myo-inositol (myoIns) and glutamate (Glu) – but not on less obvious metabolites such 
as gamma amino-butyric acid (GABA), glutamine (Gln), or glutathione (GSH). Some studies 
reported metabolite ratios only, which further complicate data interpretation.
12,13
 Moreover, 
most of these studies focused mainly on the striatum, caudate or putamen, and only a few on 
the occipital cortex (Table 1) even though abnormal metabolic alterations are also present in 
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this region.
6-8
 Furthermore, these studies used STEAM and PRESS sequences with long or 
short TE without prior test of robustness or reproducibility. The present study thus sought to 
measure an expanded neurochemical profile in both the visual cortex and the striatum of early 
affected HD patients at 3 T, using a previously optimised and validated semi-LASER 
sequence with water as an internal concentration reference and correction of concentrations 
for CSF content.   
 
MATERIAL AND METHODS 
Subjects 
The local ethics committee approved this study and all subjects signed a written informed 
consent after the nature of the procedure had been fully explained before participating in the 
study. Motor dysfunction was evaluated with the total motor score (TMS) of the Unified 
Huntington Disease Rating Scale (UHDRS) with a maximal worth score of 124. We recruited 
ten patients at the early stage of HD without medication as well as ten healthy volunteers with 
similar general characteristics – sex, age and BMI (Table 2).  
 
MR Protocol 
MRS data were acquired on 3 T whole-body Siemens Magnetom Trio scanner (Siemens 
Medical Solutions, Erlangen, Germany). We used a modified semi-LASER 
1
H MRS 
protocol
18
 that has been previously tested in healthy controls for robustness and 
reproducibility in a bi-centric study and demonstrated highly reproducible data.
19
 Using a 32-
channel head coil, 3D T1-weighted volumetric images (TR = 2530 ms, TE = 3.65 ms, 1 mm 
isotropic, FOV = 256 x 240 mm
2
, matrix size = 256 x 240) were acquired for spatial 
normalization and localization of brain volumes and for volumetric analysis of brain regions 
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of interest. Shimming and spectra acquisition were performed on a 34 x 19 x 23 mm
3
 volume-
of-interest (VOI) in the striatum, and a 25 x 25 x 25 mm
3
 VOI in the visual cortex (Figure 1). 
Automatic shimming of the voxels were achieved with FAST(EST)MAP
20
 to generate highly 
resolved spectral linewidths. The calibration and acquisition steps were performed as 
described in prior studies.
18,19,21
 The RF power for the asymmetric slice-selective 90
o
 pulse 
(duration = 2 ms) of the semi-LASER sequence (TR = 5000 ms, TE = 28 ms, averages = 64, 
vector size = 2048, acquisition time = 6 min) was calibrated by determining the power that 
produced the maximum signal. The power for the 180
o
 hyperbolic secant adiabatic full 
passage (AFP) pulses (duration = 4 ms) was set automatically based on the 90
o
 pulse. For 
better suppression of unwanted coherences with shorter spoiler gradients, AFP pulses were 
interleaved. Water suppression pulses with the variable pulse power and optimized relaxation 
delays (VAPOR) were adjusted by following signal intensities to determine the power with 
maximum water suppression. The VAPOR pulses were interleaved with outer volume 
suppression (OVS) pulses to reduce contamination from other brain regions outside the VOI 
in the visual cortex (thickness: anterior = 200 mm, posterior = 40 mm) and the striatum 
(thickness: anterior = 80 mm, posterior = 80 mm). A 7 mm margin was left between the VOI 
and the OVS slices in order to avoid signal loss in the VOI due to the transition band of the 
OVS pulse profile. Two preparation scans were performed at the beginning of spectra 
acquisition to balance the initial fluctuation of the readout on Siemens systems. Additionally, 
unsuppressed water spectra were acquired for eddy current correction (VAPOR off) and 
another (VAPOR and OVS off) was used as an internal water reference for metabolite 
quantification.
19,21
 The total scan time for each VOI that included shimming, calibration and 
spectra acquisition was approximately 10 minutes. To evaluate the cerebrospinal fluid (CSF) 
contribution to VOI, we segmented the brain and estimated the %CSF content in the VOI as 
explained below. Metabolite concentrations were then corrected for regional CSF content. 
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Metabolite quantification 
Pre-processing of data that included eddy current, phase and frequency correction and 
quantification of spectra with LCModel were performed in MATLAB as previously 
described.
19,21
 The basis set was simulated for all metabolites – alanine, ascorbate, aspartate, 
creatine, γ-aminobutyric acid (GABA), glycerophosphorylcholine (GPC), phosphocholine 
(PCho), phosphocreatine (PCr), glucose (Glc), glutamine (Gln), glutamate (Glu), glutathione 
(GSH), myoinositol (myo-Ins), scyllo-inositol (sIns), lactate, N-acetylaspartate (NAA), N-
acetylaspartylglutamate (NAAG), phosphorylethanolamine (PE) and taurine. The basis set 
also included macromolecule spectra that were acquired in healthy volunteers.
19
 Phase and 
frequency correction were performed on each subject spectra. The unsuppressed water spectra 
were used for eddy current correction. By using water from the same VOI as an internal 
concentration reference, we limited errors that otherwise could arise from the use of an 
external reference such as those related to B1 homogeneities and coil loading. Metabolite 
concentrations were corrected for CSF content and GM/WM partial volume fraction assuming 
100% water content in CSF, 78% water content in GM and 65% water content in WM as 
recommended in the LCModel manual. Even though atrophy is observed in HD, tissue water 
content seems to remain fairly similar.
22
 We thus assumed identical tissue water content in 
GM and WM in controls and patients. Metabolites were considered reliably quantified when 
Cramér-Rao lower bounds (CRLB) ≤ 20% were observed in at least half the subject 
population as this threshold allows the selection of the most reliably quantified metabolites as 
recommended in the LCModel manual. However, in order to avoid quantification bias, we 
reported the average of all concentration values for each reliably quantified metabolite, 
including those with CRLB < 999%. For metabolites exhibiting high cross-correlation 
(correlation coefficient < -0.7) – e.g. Cr and PCr; and NAA and NAAG – only the sum was 
reported (e.g. tCr for Cr and PCr; tNAA for NAA and NAAG). Spectra with water linewidth 
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> 10 Hz were excluded from the analysis. Pre-processing and quantification steps took 
approximately 3 minutes to complete. 
 
Brain tissue volume estimation 
We first extracted the coordinates used for spectroscopy measurements in the visual cortex 
and the striatum in order to reconstruct this volume of interest (VOI) for each subject using 
in-house scripts developed in MATLAB. To obtain reliable volume estimates, 3D T1 images 
were automatically segmented using Freesurfer v5.3 (https://surfer.nmr.mgh.harvard.edu/). 
The gray matter (GM)/white matter (WM) interface as well as the GM volume segmentations 
were examined and reprocessed if corrections were needed. For each subject, VOIs were 
registered to their respective 3D T1 image and the volume fractions of the GM, WM and 
cerebrospinal fluid (CSF) within each VOI were extracted and quantified using tools available 
from Freesurfer. 
 
 
Statistical analysis 
We applied a student t-test to compare neurometabolite concentrations between patients and 
controls. Pearson correlations were performed between neurometabolite concentrations and 
TMS, CAG repeat length and brain volume fractions in the VOI with Holm-Bonferroni 
multiple comparison correction.  Probability values of p < 0.05 were considered significant. 
 
RESULTS 
Reduced GM volume fractions and increased CSF fractions were observed in HD patients 
compared to controls (Figure 2). Each subject’s volume fractions were used to correct for 
partial volume effects.  
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We could not acquire one dataset from the visual cortex of a patient due to scanning time 
constraints. Hence nine datasets were reported for the visual cortex of patients. In the visual 
cortex, HD patients displayed higher tCr than controls (p = 0.032) (Figure 3A). All other 
neurometabolites (Gln, Glu, GSH, myoIns, tCho and tNAA) had similar concentrations in 
both groups. In the striatum, HD patients showed decreased Glu concentrations (p = 0.001) 
whilst the other metabolites were comparable to controls (Figure 3B). In contrast to the 
striatum, Glu levels showed a trend to increase in the visual cortex. Similarly, tCr showed a 
trend to decrease in the striatum in contrast to the visual cortex.  
In order to analyse more neurometabolites (aspartate, ascorbic acid, scyllo-inositol, lactate and 
taurine), the CRLB threshold was increased to 50%. These additional metabolites did not 
show any significant differences between patients and controls (data not shown). Overall, 
neurometabolite levels did not correlate with TMS, CAG repeat length or age.  
 
DISCUSSION 
We showed increased tCr in the visual cortex and decreased Glu in the striatum at an early 
stage of HD, but no significant changes in less prominent metabolites such as GABA, Gln or 
GSH. While the striatum is at the center of structural and metabolic changes in HD, we 
confirmed that the visual cortex is also involved in the early stage of the disease. The 
extended analysis of 10 neurometabolites in the visual cortex and 8 in the striatum was 
possible due to a previously validated semi-LASER sequence providing high SNR and 
minimal J-modulation.
 
The difference in lower number of metabolites reported for the 
striatum is due to the higher cross-correlation observed in this region. 
Most clinical protocols use PRESS and STEAM sequences, which are vendor provided 
sequences. In the previous studies compiled in Table 1, long TE protocols
23,24
 provide a 
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limited number of metabolites that can be reported since metabolites with short T2 cannot be 
measured. Other studies used short TE STEAM
12,15,25 
and PRESS
14,26,27
 protocols to report 
absolute concentrations or ratios of metabolites. However, it has been established that vendor 
sequences such as STEAM produces spectra with low SNR and PRESS has high chemical 
shift displacement artefacts.
28
 In addition, the two pairs of 180
o 
AFP pulses that we used 
preserve the J-modulation and provide consistency in measured J-coupled as well as singlet 
metabolites.
19
  
Total creatine (tCr) serves as an energetic marker and maintains brain energy homeostasis.
29
 
Its importance may stem from the limited glucose storage capability by the brain.
30
 Increased 
tCr has been reported in the brain of HD mouse models
31
 and this increase preceded the 
depletion of ATP.
32
 Patients with spinocerebellar ataxia type 1, 2 and 3, another group of 
polyglutamine disorders that share common pathophysiological pathways with HD,
33
 also 
displayed increased tCr in the vermis and the pons.
21
 In addition, the relative concentrations 
of components of energy metabolism – ATP, PCr and inorganic phosphate (Pi) – were 
previously measured using 
31
P MRS in the visual cortex of HD patients before, during and 
after visual stimulation.
7,8
 Healthy controls exhibited a normal profile, with increased Pi/PCr 
ratio during visual stimulation, followed by a return to baseline levels during recovery. In 
contrast, HD patients displayed no significant change in Pi/PCr ratio in two independent 
studies.
7,8
 The increase in tCr in the visual cortex reported here is in agreement with these 
studies. Altogether, these studies underlie that creatine metabolism is modified in the visual 
cortex of HD patients, a region that is particularly enriched in mitochondria,
7,8
 at an early 
stage of the disease and may signify a compensatory mechanism. In the striatum however, 
there was no difference in tCr concentration but there was a trend to decreased tCr. This trend 
is similar to studies performed on HD patients in the striatum,
12
 caudate
15
 and putamen.
14,15,34
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The significant decrease in the neuronal marker Glu in the striatum is in agreement with 
previous reports from the putamen.
14,15
 Decreased Glu could be due in part to the lower GM 
content in the striatal VOI. However, assuming that Glu was two-fold higher in GM than in 
WM,
35
 we calculated that the measured decrease in GM content would have resulted in a less 
than 5% decrease in Glu concentration in the VOI, and therefore did not explain the 18% 
decrease observed in our study. Since it has been shown that the striatum is highly affected in 
HD, even at the presymptomatic stage,
2
 decreased Glu concentrations could reflect neuronal 
dysfunction as a result of atrophy. Furthermore, Glu levels have been linked to metabolic 
activity.
29
 Twenty percent of brain glucose metabolism is directed to Glu synthesis through 
the Gln-Glu cycle.
36
 As HD patients display glucose hypometabolism in the striatum and 
cortex,
37
 decreased Glu levels could reflect decreased metabolic activity in HD patients.  
We did not find a difference in tNAA between patients and controls, which could be due to 
the fact that our cohort was at a very early stage of the disease. Previous studies reported no 
change in tNAA but a decrease in NAA.
12,14,15,34
 However, we have observed high cross-
correlation between NAA and NAAG, which indicates that reporting tNAA is more reliable 
than individual concentrations. It might be argued that the much smaller NAAG contribution 
should not offset any observable differences with NAA. Still, such high cross-correlations 
among the individual metabolites might lead to underestimation or overestimation of their 
actual individual values. Furthermore, GABA is another important metabolite in HD since the 
medium-sized spiny neurons that contain GABA undergo selective degeneration in the 
striatum.
38
 In 
1
H MRS experiments, however, special editing sequences are needed to 
extensively quantify the peaks at 3 T due to its overlap with other larger signals.
36
 This study 
is therefore limited in its quantification of the GABA signal and it is possible that our 
reported values might not be a true reflection of the actual GABA concentration.  
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In conclusion, this study used an optimized semi-LASER protocol to help understand the 
early neurometabolic alterations that occur in HD. We reported absolute metabolite 
concentrations and not ratios,
11,23,27,34,39 
 in order to be able to analyse the impact of each 
individual metabolite. Unlike all the aforementioned studies summarized in Table 1, we 
obtained an expanded neurochemical profile of up to 10 metabolites. Our main finding is that 
creatine metabolism is affected at an early stage of HD, which supports the use of therapies 
aiming at improving brain energy metabolism. 
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Table 1: Summary of previous 1H MRS studies in the striatum and occipital cortex 
 Striatum Caudate 
Presymptomatic vs controls 
NAA/tNAA 
  No change in any 
metabolite Gomez-Anson 2007 (n=19)
40
  
Van den Bogaard 2011 (n=11 
reported)
15 
    
Patients vs controls 
NAA/tNAA 
 Jenkins 1993 (tNAA/Cr, n=15)
39
 
 Jenkins 1998 (tNAA/Cr, n=31)
11 
 Clarke 1998 (NAA, n=6)
12 
 Van den Bogaard 2011 (n=5 
reported)
15 
mIns 
  
tCr  Clarke 1998 (Cr) (n=6)
12 
 Van den Bogaard 2011 (n=5 
reported)
15 
Glu 
 Glx Taylor-Robinson 1996 
(Glx/tCr, n=5)
23 
 
Cho/tCho 
 Jenkins 1993 (tCho/tCr, n=15)
39
 
 Jenkins 1998 (tCho/tCr, n=31)
11 
 Clarke 1998 (Cho/Cr, n=6)
12 
 
Lac 
 Jenkins 1993 (n=15)
39
 
 Jenkins 1998 (n=31)
11 
 No change in any 
metabolite 
    
Mixed presymptomatic/patients vs controls 
NAA/tNAA 
 
 Sanchez-Pernaute 1999 (n=4 PMC, 
n=6 MC)
41 
mIns 
  
tCr 
 
 Sanchez-Pernaute 1999 (n=4 PMC, 
n=6 MC)
41 
Glu 
 
 Padowski 2014 (only when 
considering ratios)  (n=6 PMC, n=4 
MC)
27 
   
Mixed presymptomatic/patients longitudinal changes 
NAA/tNAA 
  
mIns 
 
 van den Bogaard 2014 (n=7 PMC, 
n=2 MC)
25 
Cr 
 
 van den Bogaard 2014 (n=7 PMC, 
n=2 MC)
25 
Cho 
  No change in any 
metabolite 
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Table 1 continued 
 Putamen Occipital cortex 
Presymptomatic vs controls 
NAA/tNAA 
 NAA -8% but not tNAA Sturrock 2010 
(n=25)
14
 
No change in NAA but tNAA Sturrock 2015 
(n=25)
26 
 No change in any 
metabolite 
Van den Bogaard 2011 (n=9 reported)
15
 
Van Oostrom 2007 (n=19) (34)  
    
 Patients vs controls 
NAA/tNAA 
 -17%/-15% Sturrock 2010 (n=29)
14
 
 Van den Bogaard 2011 (n=5 reported)
15
 
 NAA Hoang 1998 (n=15)
34
 
 Sturrock 2015 (n=23/24)
26 
 NAA/Cr Hoang 1998
34 
mIns 
 Hoang 1998 (n=15)
34
 
 ~50% Sturrock 2010 (n=29)
14
 
 Sturrock 2015 (n=23/24)
26 
 
tCr 
 Van den Bogaard 2011 (n=5 reported)
15
 
 Hoang 1998 (n=15)
34
 
 -18% Sturrock 2010 (n=29)
14 
 
Glu 
 Van den Bogaard 2011 (n=5 reported)
15
 
 ~10% Sturrock 2010 (n=29)
14 
 
Cho/tCho 
 ~10% Sturrock 2010 (n=29)
14
 
 Hoang 1998 (n=15)
34 
 Jenkins 1998 (n=31)
11 
Lac 
 
 Jenkins 1993 (n=15)
39
 
 Jenkins 1998 (n=31)
11 
No change in any 
metabolite 
 
Taylor-Robinson 1996
23 
Hoang 1998 (abs conc)
34 
  
 Mixed presymptomatic/patients vs controls 
mIns Trend  Padowski 2014 (n=6 PMC, n=4 MC)
27 
    
 Mixed presymptomatic/patients longitudinal changes 
NAA/tNAA  van den Bogaard 2014 (n=6 PMC, n=1 MC)
25 
 
mIns 
Trend mIns/NAA  Sturrock 2015 (n = 23/24 
MC)
26 
 
Cho  van den Bogaard 2014 (n=6 PMC, n=1 MC)
25 
 No change in any 
metabolite Sturrock 2015 (n=25/22 PMC, n= 23/24 MC)
26 
  
NAA: N-acetylaspartate, tNAA: total N-acetylaspartate. Cr: creatine, tCr: total creatine, Glu: 
glutamate, Glx: glutamine and glutamate, tCho: total choline, Lac: lactate, myo-Ins: myo-inositol, 
PMC: premanifest carrier; MC: manifest carrier, abs conc: absolute concentration; : increased 
concentration; : decreased concentration 
  75 
 
  21 
Table 2: Demographic and spectroscopic parameters of participants. 
Variable Controls HD patients 
N
o
 of participants 10.0 10.0 
Gender (M/F) 3/7 3/7 
Age (years) 38.9 ± 13.8 45.6 ± 12.7 
BMI (kg/m
2
) 21.1 ± 1.7 21.6 ± 3.3 
TMS (UHDRS) 0.9 ± 1.0 13.6 ± 10.8 
#
 
CAG length  44.1 ± 4.2 
Lw striatum (Hz) 10.0 ± 1.0 8.3 ± 2.6  
Lw visual cortex (Hz) 7.8 ± 0.7 6.6 ± 1.1 * 
SNR striatum  46.7 ± 11.3 39.0 ± 16.7 
SNR visual cortex  65.6 ± 19.4 57.1 ± 14.5 
%CSF striatum  4.5 ± 1.4 12.0 ± 8.4 * 
%CSF visual cortex  7.0 ± 4.8 17.0 ± 11.5 * 
Data are presented as mean ± standard deviation and compared by t-test. BMI: body mass 
index; TMS: total motor score; SNR: signal-to-noise ratio estimated by LCModel; Lw: water 
linewidth estimated by LCModel; CSF: cerebrospinal fluid. *p<0.05 and 
#
p≤0.01  represent 
significant differences between HD patients and controls. 
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Figure 1: Voxel positioning and spectra acquired from the striatum and visual cortex of 
controls and patients. Spectra were acquired in an acquisition voxel of 34 x 19 x 23 mm
3
 in 
the striatum and 25 x 25 x 25 mm
3
 in the visual cortex using the modified semi-LASER 
sequence (TR = 5000 ms, TE = 28 ms, averages = 64). tNAA: total N-acetylaspartate, Glu: 
glutamate, Gln: glutamine, tCr: total creatine, tCho: total choline, myo-Ins: myo-Inositol. 
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Figure 2: Brain tissue volume fraction in VOI in the striatum and visual cortex. Gray matter 
(GM) was markedly reduced in the striatum and visual cortex whilst cerebrospinal fluid 
(CSF) was significantly increased. *p<0.05 and **p≤0.01 represent significant differences 
between HD patients and controls.  
 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
GM WM CSF GM WM CSF 
Striatum Visual cortex 
V
o
lu
m
e
 f
r
a
c
ti
o
n
 
Control 
Patient 
* 
** 
* 
* 
  78 
 
 
  24 
 
Figure 3: Mean metabolite concentrations obtained in the A) visual cortex and B) striatum. 
Fewer metabolites are reported for the striatum since they did not meet the quality control 
threshold unlike in the visual cortex. Asp: aspartate, Gln: glutamine, Glu: glutamate, GSH: 
glutathione, myo-Ins: myo-inositol, sIns: scyllo-inositol, Tau: taurine, tCho: total choline, tCr: 
total creatine, tNAA: total N-acetylaspartate. Error bars represent standard deviations. *p< 
0.05, #p< 0.01. 
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3.3 Perspective: Identifying biomarkers of dynamic energy metabolism 
(HDeNERGY) 
This project aims at measuring dynamic parameters of brain energy metabolism in order to 
decipher the mechanisms underlying brain energy deficit in HD and identify novel functional 
biomarkers to be used in clinical trials such as those targeting the Krebs cycle. This study 
seeks to recruit 20 patients at the early stage of HD, 20 presymptomatic individuals and 20 
healthy controls. Each subject’s participation in this study spans half a day. HDeNERGY is 
sponsored by APHP (ClinicalTrials.gov Identifier: NCT02639871). The project also 
comprises preclinical studies that are being conducted at MIRCen by Emmanuel Brouillet’s 
team in a rat model of HD. Besides the determination of the synthesis rate of phosphocreatine 
using saturation transfer 31P MRS in the BACHD rat, methodological breakthroughs at 
MIRCen includes evaluating the turnover of the Krebs cycle using 13C MRS, and the 
establishment of brain maps of pH and glutamate using chemical exchange saturation transfer. 
The clinical study was split into two phases; the first phase was the validation phase where 10 
healthy volunteers were recruited to setup and optimize the protocol. The second phase is the 
implementation of the optimized protocols in the subjects recruited for the study. Preliminary 
results from the 10 volunteers and 8 patients are presented. 
The MRS protocol includes several modalities to determine metabolic, functional and 
structural biomarkers of dynamic energy metabolism.  
 
3.3.1 
31
P magnetization transfer 
 31P MT is performed in the visual cortex as described in study 2a. Study 2a showed a trend of 
5% increase in CK in controls during visual stimulation contrary to patients. Hence we would 
like to determine the CK in a larger cohort of HD patients. CK rate calculations are made by 
assuming intrinsic T1 of PCr to be 5.03 (Du et al., 2014). A correction factor of 0.83 is applied 
assuming that steady-state intensity of PCr is not reached during γATP saturation (Chen et al., 
1997).  
Preliminary analysis of data has not yielded yet the expected results observed in study 2a. 
Here we observed a 4% increase in CK rate in controls compared to patients, but only at rest 
  80 
(p = 0.02). We did not find any differences during visual stimulation and recovery between 
the two groups. Unfortunately, the change of our MR system to Siemens Prisma, which 
occurred after the conduct of study 2a, led to a reduced field of view of the projected visual 
stimulation regardless of the different changes in stimulation setups that we performed. This 
might account for the no observable increase in CK in controls during visual stimulation. We 
are now pursuing the acquisition of data in patients, controls and premanifest individuals in 
order to reach 20 per group and see whether we can obtain similar results as reported in study 
2a, but with significant differences between controls and patients.  
  
Figure 18: Preliminary results of the rate of CK measured with 
31
P MT in the visual 
cortex of patients and controls. Controls had higher rate of CK at rest (4%) compared to 
patients (p = 0.02). No change was observed during visual stimulation and recovery phase. 
 
3.3.2 Diffusion weighted spectroscopy 
Diffusion imaging of brain water diffusion has been used over the years to detect indirect 
indicators of biological processes. DWS provides an alternate approach to directly probe 
cellular and extracellular compartments for their immediate link to biological events. By 
measuring the apparent diffusion coefficient (ADC) of certain metabolites, we can directly 
infer the level of activation of certain neurons, the microstructural properties of tissues and 
0 
0.1 
0.2 
0.3 
Controls Patients 
Rest Activation Recovery 
* 
  81 
the processes involved in particular disease processes such as inflammation or axonal damage 
(Branzoli et al., 2013; Ronen & Valette, 2015; Ercan et al., 2016). The principle of DWS is 
similar to that of DTI where diffusion sensitizing encoding gradients are coupled to the MRS 
protocol. Unlike water, metabolites are of very low concentrations and high b-values are 
needed to observe their diffusion properties. A series of alternating acquisitions of spectra 
with no diffusion gradient applied, and spectra with applied diffusion gradient, are acquired 
several times to improve the SNR. The metabolite peaks are attenuated in the presence of 
diffusion gradients. Due to this attenuation, reliable quantification can only be reported on the 
most prominent metabolites, i.e. total creatine (tCr), total N-acetylaspartate (tNAA) and total 
choline (tCho). 
In the HDeNERGY study, DWS is performed in the visual cortex (VOI = 25 x 25 x 25 mm3, 
b value = 0, 3550 s/mm2) and the corpus callosum (VOI = 8 x 15 x 32 mm3, parallel diffusion: 
b values = 0, 482, 772, 1737, 3088 s/mm2; perpendicular diffusion: b values = 0, 964, 1544, 
3474, 6176 s/mm2). We chose the visual cortex due to its reported altered metabolism in our 
31P MRS studies. The corpus callosum was chosen for its highly defined white matter 
structures and reported atrophy in some patients, as well as preclinical data showing altered 
glutamate concentrations (using CEST) in the corpus callosum of BACHD rats compared to 
wild types (team of E. Brouillet at MIRCen).  
We identified increased parallel and perpendicular diffusion of tCho in the corpus callosum, 
which may reflect increased gliosis. We found increased parallel diffusion of tCr, and a trend 
to increased perpendicular diffusion of tCr, in the corpus callosum of patients that may 
indicate an energetic compensatory mechanism. Perpendicular diffusion of tNAA was also 
significantly higher in patients than controls. Axonal damage could be an underlying reason 
for this increase (Ercan et al., 2016). We have not observed any differences yet in the visual 
cortex (Figure 19).  
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Figure 19: Preliminary results of DWS analysis. There was an increased parallel diffusion 
of tCho in patients (A) and increased perpendicular diffusion of tCho, tCr and tNAA in 
patients (B). No change was observed in the visual cortex (C). 
 
3.3.3 Resting state functional MRI (rsfMRI) 
RsfMRI has been included in this study to capture the impact of functional connectivity on 
neurometabolism and vice versa. RsfMRI relies on the blood oxygen level (BOLD) to 
determine regions of the brain that are activated during a resting state. The hemoglobin in 
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blood possesses different magnetic properties depending on whether it is oxygenated or 
deoxygenated (Pauling & Coryell, 1936). Oxygenated blood is diamagnetic, meaning it does 
not affect the MR signal. Meanwhile, deoxygenated blood is paramagnetic meaning that it 
introduces susceptibilities that cause dephasing of the nuclei spins leading to a decrease in the 
MR signal or darker images. Increase in neural activity leads to a high consumption of energy 
leading to an increase in deoxygenated blood. However, the increase in cerebral blood flow 
leads to a faster clearance of deoxygenated blood and hence increase in signal is observed. 
RsfMRI measures the brains spontaneous activity in the absence of external stimuli. At rest, 
low frequency fluctuations of the BOLD signal correlates with functional connections of 
different brain regions (Biswal et al., 1995). The advantage of rsfMRI over task related fMRI 
is that, rsfMRI can be used in all individuals, even patients who are physically incapable of 
performing certain tasks. Furthermore, network identification with rsfMRI has been shown to 
be reproducible over time except for the visual and sensorimotor networks that may be 
influenced by laboratory conditions such as the temperature in the examination room (Choe et 
al., 2015). Its reproducibility makes it a good biomarker in neurodegenerative diseases such as 
HD.  
Functional connectivity is a dynamic process and hence static correlation analysis that are 
currently used to analyze rsfMRI data are inadequate in capturing the full dynamic process of 
functional connectivity (Cole et al., 2010). The seed-based correlation analysis that was 
originally proposed (Biswal et al., 1995) is biased by the choice of seed region and size, and it 
under-represents the actual networks as it ignores other networks than the seed region being 
considered even when coupled with principal component analysis (Leonardi et al., 2013) or 
independent component analysis (Beckmann et al., 2005). This approach is also unable to 
distinguish spurious or indirect spatial correlations; that is, it is unable to tell if two nodes are 
directly correlated or their correlation is as a result of their individual correlations with a third 
node. To resolve this, partial correlation (Marrelec et al., 2006) has been proposed to account 
for spurious correlations where two nodes are considered to be linked only if their partial 
correlation in non-zero. Another problem that partial correlation fails to address is temporal 
correlations that exist in brain activity time series (Smith, 2012). Partial coherence methods 
(Salvador et al., 2005) have been used to address this issue. To extract biologically 
meaningful information, graph analysis methods (Achard et al., 2006) have been used to 
identify networks that reflect underlying anatomical connectivity. One major disadvantage of 
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these methods is that the number of components that are generated significantly influence the 
result and physiological noise components can contribute to the true neural components (Cole 
et al., 2010). More importantly, these methods rely on group analysis and do not allow 
individual network identification.   
Our collaborators at the Neuroscience Research Australia, Sydney, Australia (PI: Caroline 
Rae) have developed algorithm (Cassidy et al., 2015) that overcomes the problems of 
associated with current analytical methods. It uses autoregressive models coupled with 
frequency domain coherence to tackle the problem of temporal correlations. It incorporates 
partial coherence to solve spurious spatial correlation problems. In addition, it incorporates 
sparsity methods from statistical signal processing to avoid problems with artifacts and allow 
its use on datasets with poor quality. The algorithm has been shown to be robust at identifying 
functional networks with repeatable and reliable results even on individual subjects (Cassidy 
et al., 2015).  
In this study, we acquire high-resolution images (FOV = 204 x 204, TR = 1000 ms, TE = 30 
ms, flip angle = 74o, slice thickness = 3 mm isotropic, number of measurements = 600, 
acquisition time = 10 min) with the multiband accelerated EPI sequence (multiband 
acceleration factor = 3). The multiband acquisition scheme enables multiple slices to be 
acquired simultaneously, within the same time that it would take to acquire one slice using 
conventional schemes. Subjects are made to fix their eyes on a cross to prevent them from 
sleeping and they were instructed to refrain from moving, speaking or performing cognitive 
tasks as much as possible. After preprocessing the data that includes parcellation of 3D T1-
weighted volumetric brain image, motion and susceptibility correction of functional data, and 
co-registration of functional and volumetric images, the data is sent to our collaborators at the 
Neuroscience Research Australia, Sydney, Australia.  
Analysis of preliminary volunteer data shows that the data are of good quality and we are able 
to identify the networks (Figure 20). The main idea is not just detect the networks but perform 
statistical analysis to identify the differences between controls, patients and presymptomatic 
individuals. 
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Figure 20: Preliminary network analysis (rsfMRI) on volunteers data. 
 
3.3.4 Structural analysis 
Atrophy in presymptomatic individuals and patients will be determined by the BSI approach 
as previously explained. Furthermore, changes in white matter fibers will be evaluated using 
the fixel-based approach as detailed in study 6. In this study, however, we do not acquire 
diffusion data with only one b value.  We acquire diffusion data with multiple b values (multi-
shell) and we also utilize multiband acceleration (FOV = 208 x 208, TR = 2920 ms, TE = 71 
ms, slice thickness = 2 mm isotropic, flip angle = 90o, multiband acceleration factor = 3, b 
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values = 2500 s/mm2 (60 directions), 900 s/mm2 (32 directions) and 300 s/mm2 (8 
directions)). Acquisition of each b value is repeated but the directions are in the opposite 
phase to allow for susceptibility and distortion corrections. The use of multi-shell acquisition 
in diffusion imaging can often be time consuming. Still, this study benefits from the 
multiband acquisition scheme, which speeds up the acquisition protocol and thus we have a 
total acquisition time of 13 minutes. Furthermore, multi-shell acquisitions improve the SNR 
and contrast-to-noise ratio thereby improving the estimation of the fibers during tractography 
(Daianu et al., 2015). 
 
3.3.5 Protocol setup  
Setting up the protocol involved a lot of phantom tests and adjustment of several parameters. 
Especially with the change of MR system, the optimum flip angle for the BISTRO had to be 
recalibrated.   
With the help of an expert in DWS, Francesca Branzoli, we determined the maximum 
gradient strength and orientation of the VOI for the visual cortex and the corpus callosum. We 
also included a provision for patients who were likely to move during scans and cause the 
VOI to be shifted to a different region. Interleaving the scans with shot localizer sequences 
allowed us to readjust the VOI in case of significant movement.   
I acquire all datasets and perform quality control on all spectroscopy and imaging datasets to 
ensure reliable reporting of results. I perform the analyses of MT, DWS and diffusion 
datasets. After I preprocess rsfMRI datasets, they are then sent to Ben Cassidy from our 
collaborators team and he performs the identification of the functional networks. The 
networks are then sent back to me for statistical analysis and extraction of biologically 
meaningful connections.   
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Study 3: Standardization and optimization of 
1
H MRS protocol at 3T using 
short-echo, single-voxel semi-LASER protocol 
4.1 Introduction and objectives 
Vendor provided MR sequences – PRESS and STEAM – are mostly used for MR studies 
(Jissendi Tchofo & Baleriaux, 2009). Even in multi-centric trials, these sequences have been 
used at different field strengths to quantify and report few metabolites (Chard et al., 2002; 
Jessen et al., 2009). In MRS, short TE allows the quantification of several metabolites as J-
coupled spins such as Glu and glutamine (Gln) are easily detected. Additionally, STEAM 
sequences produce spectra with low spatial resolution whilst PRESS is prone to chemical shift 
artifacts.  
This study, sponsored by APHP (ClinicalTrials.gov Identifier: NCT01470729), sought to test 
the reproducibility of metabolite concentrations using the semi-LASER sequence which has 
twice the SNR of STEAM and is less prone to chemical shift artifacts. 
 
4.2 Materials and methods 
The study was carried out the Center for Magnetic Resonance Research (CMRR), Minnesota, 
USA and ICM, Paris, France. 24 healthy subjects from CMRR and 33 healthy subjects from 
ICM were recruited for the study. 1H MRS data were collected at 3T with the semi-LASER 
sequence (TR = 5000 ms, TE = 28 ms, averages = 64, vector size = 2048, acquisition time = 6 
min) in a 10 x 25 x 25 mm3 in the cerebellar vermis, 16 x 16 x 16 mm3 in the pons. Before 
spectra acquisition, the VOI were shimmed using FASTMAP. The RF power for the 90o 
asymmetric pulse and for water suppression were calibrated for each VOI. Outer volume 
suppression pulses were also included to eliminate contamination from other brain regions. 
Fully relaxed unsuppressed water signals were acquired at different TE values in order to 
determine the CSF contribution to the VOI. Two unsuppressed water signals were also 
acquired for eddy current correction and phase correction.  
Model basis sets were generated for spectra quantification with LCModel. Cramér-Rao lower 
bounds were used to estimate reliable metabolites to report. 
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4.3 Results 
Shimming in the pons proved to be a challenge in some instances. The semi-LASER sequence 
generated very good quality spectra with many metabolites. Using the same sequence and 
quantification procedures, we obtained similar neurochemical profiles in both control groups, 
which underlined the robustness of our method. 
 
4.5 Published article 
 
!
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NOTE
Two-Site Reproducibility of Cerebellar and Brainstem
Neurochemical Profiles With Short-Echo, Single-Voxel
MRS at 3T
Dinesh K. Deelchand,1* Isaac M. Adanyeguh,2 Uzay E. Emir,1 Tra-My Nguyen,2
Romain Valabregue,2,3,4 Pierre-Gilles Henry,1 Fanny Mochel,2,4,5,6 and G€ulin €Oz1
Purpose: To determine whether neurochemical concentrations
obtained at two MRI sites using clinical 3T scanners can be
pooled when a highly optimized, nonvendor short-echo, sin-
gle-voxel proton MRS pulse sequence is used in conjunction
with identical calibration and quantification procedures.
Methods: A modified semi-LASER sequence (TE ¼ 28 ms)
was used to acquire spectra from two brain regions (cerebellar
vermis and pons) on two Siemens 3T scanners using the same
B0 and B1 calibration protocols from two different cohorts of
healthy volunteers (N ¼ 24–33 per site) matched for age and
body mass index. Spectra were quantified with LCModel using
water scaling.
Results: The spectral quality was very consistent between
the two sites and allowed reliable quantification of at least 13
metabolites in the vermis and pons compared with 3–5
metabolites in prior multisite magnetic resonance spectros-
copy trials using vendor-provided sequences. The neuro-
chemical profiles were nearly identical at the two sites and
showed the feasibility to detect interindividual differences in
the healthy brain.
Conclusion: Highly reproducible neurochemical profiles can
be obtained on different clinical 3T scanners at different sites,
provided that the same, optimized acquisition and analysis
techniques are used. This will allow pooling of multisite data in
clinical studies, which is particularly critical for rare neurologi-
cal diseases. Magn Reson Med 73:1718–1725, 2015. VC 2014
Wiley Periodicals, Inc.
Key words: 3 Tesla; multi-site; reproducibility; spectroscopy
INTRODUCTION
Proton MR spectroscopy (1H MRS) is a noninvasive tool
that allows the measurement of a wide range of biochem-
ical compounds in the brain in both health and disease.
The method has been demonstrated to be valuable in the
evaluation of several common disorders of the central
nervous system, including tumors, neonatal hypoxia-
ischemia, inherited metabolic diseases, demyelinating
disorders, and infectious brain lesions (1). Because meta-
bolic alterations are thought to precede structural
changes, magnetic resonance spectroscopy (MRS) is
likely to provide dynamic biomarkers of neuronal dys-
function at an earlier stage of disease progression than
structural MRI. This is of even greater importance for
therapeutic approaches for which a neuroprotective
effect is expected. However, unlike structural MRI, MRS
has not gained widespread acceptance as a routine clini-
cal tool for diagnostic and prognostic purposes (2,3).
This is partially due to the relatively large variation in
metabolite concentrations or ratios reported from differ-
ent sites (4–9).
As higher magnetic fields are becoming routinely
available, the increased sensitivity and resolution they
provide can benefit metabolite quantification (10–12)
and facilitate robust clinical applications of the tech-
nique. However, with this potential, the need to stand-
ardize robust MRS acquisition and analysis methods is
critical, as also emphasized by the recent MRS Consen-
sus Group study (1). Such standardized MRS methodol-
ogy would allow pooling of data from multiple sites,
which is particularly important for clinical research and
clinical trials in rare diseases. Prior multisite MRS trials
primarily have used vendor-provided MRS sequences
(PRESS and STEAM) and were able to quantify 3–5
metabolites—such as N-acetylaspartate (NAA), total crea-
tine (tCr), total choline (tCho), and myo-inositol (Ins)—at
both 1.5T and 3T (6–9).
Recently, optimized short-echo sequences such as SPE-
CIAL (12) and semi-LASER (13) were implemented on
clinical platforms, thereby allowing an extended
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neurochemical profile consisting of both singlet and J-
coupled metabolites to be measured. Therefore, there is a
need to determine the between-site reproducibility of
such profiles.
The aim of the present study was to examine the repro-
ducibility of metabolite concentrations measured in two
brain regions using a short-echo, single-shot, full-
intensity sequence with identical experimental protocols
at two different sites on clinical 3T scanners. A previ-
ously described semi-LASER sequence (14) was used to
achieve lower apparent T2 relaxation, minimal J-coupling
evolution, and smaller chemical shift displacement errors
relative to the standard PRESS sequence. Two relatively
challenging brain regions were chosen for this two-site
comparison: the cerebellar vermis and pons (15).
METHODS
Two 3T whole-body Siemens Tim Trio (Siemens Medical
Solutions, Erlangen, Germany) scanners were used in
this study; one located at the Center for Magnetic Reso-
nance Research (CMRR) in Minnesota and the other one
at the Institut du Cerveau et de la Moelle (ICM) in Paris.
Healthy subjects who were matched for age and body
mass index (Table 1) were enrolled after giving informed
consent according to procedures approved by the Institu-
tional Review Board at CMRR and by the local ethics
committee at ICM. The standard body radiofrequency
(RF) coil was used for RF transmission, and the 32-
channel phased-array Siemens head coil was used for
signal reception. Soft pads were used to hold each sub-
ject’s head in place to minimize head movement in the
MR system. T1-weighted MPRAGE images (repetition
time [TR] ¼ 2530 ms; echo time [TE] ¼ 3.65 ms; flip
angle ¼ 7"; slice thickness ¼ 1 mm; 224 slices; field-of-
view ¼ 256 # 176 mm2; matrix size ¼ 256 # 256) were
acquired to position the volume-of-interest (VOI) for
MRS measurements. B0 shimming was achieved using an
adiabatic version of FAST(EST)MAP (16), which is avail-
able as a work-in-progress (WIP) package on the Siemens
system.
Proton spectra were acquired using a modified semi-
LASER sequence (TE ¼ 28 ms; TR ¼ 5 s; 64 averages)
(14) from two VOIs: the cerebellar vermis (10 # 25 # 25
mm3) and pons (16 # 16 # 16 mm3). Voxel placement
was based on anatomical landmarks. The fourth ventri-
cle, cervical spinal cord and the brainstem were used to
separate the cerebellum. The surfaces, lobes, lobules,
and fissures of the cerebellum were then used as land-
marks in positioning the voxel in the vermis. For pons
VOI placement, the midbrain, fourth ventricle, and
medulla were used as landmarks.
The semi-LASER sequence (14) used in this study is a
more compact version of the originally published semi-
LASER sequence (17). Briefly, the sequence consisted of
a 2-ms asymmetric slice-selective 90" pulse (18) followed
by two pairs of slice selective adiabatic full passage
pulses (4 ms duration, HS4 modulation, R25) (19), which
were interleaved, rather than applied sequentially, to
improve suppression of unwanted coherences with
shorter spoiler gradient pulses. Water suppression was
achieved with VAPOR, which was interleaved with outer
volume suppression (OVS) to suppress unwanted coher-
ences (18). A substantially lower chemical shift displace-
ment error is obtained with the semi-LASER sequence
(3.6% /ppm for the slice-selective 90" pulse and 2% /
ppm for the adiabatic full passage pulses) compared
with the standard PRESS sequence provided on the Sie-
mens platform (12%–13% /ppm).
B1 levels required for localization pulses and for water
suppression were adjusted for each voxel. Specifically,
the RF power magnitude for the 90" asymmetric pulse
was calibrated by monitoring the signal intensity while
increasing the RF power and choosing the RF power set-
ting that produced the maximum signal. The power for
the adiabatic full passage pulses was automatically set
relative to the 90" pulse. A similar procedure was per-
formed for the water suppression calibration.
On the scanner, signals from individual coil elements
were combined after correcting for phase shifts between
elements and weighting them based on the coil sensitiv-
ities (20) to generate a free induction decay. Each free
induction decay was then individually saved for shot-to-
shot frequency and phase correction before averaging.
Two nonsuppressed water spectra were acquired: one for
eddy current correction (the RF pulses of the VAPOR
scheme were turned off) and one for use as reference for
metabolite quantification (VAPOR and OVS schemes
turned off in order to eliminate magnetization transfer
effects). To evaluate the cerebrospinal fluid (CSF) contri-
bution to each VOI, fully relaxed unsuppressed water
signals were acquired at different TEs ranging from 28–
4000 ms (TR ¼ 15 s) with the entire VAPOR and OVS
scheme turned off (21).
All spectral processing was performed in MATLAB by
the same investigator prior to LCModel fitting. Eddy cur-
rent correction was performed first to correct for dis-
torted line shapes and zero-order phase. Individual shots
affected by subject motion (based on water suppression
Table 1
Demographics and Spectroscopic Parameters Measured in Two
Brain Regions
CMRR ICM Pa
Subjects scanned (N) 24 33
Sex (male/female) 13/11 15/18 0.52b
Age (years) 53 6 15 48 6 13 0.19
BMI (kg/m2) 26 6 6 25 6 4 0.47
Vermis n ¼ 24 n ¼ 33
Water linewidth (Hz) 8 6 1 7 6 1 0.06
T2 tissue water (ms) 80 6 8 80 6 7 0.93
CSF fraction (%) 11 6 5 9 6 4 0.04
SNR of NAAc 56 6 5 59 6 9 0.21
Pons n ¼ 16 n ¼ 23
Water linewidth (Hz) 8 6 1 8 6 1 0.57
T2 tissue water (ms) 67 6 4 68 6 2 0.34
CSF fraction (%) 1 6 1 2 6 2 0.16
SNR of NAAc 27 6 5 28 6 6 0.49
Values are presented as the mean 6 standard deviation.
aUnpaired, two-tailed Student’s t test except when noted
otherwise.
bChi-squared test.
cSNR was measured in the frequency domain (defined as peak
height divided by 2 times root mean square noise), and no apod-
ization functions were applied to the data.
Reproducibility of Neurochemical Profiles at 3T 1719
 92 
efficiency) were removed. Single-shot frequency correc-
tion was performed using a cross-correlation algorithm
and phase correction was performed using a least-square
fit algorithm. All steps were completely automated
except for the removal of free induction decays affected
by motion. Finally, the summed spectrum was refer-
enced based on NAA resonance at 2.01 ppm.
Spectra were then analyzed with LCModel (22) with
the water scaling option (version 6.3-0G). The model
basis set was generated based on density matrix formal-
ism as described previously (23). The basis set also
included macromolecule spectra, which were acquired
using an inversion-recovery technique in four healthy
subjects (total averages ¼ 928; TR ¼ 2.5 s; inversion time
¼ 0.75 s; VOI ¼ 15.6 mL; 5 ms duration HS5 inversion
pulse; occipital cortex). Due to the shorter T1 relaxation
time of the methylene protons of tCr at 3.93 ppm relative
to other metabolite protons (24), this resonance was pres-
ent in the metabolite-nulled macromolecule spectra and
was removed using a Hankel singular value decomposi-
tion algorithm in MATLAB. A 12.5-Hz Gaussian line
broadening was also applied to the macromolecule spec-
tra after incorporating a reference peak at 0 ppm (Sup-
porting Information). No baseline correction, zero-filling,
or apodization functions were applied to the in vivo data
prior to the analysis. LCModel fitting (Supporting Infor-
mation) was performed over the spectral range from 0.5
to 4.2 ppm.
Metabolite concentrations were determined after cor-
recting for tissue water content and CSF contributions in
the selected VOI using the water-scaling option in
LCModel. The transverse relaxation times (T2) of tissue
water and percent CSF contribution to the VOI were
obtained by fitting the integrals of the unsuppressed
water spectra acquired in each VOI at different TE values
with a biexponential fit (21), with the T2 of CSF fixed at
740 ms based on measurement of T2 of water in a small
voxel located in ventricles with the same semi-LASER
sequence (four healthy subjects; TR ¼ 15 s; VOI ¼ 0.125–
0.360 mL; 12 TE values ranging from 28 to 4000 ms), and
three free parameters: T2 of tissue water, amplitude of
tissue water, and amplitude of CSF water.
In order to obtain accurate metabolite concentrations,
corrections must be made for T2 relaxation of both water
and metabolites. In the case of semi-LASER, T2 relaxa-
tion is slowed due to the Carr-Purcell (CP) conditions,
and T2 values under CP conditions must be used for
quantification. For water, these values can be estimated
by correcting the free precession T2 value measured for
the tissue water signal at different echo times by a fixed
factor to account for CP effects. A previous study com-
pared water T2 values measured with LASER and CP-
LASER sequences at 4T and 7T (25). Extrapolating from
that study, we assumed that the T2 of water under CP
conditions is 1.5 " longer than the measured free preces-
sion T2 at 3T. Signal loss due to T2 relaxation of metabo-
lites was neglected, since the apparent T2 is sequence-
dependent. This assumption is justified by the fact that
metabolites have longer T2 such that correction factors
would be small at TE ¼ 28 ms. Nonetheless, this choice
will result in somewhat underestimated metabolite con-
centrations relative to the true concentrations in tissue.
A water content of 82% and 72% was used for the ver-
mis and pons, respectively (26,27).
Metabolites that were quantified with Cram!er-Rao
lower bounds (CRLB) #50% from at least half of the
spectra from a particular brain region were included in
the neurochemical profile. In addition, if the correlation
between two metabolites was very high (i.e., if the corre-
lation coefficient r was more negative than $0.7) in the
majority of the spectra from a region, then only their
sum was reported (e.g., tCr [creatine þ phosphocreatine]
and tCho [glycerophosphorylcholine þ phosphorylcho-
line]). If there was indication for pairwise correlation
with r from $0.5 to $0.7, then the concentration sum of
the pair was reported in addition to the individual
metabolites’ concentrations (e.g., NAA, NAAG and total
NAA [tNAA, NAA þ NAAG]), as recommended by the
LCModel manual (22). Moreover, spectra with the associ-
ated water reference linewidth greater than 10 Hz were
excluded due to trends observed in overestimating aspar-
tate and ascorbate and underestimating glutamate in
these spectra. Water linewidths >10 Hz only occurred
for spectra acquired from the pons region.
RESULTS
Using the modified semi-LASER sequence with identical
parameters and identical B0 and B1 calibration protocols
on two 3T scanners, consistently high quality 1H spectra
with comparable peak signal-to-noise ratio (SNR) were
obtained at both sites (Fig. 1A, Table 1). No noticeable
baseline distortions due to insufficient water suppression
or contamination by signals from outside the voxel, such
as out-of-phase lipids, were observed. The peak SNR in
the pons was lower than in the vermis due to the smaller
voxel size and lower sensitivity of the receive coil in this
particularly deep brain region. Examples of LCModel fits
obtained in both regions are illustrated in Figure 1B. No
obvious residual was observed around the 0.9 to 2 ppm
region, suggesting that the macromolecule spectrum
acquired from the occipital cortex is appropriate when
fitting spectra from vermis and pons. This finding is con-
sistent with a recent study (28), which showed that the
differences in macromolecule signal between gray and
white matter regions are relatively small and concluded
that a general macromolecule baseline provides suffi-
ciently accurate neurochemical profiles.
At CMRR, pons data were not collected from three
subjects due to poor B0 shimming in two cases and sub-
ject movement in one case and five spectra were rejected
due to the broad linewidth criteria. Similarly at ICM,
pons data from eight subjects were not acquired due to
poor shimming and two spectra were rejected due to
broad water linewidth. This was consistent with the
known challenges with shimming in the brainstem (29)
due to the presence of the sphenoid sinus. All spectra
from the vermis were used in the final results (Table 1).
Motion effects were minimal in this cohort of healthy
volunteers and only one single-shot in the vermis (out of
64) was excluded from the sum in one subject due to
motion.
No statistical differences were observed in the spectral
quality metrics (i.e., water peak linewidth and SNR), as
1720 Deelchand et al.
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well as tissue water T2 values between the two sites in both
brain regions (Table 1). CSF fraction was found to be
slightly higher in the vermis VOI from CMRR relative to
ICM (P ¼ 0.04). As expected, the T2 of tissue water in pons
was shorter compared with that in vermis consistent with
the fact that pons consists mainly of whitematter (30).
FIG. 1. a: Typical proton spectra obtained from the cerebellar vermis and pons in two different subjects at the two sites using semi-
LASER (TE ¼ 28 ms, TR ¼ 5 s, 64 averages) at 3T. The locations of the VOI are shown on the T1-weighted images. Spectra were proc-
essed with a 1-Hz exponential decay and 5-Hz Gaussian functions. Comparable spectral quality and pattern are apparent for each
region at both sites. b: LCModel fits of the spectra shown in panel A without any apodization functions. Top to bottom: the in vivo spec-
trum, the fit, the residual after subtracting the fit from the in vivo spectrum, and the baseline.
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Using the unsuppressed water signal as an internal
concentration reference and after correcting for T2 relaxa-
tion of water, tissue water and CSF contributions, the
concentrations of 17 metabolites were determined in the
vermis using the reliability criteria described in the
Methods. Due to lower SNR and higher cross-correlation
between metabolites in the pons compared with the ver-
mis (Supporting Information), 13 concentrations passed
the same criteria in the pons (Fig. 2).
The neurochemical profiles of the two brain regions
were nearly identical between the two sites (Fig. 2, Table
2). A comparison of the metabolite concentrations from
ICM and CMRR in each brain region (i.e., vermis and
pons) revealed no statistically significant difference
between the two sites via analysis of variance. Similarly,
no differences were observed in the metabolite quantifica-
tion precision (as determined by CRLB) between the sites
(Fig. 2), as expected based on the similar spectral quality
(Table 1). In the vermis, the mean CRLB for all singlets
(NAA, tNAA, tCr, and tCho), Ins, Glu, and Glc þ Tau was
less than 10% with the other metabolites having mean
CRLBs <35%. In the pons, NAA, tNAA, tCr, tCho, and
Ins were quantified with a mean CRLB <5%, with other
metabolites having mean CRLBs smaller than 35%.
When the relationship between the mean CRLB and
between-subject coefficients of variance (CV, mean and
standard deviation) was investigated for each brain
region and each site (Fig. 3), the CRLBs were consis-
tently lower than between-subject CV for the most reli-
ably quantified metabolites (CRLB <12%). For example,
FIG. 2. Mean metabolite concentrations (in mmol/g) and CRLB (in %) measured in the cerebellar vermis (n ¼ 24 at CMRR, n ¼ 33 at
ICM) and pons (n ¼ 16 at CMRR, n ¼ 23 at ICM) at the two sites. Error bars represent intersubject standard deviations. Asc, ascorbate;
Asp, aspartate; GABA, g-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; GSH, glutathione; Ins, myo-inositol; Lac,
lactate; NAAG, N-acetylaspartylglutamate; sIns, scyllo-inositol; Tau, taurine; tCho, total choline; tCr, total creatine; tNAA, total
N-acetylaspartate.
1722 Deelchand et al.
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the between-subject CVs for tCr, tNAA, tCho, NAA, and
Ins were in the range of 6%–12% in both the vermis
and pons, whereas their CRLBs were in the range of
2%–5%, indicating that the method has precision to
detect interindividual differences in these metabolites
in the healthy brain (Fig. 3, right). For other metabo-
lites, between-subject CVs and CRLBs were more com-
parable (metabolites that fall around the identity line in
Figure 3), indicating the measurement errors were com-
parable to or higher than physiological, interindividual
differences.
DISCUSSION
This study demonstrates that nearly identical neuro-
chemical profiles consisting of 13–17 metabolites are
obtained in two different brain regions in relatively large
healthy cohorts by different operators at two MR sites.
The acquisition of high-quality MRS data from the cere-
bellum and brainstem is particularly challenging due to
their caudal location in the head and broader intrinsic
linewidths relative to other cerebral VOI (14,15). We
were able to obtain high-quality MRS data in a dual-site
setting due the consistency of obtaining artifact-free
short TE spectra using an in-house developed and highly
optimized pulse sequence and identical B0 and B1
adjustment protocols.
The relative metabolite concentrations within and
between the two VOIs were consistent with previous pub-
lications (14,31–34). Note that the concentrations reported
are slightly underestimated relative to their true tissue val-
ues since the effects of T2 relaxation for metabolites were
not taken into account. This approach was chosen since
apparent T2s are pulse sequence-dependent (35), brain
region–dependent (24) (see also water T2s in Table 1), and
metabolite-dependent (36). While it is relatively straight-
forward to measure the water T2 in each VOI from all vol-
unteers, acquisition of region-specific T2s for all
metabolites in the reported profiles was both outside the
scope of this project and is not feasible in routine clinical
applications. Alternatively, a single correction factor could
be identified based on literature values for a different
pulse sequence; however, this would almost certainly be
inaccurate for most metabolites reported. Note, however,
that the systematic bias in metabolite concentrations
resulting from omission of the metabolite T2 correction is
inconsequential for multisite investigations provided that
the same assumptions are used in the analysis of all data.
Almost all multisite trials on clinical scanners so far
have only reported the concentrations or concentration
ratios of tNAA, tCr, tCho, and Ins (the latter only meas-
ured at short TE) using
1H spectra measured at short or
long echo-times (6–9). Although the TE of semi-LASER
used in this study is comparable to that of the vendor-
provided PRESS sequence (shortest TE of 30 ms), the
presence of the two pairs of 180! adiabatic pulses,
which act as a Carr-Purcell pulse train, helps to preserve
the J-modulation and signal intensity of metabolites
(37). As such, the semi-LASER sequence enabled the
Table 2
Mean 6 SD Metabolite Concentrations (in mmol/g) Measured in
the Cerebellar Vermis and Pons at the Two Sites
Metabolite
Vermis Pons
CMRR ICM CMRR ICM
tCr 10.1 6 0.7 9.9 6 1.1 5.1 6 0.3 5.1 6 0.6
tNAA 9.1 6 0.5 8.9 6 0.5 10.3 6 0.5 10.3 6 0.6
NAA 8.6 6 0.5 8.2 6 0.5 8.4 6 0.6 8.6 6 0.7
Ins 7.1 6 0.6 7.2 6 0.6 6.4 6 0.6 6.5 6 0.6
tCho 2.5 6 0.2 2.5 6 0.1 2.7 6 0.3 2.7 6 0.3
Glu 7.2 6 0.9 7.3 6 0.7 4.4 6 0.9 4.5 6 0.7
GlcþTau 4.5 6 0.5 4.8 6 0.8 1.9 6 0.5 2.3 6 0.6
GSH 1.6 6 0.3 1.7 6 0.3 0.9 6 0.2 1.0 6 0.2
sIns 0.5 6 0.2 0.4 6 0.2 0.5 6 0.2 0.5 6 0.2
Tau 2.4 6 0.4 2.5 6 0.4
Glc 2.1 6 0.6 2.4 6 0.7 1.5 6 0.5 1.6 6 0.6
Gln 2.5 6 0.6 2.5 6 0.6
Asc 2.0 6 0.5 1.8 6 0.4 2.0 6 0.5 1.7 6 0.3
Lac 1.0 6 0.3 0.8 6 0.4
Asp 2.3 6 0.4 2.2 6 0.5 2.1 6 0.4 2.2 6 0.5
GABA 1.8 6 0.5 1.7 6 0.6
NAAG 0.6 6 0.1 0.7 6 0.2 1.9 6 0.4 1.9 6 0.4
FIG. 3. Relationship between mean CRLB and between-subject CV for all metabolites reported in Figure 2: CV and CRLB #50% (left)
and zoomed CV and CRLB between 0 and 12.5% (right). The solid line represents the identity line.
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quantification of at least 13 metabolites in the pons and
vermis at each site, thereby showing the feasibility of
consistently measuring J-coupled metabolites in addition
to singlet metabolites between different sites.
Multisite trials utilizing 1H MRS have been challeng-
ing due to large variations in reported metabolite concen-
trations between sites, even within each site. In such
investigations the within-site CVs ranged between 2%
and 30% and between-site CVs were between 2% and
35% for singlet metabolites (5,6,9). These reproducibility
issues might be related to various factors such as the
quality of the raw spectral data, number of subjects stud-
ied, reference used for quantification, or the stability of
the MR scanner. On the other hand, multisite studies
that have used metabolite ratios (e.g., tNAA/tCr or
tNAA/tCho) have reported lower within-site CV of less
than 10% (38,39). Although quantifying ratios does not
require corrections for T2 and water content and there-
fore is easier, it does not provide a clear understanding
on how individual metabolites change under different
pathological conditions. For instance, tCr concentration,
which is generally used as an internal reference, was
reported to change in various neurological conditions
(40,41).
In the present study, we took the more challenging
approach of water scaling (also referred to as “absolute”
quantification). The within-site CV for singlet metabolite
concentrations was between 6% and 12% (Fig. 3), which
lies in the lower end of the CV range reported in prior
multisite investigations. Furthermore, the mean CRLBs,
which indicate quantification precision, were substan-
tially lower (3%–5%) than CVs for these metabolites,
indicating that the CV is dominated by between-subject
differences rather than measurement errors. This demon-
strates the feasibility of detecting interindividual differ-
ences in the healthy brain at high field, consistent with
our prior experience at 4T and 7T (11). Similarly, a
recent two-site 3T MRS imaging study using semi-
LASER reported mean CRLBs of !6% for tNAA, tCr,
tCho, and Ins in selected gray and white matter VOI in
the cerebrum and also demonstrated lower within-
subject variation in these metabolites than between-
subject variation (13). No between-site CVs are reported
in the present study, since different subjects were
scanned at each site. However, since the percent differ-
ence in metabolite concentrations between sites was very
small, the between-site CV is also expected to be low.
The semi-LASER sequence was developed and opti-
mized (i.e., spoiler gradients and OVS parameters) at
CMRR prior to the transfer to the ICM site. The only
requirements to successfully run the spectroscopy
sequence was to adjust the first- and second-order shims
using FAST(EST)MAP and to calibrate the RF power
required for the 90" and water suppression pulses. This
step was done in each study for each VOI location
because the standard slice-based voltage adjustment
done by the scanner once at the beginning of the scan-
ning session often under/overestimates the RF power
required in the selected VOI. The MRS data acquired
at the two sites using widely available commercial
hardware demonstrates that nonvendor, ready-to-use MRS
sequences can be shared among sites, generating highly
reproducible spectral quality. This is expected to facilitate
robust, multisite MRS trials where large numbers of data-
sets can be acquired in a relatively short time.
The main limitation of the current study was that the
reproducibility of neurochemical profiles was tested at
two sites using an MR scanner and hardware from the
same vendor. For more generalized conclusions, it is crit-
ical to investigate across-vendor reproducibility of neuro-
chemical profiles in larger multisite investigations. Such
efforts were reported recently in abstract form (42).
Another limitation was the need to manually initiate the
voxel-specific B1 calibrations; automating these steps as
done in standard vendor-provided packages is feasible
and will be important for seamless application in the
clinical environment.
CONCLUSION
This dual-site study shows that a wide range of metabo-
lites (singlet and J-coupled) can be quantified on clinical
3T scanners with highly reproducible neurochemical
profiles using an in-house developed and highly opti-
mized pulse sequence. These profiles can be pooled in
multisite investigations provided that the same acquisi-
tion and analysis techniques are used at all sites.
Furthermore, within each site, the between-subject
coefficients of variance for singlet resonances and myo-
inositol were substantially higher than their CRLBs, indi-
cating precision to detect interindividual differences in
the healthy brain.
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Study 4: Application of the validated 
1
H MRS protocol in SCAs  
5.1 Introduction and objectives 
Many of the published MRS studies in SCAs were performed on 1.5T MR systems. 
Currently, 3T systems are becoming widely available in many hospitals. High field MR 
systems have the advantage of increasing the SNR of the spectra and enhancing the resolution 
of J-coupled metabolites. Furthermore, most studies focused on only one SCA type due to the 
rarity of the diseases. In addition, none of these studies with the exception of (Oz et al., 2010) 
used a validated protocol that is robust and proven to have high reproducibility.  
In this BIOSCA study sponsored by APHP (ClinicalTrials.gov Identifier: NCT01470729), we 
sought to use the modified semi-LASER sequence to identify neurochemical changes in 
SCAs. 
 
5.2 Materials and methods 
This study was conducted in subjects with similar age, sex and BMI: 33 healthy controls, 16 
SCA1, 12 SCA2, 21 SCA3 and 12 SCA7 patients. Three-dimensional T1-weighted volumetric 
images (TR = 2530 ms, TE = 3.65 isotropic, field-of-view (FOV) = 256 x 240 mm
2) for spatial 
normalization and localization of brain volumes. The choice of performing spectroscopy on 
the vermis and pons is due to the prominent atrophy of these two regions in SCAs. The 
acquisition, calibration and quantification steps are as described in study 3. The CRLB 
threshold was set at 20% and spectra with water linewidth > 10 Hz were excluded from the 
analysis. 
 
5.4 Principal results 
We observed a decrease of the neuronal marker (NAA and Glu) and an increase of the glial 
marker (myo-Inositol; myo-Ins) and energetic marker (tCr). The increase in these metabolites 
may signify a compensatory mechanism in response to neuronal loss. Some neurochemicals 
correlated with the SARA score. Plotting the neurochemicals against each other allowed the 
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separation between patients with SCAs and controls. Principal component analysis was able 
to separate the metabolites and draw out the link between the significantly different 
neurometabolites and clinical parameters.  
 
5.5 Published article 
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In Vivo Neurometabolic Profiling in Patients With Spinocerebellar
Ataxia Types 1, 2, 3, and 7
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ABSTRACT: Spinocerebellar ataxias (SCAs)
belong to polyglutamine repeat disorders and are char-
acterized by a predominant atrophy of the cerebellum
and the pons. Proton magnetic resonance spectroscopy
(1H MRS) using an optimized semiadiabatic localization
by adiabatic selective refocusing (semi-LASER) protocol
was performed at 3 T to determine metabolite concen-
trations in the cerebellar vermis and pons of a cohort of
patients with SCA1 (n5 16), SCA2 (n512), SCA3
(n521), and SCA7 (n5 12) and healthy controls (n533).
Compared with controls, patients displayed lower total
N-acetylaspartate and, to a lesser extent, lower gluta-
mate, reflecting neuronal loss/dysfunction, whereas the
glial marker, myoinositol (myo-Ins), was elevated.
Patients also showed higher total creatine as reported in
Huntington’s disease, another polyglutamine repeat dis-
order. A strong correlation was found between the Scale
for the Assessment and Rating of Ataxia and the neuro-
metabolites in both affected regions of patients. Principal
component analyses confirmed that neuronal metabo-
lites (total N-acetylaspartate and glutamate) were inver-
sely correlated in the vermis and the pons to glial (myo-
Ins) and energetic (total creatine) metabolites, as well as
to disease severity (motor scales). Neurochemical plots
with selected metabolites also allowed the separation of
SCA2 and SCA3 from controls. The neurometabolic pro-
files detected in patients underlie cell-specific changes
in neuronal and astrocytic compartments that cannot be
assessed by other neuroimaging modalities. The inverse
correlation between metabolites from these two com-
partments suggests a metabolic attempt to compensate
for neuronal damage in SCAs. Because these bio-
markers reflect dynamic aspects of cellular metabolism,
they are good candidates for proof-of-concept therapeu-
tic trials. VC 2015 International Parkinson and Movement
Disorder Society
Key Words: spinocerebellar ataxia; biomarker;
movement disorders; NMR spectroscopy; neurochemi-
cal profile
Spinocerebellar ataxias (SCAs 1, 2, 3, 7) are poly-
glutamine repeat disorders inherited as an autosomal
dominant trait. The cerebellum and the brainstem are
mainly affected in SCAs,1 their atrophy being detecta-
ble several years before the predicted onset of motor
symptoms.2 Progressive ataxia is the prominent
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symptom of all SCAs. In SCA1, SCA2, SCA3, and
SCA7, ataxia is often accompanied by pyramidal
signs, sensory disturbances, muscle wasting, and brain-
stem oculomotor signs.3 Spinocerebellar ataxia 7 is
clearly distinguished from all other SCAs by the invar-
iable presence of pigmentary retinal dystrophy. Several
scales exist to assess disease state, but the Scale for the
Assessment and Rating of Ataxia (SARA) is the best
studied and validated so far.4 The SARA is, however,
of no use in presymptomatic individuals and is also
not able to identify subtle differences that can serve as
endpoints in future therapeutic trials.5 Because SCAs
are rare, studying a large cohort with adequate power
for clinical trials is a major hindrance.6 Magnetic reso-
nance spectroscopy (MRS) offers a non-ionizing and
noninvasive approach for quantitative information on
the relationship between metabolism and clinical func-
tion in patients with neurodegenerative diseases.7
Moreover, MRS allows the identification of in vivo
alterations in brain metabolite concentrations that are
likely to occur before brain atrophy8 and may be
amended by early therapeutic intervention.
Changes in brain metabolites in SCAs have been
previously studied with MRS but mainly on a 1.5-
Tesla MR system, with smaller cohorts, and none
included SCA7 patients.9-12 Most of these studies only
reported metabolite ratios, which complicate data
interpretation.13,14 A few MRS studies also have been
implemented on a 4-Tesla MR system but only in
SCA1, SCA2, and SCA6.15,16 Furthermore, 4-Tesla
systems are uncommon, and MRS data obtained in
patients with SCAs on clinical 3 Tesla scanners, such
as those now widely available in hospitals, are lacking.
In this context, the purpose of our study was to iden-
tify in vivo metabolic biomarkers in a large cohort of
patients with SCA1, SCA2, SCA3, and SCA7 on a 3-
Tesla MR system commonly used in hospitals.
Methods
Experimental procedures were approved by the local
ethics committee (AOM10094, CPP Ile de France VI,
Ref: 105-10). The MRS data were acquired on a 3-
Tesla whole-body Siemens Magnetom Trio scanner
(Siemens Medical Solutions, Erlangen, Germany). All
participants were older than 18 y and signed a written
informed consent before participating in the study.
Patients and Controls
We recruited 16 patients with SCA1, 12 patients
with SCA2, 21 patients with SCA3, and 12 patients
with SCA7 as part of the BIOSCA study
(NCT01470729). All patients underwent neurological
examinations. Thirty-three healthy volunteers with no
history of neurological diseases and with a median
age, sex, and body mass index (BMI) similar to the
patient groups were also recruited (Table 1). The
SARA was used to evaluate the severity of the cerebel-
lar ataxia.4 The scale ranges from 0 (no cerebellar
symptoms) to 40 (most severe cerebellar symptoms).
MR Protocol
A modified semiadiabatic localization by adiabatic
selective refocusing (semi-LASER) sequence was used
for 1H MRS.17 This sequence provides approximately
twice the signal-to-noise ratio (SNR) compared with the
stimulated-echo acquisition mode (STEAM) sequence,
is less prone to motion artifacts compared with the spin
echo full-intensity-acquired localization (SPECIAL)
sequence, and has the lowest chemical shift displace-
ment artefact.18 Three-dimensional T1-weighted volu-
metric images (TR5 2530 ms, TE5 3.65 ms, 1 mm
isotropic, field-of-view (FOV)5 256 3 176 mm2,
matrix size5256 3 256) were acquired for spatial
TABLE 1. Demographic and spectroscopic parameters of all subjects
Variable Control SCA1 SCA2 SCA3 SCA7
No of participants 33 16 12 21 12
Sex (M/F) 15/18 9/7 7/5 9/12 6/6
Age (y) 486 13 446 16 456 13 516 12 466 14
BMI (kg/m2) 256 4 246 6 266 5 246 4 236 3
SARA score 0.76 0.9 11.16 6.2c 12.66 6.0c 13.26 7.1c 9.26 7.2c
CAG length 476 7 406 3 696 6 426 5
Disease duration (y) 76 7 106 6 96 5 96 5
Lw vermis (Hz) 7.36 0.6 6.46 1.1a 5.66 1.1c 6.66 1.5a 6.76 1.2
Lw pons (Hz) 8.16 0.9 8.06 1.6 6.06 1.5c 7.66 1.1 7.76 0.8
SNR vermis 336 6 316 6 276 5b 316 4 296 4
SNR pons 216 3 196 3 166 3b 166 3c 186 4
% CSF vermis 96 4 206 8c 336 10c 226 8c 196 8c
% CSF pons 26 2 26 2 86 5c 36 2 26 1
SNR, signal-to-noise ratio; Lw, water linewidth; CSF, cerebrospinal fluid.
Data are presented as mean6SD and compared by 1-way ANOVA with Dunnett correction.
a
P< 0.05, represents significant difference between SCAs and controls.
b
P< 0.01.
c
P< 0.001.
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normalization and localization of brain volumes. Shim-
ming was performed on a 25 3 10 3 25 mm3 volume-
of-interest (VOI) in the vermis, and a 16 3 16 3
16 mm3 VOI in the pons, using a fast automatic shim-
ming technique with echo-planar signal trains using
mapping along projections, FAST(EST)MAP.19 The
radiofrequency (RF) power for the 90! asymmetric
pulse of the semi-LASER sequence and the variable
pulse power and optimized relaxation delays (VAPOR)
water suppression pulses were calibrated for each VOI.
The power for the 90! excitation pulse also served as
the basis for setting the power for the outer volume sup-
pression (OVS) pulses. A Siemens 32-channel head coil
was used to collect signals from the VOI in the vermis
and pons of participants using the semi-LASER
sequence (TR55000 ms, TE5 28 ms, Averages564).
The VAPOR water suppression pulses in combination
with three-dimensional OVS pulses allowed for
improved localization and water suppression perform-
ance. Two unsuppressed water spectra were acquired:
one for eddy current correction (the radiofrequency
pulses of the VAPOR scheme were turned off) and one
for use as reference for metabolite quantification
(VAPOR and OVS schemes turned off to eliminate
magnetization transfer effects). Unsuppressed water
spectra were also acquired at a series of TE values
(TE528 – 4000 ms; TR5 15,000 ms for full relaxation)
to evaluate the cerebrospinal fluid (CSF) contribution to
the VOI.20 The total acquisition time per voxel, includ-
ing power calibrations, metabolite spectrum acquisi-
tion, and water reference acquisition for quantification
and CSF evaluation, was approximately 20 min.
Metabolite Quantification
Spectral processing and metabolite quantification
were performed in the frequency domain using LCMo-
del21 as described previously.22 The model spectra
(basis set) were generated to include the following
metabolites: alanine, ascorbate, aspartate, creatine, g-
aminobutyric acid, glycerophosphorylcholine, phos-
phorylcholine, phosphocreatine (PCr), glucose, gluta-
mine, glutamate (Glu), glutathione (GSH), myoinositol
(myo-Ins), scyllo-inositol, lactate, N-acetylaspartate
(NAA), N-acetylaspartylglutamate (NAAG), phos-
phorylethanolamine (PE), taurine, and experimentally
measured macromolecules, as illustrated in Supple-
mental Data eFigure 1. Preprocessing steps included
shot-to-shot phase and frequency correction as well as
eddy-current compensation using the unsuppressed
water spectra acquired from the same VOI. Metabolite
concentrations were obtained using water as an inter-
nal concentration reference. Concentrations were cor-
rected for cerebrospinal fluid (CSF) content,
determined by fitting the integrals of the unsuppressed
water spectra at different TE values with a bi-
exponential fit.20 Tissue water content was assumed at
82% for vermis and 72% for pons.23,24 The T2 of
CSF was fixed at 740 ms based on experimental mea-
surement. The water signal at TE5 28 ms used as a
concentration reference was corrected for signal loss
caused by T2 relaxation. Because metabolites have
longer T2 than water, the loss of signal caused by T2
relaxation of metabolites at TE528 ms was
neglected.22 Tissue concentrations of glucose and lac-
tate were corrected for CSF contribution to the VOI
assuming 3.2 mM glucose and 1.8 mM lactate in
CSF.15 Only metabolites quantified with mean
Cram!er-Rao lower bounds (CRLB), which are esti-
mated errors of metabolite quantification, of 20% or
less are reported. The 20% CRLB threshold allows
the selection of the most reliably quantified metabo-
lites, as outlined by the LCModel manual and the
MRS Consensus Group.25,26 We calculated and
reported the average of all concentration values of
reliably quantified metabolites, including values with
high CRLB but excluding metabolites with
CRLB5 999%. Only the sum of metabolites was
reported if the correlation between two metabolites
was consistently high (correlation coefficient< –0.7) in
a given region (eg, total creatine, tCr5Cr1PCr).
Similarly, when the correlation coefficient was in the
range of 20.5 to 20.7, the sum of the two correlated
metabolites was reported in addition to the individual
metabolites (eg, NAA, NAAG, and tNAA5
NAA1NAAG). Spectra with water linewidth greater
than 10 Hz were excluded from data analysis.
Approximately 3 min were required for preprocessing
and quantification of each spectrum.
Statistical Analysis
Participant characteristics, spectral quality, and
metabolite concentrations—separately for the vermis
and the pons—were analyzed using analysis of var-
iance with a Dunnett multiple comparison test to com-
pare each SCA type with the controls. For each SCA
type separately, using those regions and metabolites
showing significant SCA versus control differences,
Pearson correlation was performed between the
metabolite and SARA score, CAG repeat length, and
disease duration; these P values were corrected for
multiple testing using the step-down Bonferroni proce-
dure,27 separately for pons and vermis. Using patient
data only, clinical characteristics and concentrations
of metabolites that were significantly different in
patients compared with controls were grouped into
two principal components using principal component
analysis (PCA). Principal component analysis was per-
formed to investigate the global interaction between
the selected metabolites and the clinical parameters
across patient groups using XLSTAT. In addition, the
metabolites that showed the largest differences
between patients and controls were plotted against
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each other to find ratios that could separate patient
groups from the control group. A partial least squares
discriminant analysis was also performed on the entire
set of metabolites to identify the variables with class
separation information using XLSTAT.
Results
Data Quality Control
Good quality spectra with a high SNR and excellent
resolution were consistently obtained from both con-
trols and patients. The SNR was 6% to 24% lower
and water linewidth 1 to 2 Hz narrower in some
patient groups than controls, likely because of the
higher CSF fraction in patients’ vermis and pons, espe-
cially in patients with SCA2 in whom cerebellar and
brainstem atrophy was the most severe and percent
CSF highest (Table 1). Pons data were rejected in one
patient with SCA1, one patient with SCA2, one
patient with SCA7, four patients with SCA3, and two
healthy control subjects because of broad water line-
width (>10 Hz). Alanine, aspartate, ascorbate, g-
aminobutyric acid, lactate, phosphorylcholine, and PE
did not meet the mean CRLB criterion of 20% or
greater in both the vermis and pons. In addition,
NAAG did not meet this criterion in the vermis,
whereas creatine, glucose, glutamine, GSH, PCr, and
taurine did not meet the criterion in the pons. Our
control data were also part of a two-site reproducibil-
ity study previously published in which the two partic-
ipating centers obtained consistent spectral quality and
similar neurochemical concentrations in controls by
using the same MRS pulse sequence (semi-LASER) in
conjunction with identical calibration and quantifica-
tion procedures.22
Neurochemical Alterations in Patients With
SCAs
In patients with SCAs, NAA and tNAA were signifi-
cantly lower than in controls in both the vermis and
the pons (Fig. 1). Glu was also significantly lower in
the vermis of patients with SCA3 and the pons of
patients with SCA2 and SCA3 (Fig. 1). Lower NAA, a
marker of neuronal loss/dysfunction, in the vermis and
the pons of patients was associated with significantly
higher concentrations of myo-Ins, a putative glial
marker, and tCr, a marker of energy metabolism (Fig.
1). Neurochemical alterations tended to be more pro-
nounced in patients with SCA2 and SCA3 (Fig. 1 and
Supplemental Data eFig. 2 and eFig. 3).
Correlation Between Disease Parameters and
Neurochemical Concentrations
A strong negative correlation was found between
SARA scores and tNAA in the vermis of patients with
SCA7 and in the pons of patients with SCA3 and
SCA7 (Fig. 2). Total creatine also strongly correlated
with SARA scores in the vermis of patients with SCA1
FIG. 1. Mean concentrations of metabolites that showed significant differences in the vermis and the pons of patients with SCA1, 2, 3, 7 versus
controls. P values represent Dunnett-corrected statistically significant differences between patients and controls differences (*P< 0.05; #P< 0.01;
†P< 0.001). Lower neuronal markers tNAA and Glu in patients are associated with higher glial marker myo-Ins and higher-energy marker tCr. Error
bars represent standard deviations (SDs). SCA, spinocerebellar ataxia; tNAA, N-acetylaspartate and N-acetylaspartylglutamate; Glu, glutamate; tCr,
creatine1phosphocreatine.
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and in the pons of patients with SCA3 (Fig. 2). Fur-
thermore, SARA scores correlated with myo-Ins in the
pons of patients with SCA3 (Fig. 2). However, CAG
repeat length and disease duration did not correlate
with the concentration of any neurochemical (Supple-
mental Data eTable).
Using patient data only, PCA was used for metabo-
lites with significant differences between patients and
controls—tNAA, myo-Ins, tCr, and Glu—as well as
for disease parameters of interest in SCAs—SARA,
CAG repeat length, and disease duration. The first
two principal components explained 57.18% and
FIG. 2. Correlation between clinical scores and neurochemical concentrations in the vermis and the pons of patients with SCAs. SARA scores corre-
lated with (A) tCr in SCA1 vermis, (B) tNAA in SCA7 vermis, (C) myo-Ins in SCA3 pons, (D) tCr in SCA3 pons, (E) tNAA in SCA3 pons, and (F) tNAA
in SCA7 pons. Metabolites that showed Dunnett significance when each SCA type was compared with controls were included in the correlation
analysis. P values of the correlations have been corrected for multiple testing with step-down Bonferroni method. SCA, spinocerebellar ataxia;
SARA, Scale for the Assessment and Rating of Ataxia; tCr, creatine1phosphocreatine; tNAA, N-acetylaspartate and N-acetylaspartylglutamate;
myo-Ins, myoinositol.
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63.94% of the variance in the vermis and the pons,
respectively (Fig. 3). Principal component analysis
separated the neuronal markers—tNAA and Glu—
from the glial (myo-Ins) and energetic markers (tCr)
in both vermis and pons (Fig. 3). Among the disease
parameters, PC1 further showed that the motor score
(SARA) was the only one inversely correlated with
the neuronal markers and correlated with the glial
and energetic markers in both vermis and pons (Fig.
3). Of note, PCA showed a negative correlation
between CAG repeat length and disease duration
(Fig. 3).
Separation Between Patients and Controls
Using Neurochemical Concentrations
The concentrations of metabolites that showed the
largest differences between patients and controls—
tNAA, tCr, myo-Ins, and Glu—were plotted against
each other to determine the separation between
patient and control groups. These neurochemical plots
demonstrated the separation of patients with SCA2
and SCA3 from controls in both vermis and pons (Fig.
4). However, we could not clearly separate patients
with SCA1 and SCA7 from controls (data not shown).
In addition, we used partial least squares discriminant
analysis to identify the variables with class separation
information, but we were unable to obtain a good sep-
aration between the different SCAs (data not shown).
Likewise, although MRS allowed discriminating meta-
bolic profiles from patients and controls as well as
correlating patients’ metabolic profile with clinical sta-
tus, it did not reveal metabolic profiles characteristic
of any of the SCA types.
Discussion
This is the first study reporting neurochemical profil-
ing on a large cohort of patients with SCAs (SCA 1,
2, 3, and 7), using a 3 Tesla clinical MR system. In
the vermis and the pons, patients displayed lower
NAA, a neuronal marker, higher myo-Ins, a glial
marker, and higher total Cr compared with controls.
Glu, another neuronal marker, was also lower in
patients’ vermis (SCA3) and pons (SCA2 and SCA3).
Our control data also have been part of a two-site
study to establish the reproducibility of our methods,
which underscores the robustness of our findings.22
Although the CRLB of 20% or less criterion is fairly
conservative, quantification of some metabolites such
as GSH from short-TE spectra still requires caution,
because their quantification may be sensitive to small
changes in the baseline, even with the excellent spec-
tral quality achieved in this study. However, all of the
main findings reported here focus on metabolites
(NAA, myo-Ins, tCr, Glu) that have the most promi-
nent resonances and are therefore visually apparent in
spectra.
The significant decrease in NAA and Glu observed
in patients with SCAs, likely reflecting neuronal loss/
dysfunction in those structures,1 is in agreement with
prior MRS studies in SCAs.28 We also observed the
decrease of NAA in the pons to be more substantial
than that in the vermis. This is similar to the observa-
tions in SCA1 studies15 and may be attributable to a
more pronounced pathological involvement and atro-
phy in the pons.29 Conversely, the increase in myo-
Ins, a six-carbon sugar that serves as an intermediate
in the metabolism of membrane and myelin phospholi-
pids,30 can indicate damage to myelin sheaths as a
result of neurodegeneration resulting in increased con-
centration of free myo-Ins. As a glial marker, the
increase in myo-Ins levels in response to neuronal loss
also may be an attempt to improve glial proliferation
to modulate vascular and metabolic activities and
FIG. 3. Principal component analysis (PCA) of metabolites of interest
and disease characteristics of patients with SCAs. The first two com-
ponents accounted for 57.4% and 64% variation in the vermis and
the pons, respectively. PCA was able to separate the neuronal
markers—tNAA and Glu—from the energetic marker (tCr), the glial
marker (myo-Ins) and the SARA score. SCA, spinocerebellar ataxia;
tNAA, N-acetylaspartate and N-acetylaspartylglutamate; Glu, gluta-
mate; tCr, creatine1phosphocreatine; myo-Ins, myoinositol; SARA,
Scale for the Assessment and Rating of Ataxia.
N E U R O M E T A B O L I C P R O F I L I N G
Movement Disorders, Vol. 30, No. 5, 2015 667
 107 
FIG. 4. Separation between patients with SCAs and controls by plotting the concentrations of neurochemicals against each other. The concentra-
tions of metabolites that showed significant differences in patients—tNAA, tCr, myo-Ins, and Glu—were plotted against each other to determine the
ratio that could separate subjects into patient and control groups, with almost no overlap. SCA2 has the best separation with at most one dataset
overlapping with controls. SCA, spinocerebellar ataxia; tNAA, N-acetylaspartate and N-acetylaspartylglutamate; Glu, glutamate; tCr, creatine1phos-
phocreatine; myo-Ins, myoinositol.
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therefore to compensate for neuronal loss.31 This pin-
points the important role of non-neuronal cells in
SCAs, especially astrocytes that play key roles in brain
homeostasis through their neurovascular and neuro-
metabolic coupling with neurons—ie, neurotransmitter
recycling and provision of energy substrates.32
Furthermore, we observed a significant increase in
tCr, an energetic marker often used in prior studies as
a concentration reference in MRS,29 in both the ver-
mis33 and the pons of patients. Because of the limited
ability of the brain to store glucose, the creatine
kinase/PCr system is important to keep up with the
high energy demands of neurons.34 Because mitochon-
drial creatine kinase activity suppresses formation of
free radicals within the mitochondria,35,36 the increase
in tCr might be an attempt to increase Cr levels to
suppress formation of free radicals and increase neuro-
protection. Changes in creatine and PCr have been
reported in Huntington’s disease (HD), another poly-
glutamine disease that shares pathophysiological com-
monalities with SCAs.37 Using microwave fixation
techniques, which instantaneously inactivate brain
enzymatic activities and preserve in vivo levels of
analytes, increased levels of creatine and PCr were
reported in HD mice brain. The increase of tCr pre-
ceded decreased adenosine triphosphate levels as
early as 4 weeks of age in presymptomatic mice.38
Similarly, increased tCr39 and significant changes in
[PCr]/[Cr] ratio40 have been reported in the brains of
HD mouse models at an early age using 1H MRS
techniques. Recently, we also described abnormal
ratios of inorganic phosphate/PCr using 31P MRS
during brain activation in patients with HD at an
early stage of the disease, confirming altered brain
bioenergetics in HD.41 Therefore, the increase of tCr
in patients with SCAs is comparable to the dysregula-
tion of the tCr pool that we observed in patients and
animal models with HD. Accordingly, determining
whether the above-mentioned mechanisms are acti-
vated at a presymptomatic stage of SCAs would be
interesting.
Higher disease severity, reflected by higher SARA
scores, was associated with lower tNAA concentration
and higher concentrations of myo-Ins and tCr in both
the vermis and the pons of several SCA types. More-
over, the PCA confirmed that neuronal metabolites
(tNAA and Glu) varied inversely in the vermis and the
pons to glial metabolites (myo-Ins), energetic metabo-
lites (tCr), and disease severity (SARA score) in
patients with SCAs. This inverse correlation suggests
that the metabolic attempt to compensate for neuronal
damage is critical to SCAs’ pathophysiology, even
more as the metabolic changes are associated with dis-
ease severity scores. The absence of correlations
between neurochemical concentrations and CAG
repeat length or disease duration may be partly
explained by the limited dynamic range in CAG and
duration.
Using neurochemical plots with our metabolites of
interest (tNAA, myo-Ins, tCr, and Glu), we were able
to separate patients with SCA2 and SCA3 from con-
trols but not SCA1, unlike what was previously
reported.15 Moreover, metabolic profiles could not
discriminate the different SCAs from one another.
Altogether, this study indicates that, rather than pro-
viding subtype-specific information about SCAs, MRS
has the potential to unravel early metabolic/cellular
changes in various SCAs, which are likely to occur
before brain atrophy. Neurometabolic profiles also
provide cell-specific information on neurons and astro-
cytes, which cannot be assessed in vivo by other neu-
roimaging modalities. Because these biomarkers reflect
dynamic aspects of cellular metabolism and mirror
disease severity, they also may be of special interest to
establish proof-of-concepts for drugs before the evalu-
ation of clinical outcome measures in phase III thera-
peutic trials. Our previous report of highly
reproducible data in controls in a two-site study sup-
ports the claim that these biomarkers can be used in
multicentric trials.22
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Alterations in neurochemicals in localized proton MR spectra obtained from healthy controls and patients. Arrows show increase or decrease in metabolites in 
patient brain compared to control. Ala, Asp, Asc, GABA, Lac, PCho and PE did not meet the mean CRLB criterion of ≤ 20% in both the vermis and pons. In 
addition, NAAG did not meet this criterion in the vermis, whilst Cr, Glc, Gln, GSH, PCr and Tau did not meet the criterion in the pons A: Proton spectra were 
obtained in the vermis of subjects using semi-LASER sequence (TE = 28 ms, TR = 5 s, 64 averages) at 3 T. Alterations are pronounced in the vermis of 
patients with SCA compared to healthy controls. B: Proton spectra obtained in the pons of subjects using semi-LASER sequence (TE = 28 ms, TR = 5 s, 64 
averages) at 3 T. Changes in neurochemicals are evident in the pons of patients with SCA compared to controls.  
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!
Neurochemical profiles in controls and patients with SCA at 3 T. A: Mean metabolite concentrations (µmol/g) measured in the vermis of healthy controls (n = 
33) and patients with SCA (SCA1, n = 16; SCA2, n = 12; SCA3, n = 21; SCA7, n = 12). B: Mean metabolite concentrations (µmol/g) measured in the pons of 
healthy controls (n = 23) and patients with SCA (SCA1, n = 10; SCA2, n = 8; SCA3, n = 14; SCA7, n = 10). p values represent Dunnett-corrected statistically 
significant differences between patients and controls (* p < 0.05; # p < 0.01; † p < 0.001). Error bars represent standard deviations (SDs).
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Supplementary eTable: Correlations of metabolites in the vermis and pons of each SCA type with SARA score, CAG repeat 
length and disease duration (DD) 
Region Group Variable SARA_corr Raw_p Holm_p CAG_corr Raw_P Holm_P DD_corr Raw_P Holm_p 
VERMIS SCA1 myo-Ins 0.254 0.342 0.683 0.339 0.199 0.597 -0.110 0.708 1.000 
 SCA1 tCr 0.639 0.008 0.023 0.313 0.238 0.597 0.227 0.435 1.000 
 SCA1 tNAA -0.113 0.677 0.683 -0.271 0.309 0.597 0.011 0.971 1.000 
 SCA2 GSH 0.422 0.172 0.780 0.341 0.278 0.690 0.177 0.582 1.000 
 SCA2 myo-Ins 0.336 0.285 0.780 0.547 0.066 0.330 0.122 0.706 1.000 
 SCA2 Tau 0.365 0.245 0.780 0.509 0.091 0.364 0.169 0.599 1.000 
 SCA2 tCr 0.189 0.557 1.000 -0.118 0.715 0.715 0.316 0.317 1.000 
 SCA2 tNAA -0.437 0.156 0.780 -0.375 0.230 0.690 0.065 0.842 1.000 
 SCA3 Glu -0.390 0.08 0.160 -0.064 0.801 1.000 -0.182 0.443 0.886 
 SCA3 myo-Ins 0.482 0.027 0.135 -0.231 0.356 1.000 0.362 0.117 0.468 
 SCA3 Tau 0.461 0.036 0.144 -0.159 0.529 1.000 0.544 0.013 0.065 
 SCA3 tCr 0.455 0.038 0.144 -0.158 0.532 1.000 0.259 0.269 0.807 
 SCA3 tNAA -0.356 0.114 0.160 0.156 0.536 1.000 -0.056 0.813 0.886 
 SCA7 Gln 0.454 0.138 0.138 -0.066 0.838 0.838 -0.214 0.552 0.552 
 SCA7 tNAA -0.668 0.0175 0.035 -0.412 0.183 0.366 -0.416 0.231 0.462 
PONS SCA1 tCr 0.603 0.065 0.130 -0.265 0.459 0.918 0.529 0.178 0.356 
 SCA1 tNAA -0.436 0.208 0.208 -0.094 0.796 0.918 -0.319 0.442 0.442 
 SCA2 Glu -0.701 0.053 0.212 -0.491 0.216 0.471 -0.090 0.832 1.000 
 SCA2 Ins 0.383 0.349 1.000 0.796 0.018 0.090 -0.165 0.696 1.000 
 SCA2 tCho 0.206 0.624 1.000 -0.550 0.157 0.471 0.335 0.417 1.000 
 SCA2 tCr -0.077 0.856 1.000 0.301 0.469 0.471 -0.317 0.444 1.000 
 SCA2 tNAA -0.802 0.017 0.083 -0.607 0.110 0.440 -0.201 0.633 1.000 
 SCA3 Glu -0.263 0.365 0.365 0.081 0.784 1.000 -0.379 0.202 1.000 
 SCA3 myo-Ins 0.685 0.007 0.021 -0.178 0.542 1.000 0.277 0.360 1.000 
 SCA3 tCr 0.644 0.013 0.026 -0.320 0.265 0.795 0.119 0.699 1.000 
 SCA3 tNAA -0.817 <0.001 0.002 0.368 0.195 0.780 -0.278 0.358 1.000 
 SCA7 tNAA -0.791 0.007 0.007 -0.272 0.447 0.447 -0.468 0.242 0.484 
ANOVA was used to compare each SCA type to control group and adjusted for multiple comparison with Dunnett correction. Only SCA types that were 
Dunnett significant from controls were included in the correlation analysis.  The correlation is presented under SARA_corr, CAG_corr and DD_corr. The 
uncorrected p value and the Holm corrected p value are presented under Raw_p and Holm_p respectively.  
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Study 5: Autosomal dominant ataxia: identification of imaging biomarkers 
with high effect size 
6.1 Introduction and objectives 
Currently, the most common clinical scores for rating disease severity in patients with SCA 
are the Scale for the Assessment and Rating of Ataxia (SARA) (Schmitz-Hübsch et al., 2006) 
and the Composite Cerebellar Functional Severity Score (CCFS) (du Montcel et al., 2008). 
However, in therapeutic trials of very rare disorders like SCAs, the low effect sizes of clinical 
scores would likely require a large number of patients making these trials hardly feasible. 
Clinical scores are not able either to detect macro- and microstructural changes such as 
atrophy and metabolic alterations that may occur before, during and after symptoms onset. 
Another important caveat of clinical scales is that, by definition, they cannot be used to 
evaluate premanifest individuals. Hence, there is a need for biomarkers with effect sizes 
greater than clinical scores that can be used on small sample sizes of patients with SCA. 
Magnetic resonance imaging (MRI) techniques provide a unique way to probe changes 
occurring before symptoms onset and were shown in Huntington disease, another 
polyglutamine repeat disorder, to be more sensitive than any motor or cognitive task to track 
disease progression once symptoms have developed (Tabrizi et al., 2012; Tabrizi et al., 2013). 
Still, most of the volumetric studies performed in SCAs (Yamada et al., 2008; Durr, 2010; 
Schulz et al., 2010; Rüb et al., 2013) have not investigated the rate of atrophy over time. 
Other imaging studies in SCAs have looked at the brain diffusion properties, which give 
information on the microstructural changes related to the disease (Della Nave et al., 2004; 
Guerrini et al., 2004; Mandelli et al., 2007; Prakash et al., 2009; Alcauter et al., 2011; 
Guimarães et al., 2013; Kang et al., 2014; Hernandez-Castillo et al., 2015; Mascalchi et al., 
2015; Rozenfeld et al., 2015; Hernandez-Castillo et al., 2016; Yoo & Oh, 2017),. 
Unfortunately, most of these studies only reported diffusion metrics such as fractional 
anisotropy (FA) that is not able to account for different fiber populations within a voxel.  
This study was a follow-up of study 4. In this study (ClinicalTrials.gov Identifier: 
NCT01470729), we focused on imaging biomarkers of SCA. We compared manual and 
automatic segmentation of brain volume for their effectiveness to capture atrophy in a unique 
cohort of patients with SCA1, SCA2, SCA3 and SCA7. Furthermore, we investigated white 
matter microstructural changes in SCA using, not only conventional diffusion tensor imaging 
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(DTI) metrics – FA and radial diffusivity (RD) –, but also a novel tractography method to 
determine differences in the fiber density (FD) and fiber cross-section (FC) called whole brain 
fixel (i.e. specific fiber population in a voxel) based analysis (FBA) (Raffelt et al., 2012b; 
Raffelt et al., 2015; Raffelt et al., 2017). Likewise, we looked at the correlation between 
clinical scores, atrophy, DTI and FBA metrics. 
 
6.2 Materials and methods 
The local ethics committee (AOM10094, CPP Ile de France VI, Ref: 105-10) approved the 
study. All participants were over 18 years and signed a written informed consent after the 
experimental procedure was fully explained before they participated in the study. In addition, 
participants had to have the ability to undergo an MRI. MRI acquisitions were performed on a 
3 T whole-body Siemens MAGNETOM Trio scanner (Siemens Medical Solutions, Erlangen, 
Germany). The MRI system was upgraded during the study period and hence twelve datasets 
were acquired on a 3 T whole-body Siemens MAGNETOM Prisma scanner (Siemens 
Medical Solutions, Erlangen, Germany).  
 
6.2.1 Participants 
Participants were recruited as part of the BIOSCA study (NCT01470729) and only those who 
could perform MRI and complete the follow-up imaging protocol were reported. Despite the 
scarcity of SCAs, we were able to enroll a large cohort of patients so that the pooled dataset 
included 15 patients with SCA1, 12 patients with SCA2, 20 patients with SCA3 and 10 
patients with SCA7. Twenty-four healthy individuals of similar general characteristics – 
median age, sex and BMI – were also included (Table 2). Ataxia severity was evaluated with 
the SARA score, which ranges from 0 (no cerebellar symptoms) to 40 (most severe cerebellar 
symptoms) (Schmitz-Hübsch et al., 2006), and the CCFS, a composite score obtained from a 
nine-hole pegboard test and a click test (du Montcel et al., 2008). 
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6.2.2 Imaging protocol 
The Siemens volume-transmit 32-receive coil array was used for the imaging protocol. 3D 
T1-weighted volumetric images (TR = 2530 ms, TE = 3.65 ms, slice thickness = 1 mm 
isotropic, field of view (FOV) = 256 x 256 mm2, matrix = 256 x 256) were acquired for 
volumetric analyses of brain regions of interest. Images were inspected immediately after 
acquisition and those with motion artifacts were reacquired immediately. Each participant had 
two time points of acquisition at baseline and at 24 months in order to evaluate the rate of 
atrophy.  
Due to method development, diffusion imaging was only performed at 24-month. DTI data 
were acquired along 60 isotropic directions with echo-planar spin-echo sequence (TR = 10000 
ms, TE = 89 ms, slice thickness = 2 mm isotropic, FOV = 220 x 220 mm
2, matrix = 110 x 110, 
flip angle = 90o, 34 reference lines, b value = 1500 s/mm2). The directions were interleaved 
with five non-diffusion weighted reference images (b0 images, b value = 0 s/mm2) at every 12 
directions. Another b0 image with opposite phase-encode blip was acquired. The b0 images 
were used for correcting motions, eddy currents geometric distortions, and susceptibility-
induced off-resonance field distortions. 
 
6.2.3 Volumetric analysis 
The 3D T1-weighted volumetric images were processed to evaluate the rate of atrophy. The 
images were first manually segmented by hand using ITK-SNAP (Yushkevich et al., 2006). 
Manual segmentation was performed because it remains the gold standard. It is however time 
consuming and very laborious. Hence, it was performed only on the cerebellar vermis that is 
the region mostly affected in this pathology, and a region from which neurometabolic findings 
were previously reported (Oz et al., 2010; Adanyeguh et al., 2015). The images were first 
linearly aligned along the midline using the FMRIB's Linear Image Registration Tool 
(Jenkinson et al., 2002). The mid-sagittal slice was located and, starting from the apex of the 
fourth ventricle, the vermis lobules (Courchesne et al., 1988) were delineated whilst 
excluding the cerebellar tonsils. This was repeated on eight more slices – four slices each to 
the right and left of the mid-sagittal slice. The number of slices was limited to nine due to the 
poor contrast in the subsequent slices when the vermis could not be clearly separated from the 
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tonsils and the cerebellar hemispheres. In order to limit bias, only one rater performed the 
delineation to extract the volume of the cerebellar vermis. The volume was normalized to the 
total intracranial volume estimated from the next step. 
Freesurfer version 5.3 was used to automatically segment the brain including the subcortical 
structures (Fischl et al., 2002). Segmentation of the pons was based on probabilistic atlas and 
Bayesian inference approach (Iglesias et al., 2015) implemented in Freesurfer version 6. The 
segmented images were visually inspected to detect segmentation errors and the need for 
manual editing. The segmentation process was however very good and there was no need for 
manual correction.  
 
6.2.4 Rate of atrophy 
The volumes of the cerebellum and the pons estimated from automatic segmentation and 
normalized to the intracranial volume were used to evaluate the rate of atrophy. The two 
regions were chosen because they are primarily affected in SCAs (Yamada et al., 2008). 
Atrophy was calculated as the percentage change relative to baseline and normalized by the 
duration (time between visits in months) as represented in the equation below (Reetz et al., 
2013).  
!"#$!!"!!"#$%ℎ! =
!"##"$%&!!"#$% − !"#$%&'$!!"#$%
!"#$%&'$!!"#$%
!"#"$!!"#$%&'(!(!"#$ℎ!)
 
 
6.2.5 Diffusion tensor imaging 
The DTI datasets were visually inspected for head movements, missing volumes and spike 
noise. Data with extensive artifacts were excluded from the analyses. The diffusion data were 
also denoised (Veraart et al., 2016a; Veraart et al., 2016b) to improve the signal to noise ratio 
(SNR). Tools available in FMRIB Software Library (FSL) version 5.0.8 
(http://www.fmrib.ox.ac.uk) were used for processing the data. The FSL brain extraction tool 
(BET) (Smith, 2002) was used to strip the skull and create a DTI mask. Eddy current 
correction was performed to correct for motion and geometric distortions.  A combination of 
topup (Andersson et al., 2003; Smith et al., 2004) and eddy (Andersson & Sotiropoulos, 2016) 
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were applied to achieve optimal eddy current and motion correction as well as susceptibility-
induced off-resonance field distortion correction. The diffusion tensor model was then fitted 
to generate diffusion metrics such as FA and RD. FA indicates fiber integrity and decreased 
FA usually reflects reduced fiber bundle. RD represents diffusion across the fibers and 
increased RD often correlates with changes in axonal diameter, demyelination or myelin 
injury. Tract based spatial statistics with threshold-free cluster enhancement (Smith et al., 
2006) were performed on the diffusion metrics – FA and RD – to compare the SCA groups 
with controls using FSL randomise (Winkler et al., 2014) at p < 0.05. FSL randomise was also 
used to evaluate the correlation between FA and cerebellar and pontine atrophy. All statistical 
tests with FSL randomise were performed with 5000 permutations and family-wise error 
correction of significance at p < 0.05. 
 
6.2.6 Tractography - Fixel based analysis 
Tractography, also known as fiber tracking, provides a way to extract complex white matter 
pathways, which otherwise are underestimated using the diffusion tensor model. Though the 
DTI model is widely used, it is limited in its ability to distinguish between different fiber 
populations within a voxel (Alexander et al., 2001; Alexander et al., 2002). In this study, we 
reported whole brain statistical analysis on specific fiber populations in a voxel known as 
fixel (Raffelt et al., 2015; Raffelt et al., 2017). The processing steps have previously been 
fully detailed (Raffelt et al., 2012b; Raffelt et al., 2015; Raffelt et al., 2017) and were 
performed using the MRtrix software version 0.3.15. The diffusion data were denoised 
(Veraart et al., 2016a; Veraart et al., 2016b) to improve the SNR and upsampled by a factor of 
2 to improve the contrast. FSL BET (Smith, 2002) was used to create the brain mask since the 
mask creation process suggested by MRtrix left holes in the mask, which affected subsequent 
steps. Motion artifacts, eddy current and susceptibility-induced off-resonance field distortion 
were corrected with FSL tools as described. The data were then corrected for field 
inhomogeneity (Tustison et al., 2010) and the image intensity was normalized across all 
subjects. The constrained spherical deconvolution (CSD) approach that accounts for non-
white matter tissue composition (Dhollander et al., 2016) was used to estimate the fiber 
orientation distribution (FOD) (Jeurissen et al., 2014) from the averaged response function of 
all subjects. An equal number of controls (n = 20) and SCA patients (n = 20) was used to 
generate a population template for the FOD to which all subjects’ FOD was registered 
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(Raffelt et al., 2011; Raffelt et al., 2012a). The FODs in the template space were segmented to 
estimate FD, FC and a combination of both, FDC (Raffelt et al., 2017). FD relates to the 
volume of the intra-axonal compartment for a specific fiber population (fixel) whilst FC refers 
to the volume perpendicular to the fiber bundle. Following the recommendations from the 
MRtrix manual, whole brain tractogram (Tournier et al., 2010) of the template image was 
generated with 20 million tracts after which it was filtered to 2 million tracts to reduce biases 
and generate an anatomically meaningful tractogram (Smith et al., 2013). The connectivity-
based fixel enhancement (Raffelt et al., 2015) was used to perform statistical analysis between 
the SCA groups and controls on FD, FC and FDC with 5000 permutations and family-wise 
error corrected significance at p < 0.05. For each SCA group, a mask was created from 
regions that showed significant differences in FDC and this was used to extract the fixel 
values that were then used for correlation analysis with clinical parameters and the rate of 
atrophy. 
 
6.2.7 Statistical analysis 
The effect size for clinical scores, manual segmentation and automatic segmentation by 
Freesurfer was calculated as the mean change to the standard deviation of the change (Reetz 
et al., 2013).  
!""#$%!!"#$ = !
!"##"$%&!!"#$% − !"#$%&'$!!"#$%
!"#$%&'$!!"#$%
!"#"$!!"#$%&'(!(!"#$ℎ!)
!"(!ℎ!"#$!!"!!"#$%)
 
Where SD represents standard deviation.  
Since diffusion and tractography metrics were measured at one time point, the effect size for 
FA and FDC were calculated between the SCA groups and the controls using Cohen’s d 
represented in the following equation (Cohen, 1988): 
! = !
!! − !!!
!"
!
!
+ !!"
!
! /2
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where M1 = mean value for controls, M2 = mean value for a specific SCA, SD1 = standard 
deviation of controls and SD2 = standard deviation of the specific SCA group.   
The scale for the effect size was set at 0.2, 0.5, 0.8, 1.2 and 2.0 as small, medium, large, very 
large and huge changes, respectively (Cohen, 1988; Sawilowsky, 2009). 
Within group difference in clinical parameters between baseline and follow-up were evaluated 
with paired t-test. One way ANOVA with Bonferroni multiple test correction was used to 
determine between group differences of clinical parameters at each time point. The rate of 
atrophy was evaluated with ANOVA and when significant, Dunnett test was performed to 
correct for multiple comparison between each SCA group and the control group. For each 
SCA group separately, Pearson correlation was performed between FDC values, the rate of 
atrophy and clinical parameters with the step-down Bonferroni multiple correction approach 
(Holm, 1979); p values of < 0.05 were considered significant. 
 
6.3 Results 
6.3.1 Clinical score 
Patients with SCA showed decreased motor performance abilities with increased SARA 
scores and CCFS after 24 months (Figure 21). There was no difference, though, in the SARA 
scores and CCFS across the SCA groups at baseline and after 24 months.  
 
6.3.2 Volumetric analysis 
Manual segmentation only focused on the vermis and no change in volume was observed after 
24 months except in SCA7 (Figure 22a). However, automatic segmentation with Freesurfer 
showed decreased cerebellar and pontine volume after 24 months in all SCA groups, and even 
among healthy controls  (p < 0.05) (Figure 22b and 22c). With its sensitivity to change over 
time, the rate of atrophy performed on the values obtained from Freesurfer segmentation 
showed a faster rate of atrophy in patients with SCA compared to controls in both the 
cerebellum and the pons (p < 0.05) (Figure 23). 
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6.3.3 Diffusion tensor imaging 
Diffusion data were not acquired for 2 patients with SCA1, 2 patients with SCA3, 3 patients 
with SCA7 and 2 healthy controls. Datasets that did not meet the quality control criteria and 
had to be rejected for one patient with SCA1, 2 patients with SCA2, 2 patients with SCA3 and 
one healthy control. All SCA groups displayed decreased FA compared to controls, except for 
patients with SCA7 (Figure 24a). Additionally, RD was increased across all SCA groups 
compared to controls (p < 0.05) (Figure 24b). Most of the changes in diffusion metrics were 
localized to the cerebellar and cerebral peduncles, as well as the pontine crossing tracts. 
However, the corticospinal tract (CST), corona radiata and internal capsule were also affected 
in patients with SCA1 and SCA2. Furthermore, the corpus callosum was altered in patients 
with SCA2. Of note, atrophy in the cerebellum and the pons correlated with FA in patients 
with SCA1 (Figure 24c and 24d).  
 
6.3.4 Fixel Based Analysis 
The preprocessing steps yielded improved SNR and contrast in the datasets (Figure 25). A 
visual inspecting the FODs already shows some differences between controls and SCAs, with 
controls having more fiber distributions in the CST than SCAs (Figure 26). Using the 
template fixel mask and template tractogram and performing connectivity-based fixel 
enhancement statistics on the subject groups revealed decreased FD, FC and FDC in the CST 
of all SCA patients compared to controls (p < 0.05). A significant decrease of FD was also 
observed in the corpus callosum of SCA7 patients (p < 0.05) (Figure 27). FDC correlated with 
the SARA score and CCFS in patients with SCA1 and SCA3. Furthermore, FDC correlated 
with cerebellar atrophy in patients with SCA1 (Figure 28). 
 
6.3.5 Effect size 
Clinical scores and brain volume were assessed at baseline and follow-up so that effect sizes 
could be calculated using the method proposed by Reetz et al. (Reetz et al., 2013). Clinical 
scores showed low effect size (<0.8) whilst segmentation with Freesurfer showed high effect 
size (>1.2) (Table 3) in patients with SCA. Manual segmentation showed low effect size 
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(<0.5). Using the Cohen’s d (Cohen, 1988), FA, the most common DTI metric, and FDC, a 
tractography metric, also showed high effect sizes (>1.2 and >2.0, respectively). Likewise, the 
effect sizes of FDC were on average 1.2 times higher than those of FA (Table 3). 
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Table 2: Demographic parameters of participants.  
Variable Control SCA1 SCA2 SCA3 SCA7 
# Participants 24 15 12 20 10 
Sex (M/F) 11/13 9/6 7/5 8/12 5/5 
Age (yr)
a
 50±13 43±15 45±13 51±12 48±14 
Age (yr)
b
 52±13 45±15 47±13 53±12 50±14 
BMI (Kg/m
2
)
a
 25.3±3.9 23.6±6.3 25.7±4.6 23.7±4.5 22.1±1.8 
BMI (Kg/m
2
)
b
 25.3±3.6 23.6±6.7 26.6±4.4 24.1±4.8 22.7±2.6 
SARA score
a
 0.8±0.8 10.7±6.3† 12.6±6.0† 13.0±7.2† 8.3±7.4† 
SARA score
b
 0.7±0.7 13.2±7.0† 14.4±6.3† 15.2±7.5† 9.5±8.3† 
CCFS
a
! 0.9±0.1! 1.0±0.1†! 1.1±0.1†! 1.0±0.1†! 1.0±0.2#!
CCFS
b
! 0.8±0.0! 1.1±0.2†! 1.1±0.2†! 1.1±0.1†! 1.0±0.2#!
CAG length  47±7 40±3 69±6 41±3 
Disease 
duration
a
 
 7±6 10±6 9±5 9±6 
Disease 
duration
b
 
 9±6 12±6 11±5 11±5 
aParameters at baseline; bparameters at follow-up. Data are presented as mean ± standard 
deviation. †p ≤ 0.001 and #p ≤ 0.01 represent significant differences between SCAs and 
controls. There was no difference in the other demographic parameters between the SCAs. p 
values were obtained with one-way ANOVA and Bonferroni correction. 
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Table 3: Effect size of clinical scores and brain imaging parameters 
 Clinical scores  Brain volumetry  Diffusion imaging 
 SARA  CCFS  FS cerebellum FS pons MN vermis  FA FDC 
SCA1 0.75 -0.40  -1.49 -1.43 -0.11  1.76 1.87 
SCA2 0.77 0.17  -1.45 -1.77 0.18  1.88 2.36 
SCA3 0.82 0.67  -1.15 -1.29 0.31  2.42 3.16 
SCA7 0.05 0.82  -1.66 -3.43 -0.70  2.10 2.65 
Control -0.10 -0.21  -0.83 -0.44 0.16  - - 
FS cerebellum and FS pons: Automatic Freesurfer segmentation of cerebellum and pons; Manual vermis: manual segmentation of the vermis. 
The following key represents the effect size:  0.2: small, 0.5: medium, 0.8: large, 1.2: very large, 2.0: huge changes (Cohen, 1988; Sawilowsky, 
2009). 
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Figure 21: Change in clinical scores after 24 months. All SCAs showed an increase in 
SARA scores that reached significance in SCA1, SCA2 and SCA3. CCFS was also 
significantly increased in SCA3 and SCA7. Error bars represent standard error of mean 
(SEM) (* p < 0.05, 
#
 p ≤ 0.01). 
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Figure 22: Change in regional volume after 24 months. A) Manual segmentation of the 
vermis showed a significant change in volume only in SCA7. Freesurfer segmentation 
showed that there is a decrease in the B) cerebellum and C) pons in the controls and patients 
with SCA over 24 months. Error bars represent standard error of mean (* p < 0.05, 
#
 p ≤ 0.01, 
†
 p ≤ 0.001). 
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Figure 23: Rate of atrophy in the cerebellum and pons. A faster rate of atrophy is observed 
in patients with SCA compared to controls in both the cerebellum and pons with a faster rate 
in the pons (* p < 0.05, # p ≤ 0.01, † p ≤ 0.001). 
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Figure 24: Tract based statistical analysis of FA and RD in SCAs and controls. (A) Red-
yellow highlights show areas of decreased FA in SCAs (p < 0.05). (B) Pink regions show 
areas of increased RD in SCAs (p < 0.05). FA correlated with (C) cerebellar atrophy and (D) 
pontine atrophy in SCA1 (p < 0.05) (Red highlights). 
SCA2 SCA1 SCA3 SCA7 A 
B SCA2 SCA1 SCA3 SCA7 
D C 
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Figure 25: The preprocessing steps of the diffusion data for FBA. The diffusion data were 
denoised (Veraart et al., 2016a; Veraart et al., 2016b) and upsampled by a factor of two to 
improve SNR and contrast. The upsampled data were then corrected for motion, eddy current 
and susceptibility distortions as well as bias and intensity correction using FSL and MRtrix. 
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Figure 26: Distribution of fibers in the CST in SCAs and controls. Visual inspection of 
the FODs seems to show that controls have more fiber distributions than SCAs. 
 
Control SCA1 SCA2 SCA3 SCA7 
  133 
 
Figure 27: Connectivity-based fixel enhancement on FD, FC and FDC. A) The fixel mask 
and tractogram used for the statistics. (B) FD, FC and FDC are significantly reduced in the 
CST of SCAs (p < 0.05 with family-wise error correction). Fiber colors are directional: blue = 
superior-inferior direction; red = left-right direction; green = anterior-posterior direction. 
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Figure 28: FDC correlation with clinical scores and cerebellar atrophy. FDC correlated 
negatively with (A) SARA score and (B) CCFS in SCA1 and SCA3. (B) FDC correlated 
negatively with cerebellar atrophy in SCA1. 
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6.4 Discussion 
This study compared clinical scores and imaging parameters in terms of sensitivity to change 
in a unique cohort of patients with SCA1, SCA2, SCA3 and SCA7. We identified high effect 
sizes for volumetric and tractography parameters compared to clinical scores. Likewise, we 
advocate to use these imaging parameters in upcoming clinical trials in SCAs. In addition, we 
report a new approach (FBA) to probe white matter fiber integrity in SCAs. FBA allows the 
analysis of individual fibers in each voxel making it more sensitive and robust compared to 
FA, the conventional DTI metric. We showed that FA may not be a reliable metric for use in 
clinical trials as it detected no microstructural change in SCA7. Instead, using FBA analyses, 
we identified white matter fiber changes in the CST of all SCAs, including SCA7.  
Volumetric studies performed in SCA have reported smaller brain regions compared to 
controls, including the cerebellum, brainstem and cerebellar peduncles (Yamada et al., 2008; 
Durr, 2010; Schulz et al., 2010; Rüb et al., 2013). The rate of volumetric change, though, has 
only been reported by Reetz et al. (Reetz et al., 2013) who compared the rate of atrophy 
across patients with SCA1, SCA3 and SCA6, but not with controls. They reported greater 
atrophy in the brainstem and left cerebellar hemisphere in patients with SCA1 compared to 
SCA3 (Reetz et al., 2013). In patients with SCA1 and SCA3, Reetz et al. also reported large 
effect sizes for the SARA scores (>1.2) and the pons atrophy (>0.8) but low effect sizes 
(<0.8) for the cerebellum (Reetz et al., 2013). In contrast, we reported atrophy rates in patients 
with SCA1, SCA2, SCA3 and SCA7 in reference to healthy controls. Our data were acquired 
on a 3 T MR system that gives twice the image resolution and contrast compared to the 1.5 T 
system used in the study by Reetz et al. In our estimation of brain volumes, we also used a 
fully automated method without user interference whilst Reetz et al. used a semi-automated 
method that included user defined regions of interest. Although our findings need to be 
confirmed in an independent cohort using the same methodologies and high spatial resolution, 
we found high effect sizes for the rate of atrophy of the cerebellum and the pons compared to 
the SARA and CCFS. The discrepancy between the rate of clinical progression and brain 
atrophy was especially striking for patients with SCA7. This may be, in part, explained by the 
small sample size of this patient group (n = 10) and their relative early symptomatic stage. 
Nonetheless, SCA7 is a severe disease, as outlined by the common occurrence of additional 
non-neurological symptoms (retina, heart), so that a fast rate of brain atrophy is expected. 
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Using diffusion tensor metrics, we observed decreased FA across several tracts, with the 
exception of SCA7, associated with increased RD in all SCA groups, including SCA7. 
Decreased FA in the corpus callosum of patients with SCA2 is in agreement with previous 
studies (Hernandez-Castillo et al., 2015; Mascalchi et al., 2015). In contrast to Kang et al. 
(Kang et al., 2014), we did not find any change in FA and RD in the corpus callosum, internal 
capsule and corona radiata in patients with SCA3. These previous DTI studies conducted in 
SCAs did no make mention of the quality control process used to include or reject data with 
missing volumes or spikes. It is therefore possible that the noise in their dataset contributed to 
the statistically significant differences found in many brain regions.  
Even though TBSS is highly favored due to its elimination of user drawn regions of interest 
and reasonable control on misalignments that may arise when different images are registered 
together, it is still limited as it is highly dependent on FA. But FA cannot differentiate 
between different fiber populations in a voxel (Alexander et al., 2001; Alexander et al., 2002), 
hence the need for higher-order models. To resolve the limitations of FA, Rozenfeld et al. 
performed fiber tracking using the deterministic approach that assumes that fibers have a 
single orientation within each voxel, and requires prior knowledge of the orientation of fibers 
before its application (Rozenfeld et al., 2015). However, one cannot be certain of the 
orientation of the fibers as each voxel contains several populations of axons that may be 
oriented in different directions. With high uncertainty in estimating the fiber direction and 
evaluating crossing fibers, the deterministic approach is therefore less robust and less 
sensitive as compared to the probabilistic approach (Petersen et al., 2016; Schlaier et al., 
2017) that overcomes the problem of uncertainty in fiber orientation and accounts for multiple 
fibers in each voxel. Kang et al. (Kang et al., 2014) and Prakash et al. (Prakash et al., 2009) 
used the probabilistic approach but with algorithms that have more fiber orientation error rate 
and low fiber detection rate as compared to the non-negativity CSD approach (Tournier et al., 
2007; Wilkins et al., 2015). This is why we chose to implement fiber tract specific analysis, 
i.e. FBA, in our SCA cohort. FBA has been successfully applied in traumatic brain injury 
(Wright et al., 2017) and in motor neuron disease (Raffelt et al., 2015; Raffelt et al., 2017). In 
our study, FBA revealed decreased FD in the pontine crossing, CST, cerebral peduncle, 
internal capsule and corona radiata in patients with SCA1, SCA2 and SCA3. In patients with 
SCA7, contrary to the results obtained with FA, FD was decreased in the corpus callosum and 
cerebral peduncles. Decreased FD could either be a result of atrophy leading to a decrease in 
the volume, or dense packing of the axons leading to reduced axonal volume. However, 
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decreased FC suggested a reduced number of axons in these regions in patients with SCA. 
Furthermore, FDC correlated with cerebellar atrophy in patients with SCA1 and the clinical 
scores in patients with SCA1 and SCA3. Hence, we can attribute the combined effect of FD 
and FC to brain atrophy and reduction in the number of fibers in SCAs.  
In conclusion, clinical scores such as the SARA and the CCFS are widely used to evaluate 
ataxia, but their low effect sizes make them less suited for therapeutic trials in very rare 
disorders like SCAs. Furthermore, they cannot be of use in presymptomatic individuals. 
Using volumetry methods that limit user interference, and tractography techniques with CSD 
approach (i.e. FBA) that are sensitive to subtle changes otherwise overlooked by DTI metrics 
(e.g. FA), we identified biomarkers with very large effect sizes in SCAs, making them 
suitable for therapeutic trials. Since a single biomarker is likely to fail reflecting the 
complexity of the neurodegenerative cascades leading to the onset and progression of SCAs, a 
multimodal biomarkers approach, aiming at the integration and visualization of multivariate 
datasets, can also be applied, as recently shown in our SCA cohort at baseline (Garali et al., 
2017).  
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Study 6: A strategy for multimodal data integration: application to 
biomarkers identification in spinocerebellar ataxia 
7.1 Introduction and objectives 
Using individual methods can help answering questions pertaining to specific areas of a 
disease. For example, MRS benefits from identifying alterations to metabolites due to the 
disease whilst DTI gives information on the structural integrity of white matter fibers in the 
brain.  However, in order to fully understand the biochemical basis of the disease, a process 
that is capable of integrating multi-datasets from different modalities is crucial. Likewise, to 
understand the pathophysiology of polyglutamine diseases and identify robust biomarkers, 
several modalities including imaging, metabolomics, transcriptomics, lipidomics, among 
others, have been used to obtain measures that could best explain the underlying disease 
mechanisms. In light of these growing number of modalities, new statistical approaches are 
needed of data integration to relate the modalities to i) better explain the disease and ii) 
identify biomarkers with high effect sizes. 
This study presents a statistical approach of data integration using reported – MRS and 
volumetric data – and unreported data – metabolomics, lipidomics and calorimetric data – 
from studies 5 and 6 performed at baseline on the SCA dataset (ClinicalTrials.gov Identifier: 
NCT01470729). 
 
7.2 Materials and methods 
This study was performed using data collected at baseline from studies 5 and 6. In addition to 
the MRS and volumetric data presented in the previous studies, other modalities such as 
calorimety, metabolomics and lipidomics datasets were included.  
Multivariate analyses were performed using the regularized generalized canonical correlation 
analysis (RGCCA).  RGCCA works to reduce the number of blocks (modalities) into 
variables that summarize the information between and within each block. RGCCA was 
coupled with its sparse generalized canonical correlation analysis (SGCCA), a variable 
selection procedure that can identify most relevant features that are linked between and within 
each block. Since in SCA the atrophy of the pons progresses faster than in the cerebellum, we 
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chose to identify the link between the pons atrophy and changes observed with the other 
modalities (MRS, volumetry, calorimety, metabolomics and lipidomics).  
 
7.3 Principal results 
This method of RGCAA/SGCAA was able to take into account the heterogeneous nature and 
sizes of the datasets obtained from different modalities in patients with SCA and controls. 
Separation between patients and controls was best achieved with the MRS modality. Among 
patients with SCA, SCA7 was separated from the other SCAs due to the possible influence of 
certain lipid species (sphingolipids and phospholipids) detected in plasma by lipidomic 
analyses.  
 
7.4 Perspective 
The next step is to apply this statistical method on the longitudinal dataset (baseline and 24 
months) of the BIOSCA study, as well as on the multimodal datasets from the ongoing studies 
conducted in HD (TRIHEP3, REVHD, HDeNERGY). 
 
7.5 Published article 
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Abstract
The growing number of modalities (e.g. multi-omics, imaging and clinical data) characterizing a given disease provides
physicians and statisticians with complementary facets reflecting the disease process but emphasizes the need for novel
statistical methods of data analysis able to unify these views. Such data sets are indeed intrinsically structured in blocks,
where each block represents a set of variables observed on a group of individuals. Therefore, classical statistical tools can-
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Here, we provide practical guidelines for the use of RGCCA/SGCCA. We also illustrate the flexibility and usefulness of
RGCCA/SGCCA on a unique cohort of patients with four genetic subtypes of spinocerebellar ataxia, in which we obtained
multiple data sets from brain volumetry and magnetic resonance spectroscopy, and metabolomic and lipidomic analyses.
As a first step toward the extraction of multimodal biomarkers, and through the reduction to a fewmeaningful components
and the visualization of relevant variables, we identified possible markers of disease progression.
Key words: data integration; Regularized Generalized Canonical Correlation Analysis; biomarker discovery; spinocerebellar
ataxia
Introduction
The growing number of modalities (e.g. multi-omics, imaging
and clinical data) characterizing a given disease provides phys-
icians and statisticians with complementary facets of the dis-
ease process. However, novel statistical methods of data
analysis are needed to unify these views. This data set is indeed
intrinsically structured in blocks, where each block represents a
set of variables observed on a group of individuals. The number
and the nature of the variables can differ from one block to an-
other. Therefore, classical statistical tools cannot be applied
without altering the structure of the multiblock data set. The in-
tegration and visualization of these multivariate data sets is
also challenging, explaining the need of dedicated modeling al-
gorithms able to cope with the inherent properties of these
structured data sets.
In this article, we present the principles of regularized gener-
alized canonical correlation analysis (RGCCA) [1, 2], and its
sparse generalized canonical correlation analysis (SGCCA) coun-
terpart [3], a component-based framework for the integrative
exploration of multimodal and high-dimensional data sets. We
apply it to an original multiblock data set generated from a
unique, considering the rarity of these diseases, cohort of pa-
tients with spinocerebellar ataxia (SCA) and controls. We show
how the obtained results are useful, as SGCCA allows both the
extraction of biomarkers and the reduction of the multiblock
data sets into a few meaningful components that can be easily
described as a set of graphical representations. The main object-
ives of the article are thus to provide users with practical guide-
lines for the application of RGCCA and SGCCA, and to illustrate
their versatility and relevance on the SCA data set.
This article is organized as follows. In ‘Multiblock compo-
nent methods’ section, the RGCCA and SGCCA optimization
problems are briefly presented, and a synthetic overview of
methods, which are special cases of RGCCA/SGCCA, is given. In
‘Practical guidelines for using RGCCA and SGCCA’ section, prac-
tical guidelines defining how to use RGCCA/SGCCA are pro-
vided. ‘Case study: the SCA data set’ section illustrates on a real
and challenging multiblock data set, the usefulness of RGCCA/
SGCCA for data integration.
Multiblock component methods
The following section describes a general framework for multi-
block component methods, RGCCA and variations, that was pre-
viously published [1–3] and assessed [4–6]. For the sake of
comprehension of the use of these methods, their theoretical
bases will be briefly described in the next subsections. In short,
RGCCA is a rich technique that encompasses several important
multivariate analysis methods (see Table 1 for the overview).
The objective of RGCCA is to find, for each block, a weighted
composite of variables (called block component) summarizing
the relevant information between and within the blocks. The
block components are obtained such that (i) block components
explain well their own block and/or (ii) block components that
are assumed to be connected are highly correlated. Indeed,
RGCCA can process a priori information defining which blocks
are supposed to be linked to one another, thus reflecting
hypotheses about the biology underlying the data blocks. In
addition, RGCCA integrates a variable selection procedure,
called SGCCA, allowing the identification of the most relevant
features. Finally, as a component-based method, RGCCA/SGCCA
can provide users with graphical representations to visualize
the sources of variability within blocks and the amount of cor-
relation between blocks.
Regularized generalized canonical correlation analysis
We consider J data matrices X1; . . . ; Xj; . . . ; XJ. Each n! pj data
matrix Xj ¼ xj1; . . . ;xjpj
h i
is called a block and represents a set
of pj variables observed on n individuals. The number and the
nature of the variables may differ from one block to another,
but the individuals must be the same across blocks. We as-
sume that all variables are centered. The objective of multi-
block component methods is to find block components
yj ¼ Xjwj; j ¼ 1; . . . ; J (where wj is a column vector with pj
elements) summarizing the relevant information between and
within the blocks. The second-generation RGCCA [2] subsumes
50 years of multiblock component methods (see [2] for a com-
plete review). It provides important improvements to the ini-
tial version of RGCCA [1] and is defined as the following
optimization problem:
maxw1 ;...; wJ
XJ
j;k¼1
cjkgðcovðXjwj; XkwkÞÞ
s:t: ð1% sjÞvarðXjwjÞ þ sjkwjk
2
2 ¼ 1; j ¼ 1; . . . ; J
; (1)
where:
• The scheme function g is any continuous convex function and
allows to consider different optimization criteria. Typical choices
of g are the identity (leading to maximizing the sum of covari-
ances between block components), the absolute value (yielding
maximization of the sum of the absolute values of the covari-
ances) or the square function (thereby maximizing the sum of
squared covariances).
• The design matrix C ¼ fcjkg is a symmetric J! J matrix of non-
negative elements describing the network of connections be-
tween blocks that the user wants to take into account. Usually,
cjk ¼ 1 for two connected blocks and 0 otherwise.
• The sj are called shrinkage parameters ranging from 0 to 1.
Setting the sj to 0 will force the block components to unit vari-
ance (var Xjwj
! "
¼ 1), in which case the covariance criterion
boils down to the correlation. The correlation criterion is better
2 | Garali et al.
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in explaining the correlated structure across data sets, thus dis-
carding the variance within each individual data set. Setting sj
to 1 will normalize the block weight vectors (w>j wj ¼ 1), which
applies the covariance criterion. A value between 0 and 1 will
lead to a compromise between the two first options and corres-
pond to the following constraintw>j sjIþ 1# sj
! "
ð1=nÞX>j Xj
# $
wj ¼ 1
in Equation (1). The choices sj ¼ 1, sj ¼ 0 and 0 < sj < 1 are, re-
spectively, referred asModes A, B and Ridge.
From optimization problem in Equation (1), the term ‘gener-
alized’ in the acronym of RGCCA embraces at least three no-
tions. The first one relates to the generalization of two-block
methods—including Canonical Correlation Analysis [8],
Interbattery Factor Analysis [9] and Redundancy Analysis [10]—
to three or more sets of variables. The second one relates to the
ability of taking into account some hypotheses on between-
block connections: the user decides which blocks are connected
and which ones are not. The third one relies on the choices of
the shrinkage parameters allowing to capture both correlation
or covariance-based criteria.
Variable selection in RGCCA: SGCCA
The quality and interpretability of the RGCCA block compo-
nents yj ¼ Xjwj; j ¼ 1; . . . ; J are likely affected by the usefulness
and relevance of the variables of each block. Accordingly, it is
an important issue to identify within each block a subset of
significant variables that are active in the relationships be-
tween blocks. SGCCA extends RGCCA to address this issue of
variable selection. Specifically, RGCCA with all sj; j ¼ 1; . . . ; J
equal to 1 is combined with an L1 penalty that gives rise to
SGCCA [3]. The SGCCA optimization problem is defined as
follows:
max
w1 ;...;wJ
XJ
j;k¼1
cjkg
#
covðXjwj; XkwkÞ
$
s:t:
kwjk2 ¼ 1
kwjk1 & sj
; j ¼ 1; . . . ; J;
(
(2)
where sj is a user-defined positive constant that determines
the amount of sparsity for wj; j ¼ 1; . . . ; J . The smaller the sj,
the larger the degree of sparsity forwj.
Higher stage block components
It is possible to obtain more than one block component per
block for RGCCA and SGCCA. Higher stage block components
can be obtained using a deflation strategy [1]. This strategy
forces all the block components within a block to be uncorre-
lated. This deflation procedure can be iterated in a flexible way.
It is not necessary to keep all the blocks in the procedure at all
stages: the number of components summarizing a block can
vary from one block to another [2].
Implementation
The function rgcca()of the RGCCA package [26] implements a
monotonically convergent algorithm for the optimization prob-
lem in Equation (1), i.e. the bounded criterion to be maximized
increases at each step of the iterative procedure, which hits at
convergence a stationary point of Equation (1). Two numerically
equivalent approaches for solving the RGCCA optimization
problem are available. A primal formulation described in [1] re-
quires the handling of matrices of dimension pj ' pj. A dual for-
mulation described in [27] requires the handling of matrices ofT
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dimension n! n. Therefore, the primal formulation of the RGCCA
algorithmwill be used when n " pj, and the dual formwill be pre-
ferred when n < pj. The rgcca() function of the RGCCA package
implements these two formulations and selects automatically
the best one. The SGCCA algorithm is similar to the RGCCA algo-
rithm and keeps the same convergence properties. The algorithm
associated with the optimization problem in Equation (2) is avail-
able through the function sgcca() of the RGCCA package.
Moreover, multiblock data faces two types of missing data
structure: (i) if an observation i has missing values on a whole
block j and (ii) if an observation i has some missing values on a
block j (but not all). For these two situations, it is possible to ex-
ploit the algorithmic solution proposed for partial least squares
(PLS) regression path modeling to deal with missing data ([28],
p. 171). Work is in progress to implement this missing data solu-
tion within the RGCCA package.
Special cases of RGCCA
Many different multiblock methods were published for 50 years.
The choice of the ‘best’ multiblock method must be in line with
the nature of the data set and the objective of the analysis. The
introduction of the design matrix C, the shrinkage parameters
sjs’ and the scheme function g makes RGCCA highly versatile. A
practical guideline for appropriately specifying these extra par-
ameters is proposed in the next two sections. From a statistical
data analysis perspective, RGCCA subsumes a remarkably large
number of well-known methods as particular cases—including
principal component analysis (PCA) [7], generalized Canonical
Correlation Analysis (GCCA) [12], PLS regression [10], consensus
PCA (CPCA) [16], hierarchical PCA (HPCA) [14], multiple co-
inertia analysis (MCOA) [15], etc. For an exhaustive list of meth-
ods, see[2]. All the methods cited above (and many others) are
recovered with RGCCA by appropriately defining the triplet
C; sj; g
! "
. Table 1 gives the correspondence between the triplet
C; sj; g
! "
and the associated methods. SGCCA offers a sparse
counterpart to all the covariance-based methods of RGCCA.
RGCCA/SGCCA provides a framework for exploratory data ana-
lysis of multiblock data sets that has immediate practical conse-
quences for a unified statistical analysis and implementation
strategy. It is noteworthy that a complete review on dimension re-
duction approaches for simultaneous exploratory analyses of mul-
tiple data sets, and especially multi-omics data sets, has been
recently published [5]. In that review, RGCCA/SGCCA is discussed
and appears to occupy a key position as many of the single-block,
two-block and multiblock component methods—referred as PCA
(Principal Component Anlaysis), sPCA (sparse Principal Component
Anlaysis), CCA (Canonical Correlation Analysis), RDA (Redundancy
analysis), rCCA (Regularized canonical correlation), sCCA (sparse
Regularized canonical correlation), PLS (Partial Least Squares), sPLS
(sparse Partial Least Squares), sPLSDA (sparse Partial Least Squares
- dicriminant analysis), cPCA (consensus PCA), CIA (Co-Inertia
Analysis), multiple factor analysis (MFA), MCIA (Multiple Co-Inertia
Analysis) and GCCA (Generalized Canonical Correlation Analysis)—
are special cases of RGCCA/SGCCA.
In the next section, we provide some guidelines to choose
the triplet C; sj; g
! "
according to the objectives of the user and
the nature of the data.
Practical guidelines for using RGCCA
and SGCCA
There are eight steps, discussed hereafter, that need to be
applied: (i) construction of the multiblock data set, (ii)
preprocessing, (iii) definition of the between-block connections,
(iv) determination of the shrinkage or sparsity parameters, (v)
choice of the scheme function, (vi) determination of the number
of components per block, (vii) visualization of the results and
(viii) assessment of the reliability of parameter estimates.
Construction of the multiblock data set
The variables that compose each block have to be defined care-
fully: not only according to their nature (e.g. one block that con-
tains all the voxels of an image, one block for all the
metabolites, etc.) but also according to external information.
Nowadays, a huge amount of external information is available
and can be used to define each block. For example, a block that
contains all the metabolites can be divided into several data
blocks; hence, metabolites belonging to one pathway are gath-
ered within the same block. A block that contains all the voxels
of an image can be grouped by regions: voxels belonging to one
specific region are then gathered within the same block. This
grouping strategy makes more interpretable blocks and facili-
tates the interpretation of the RGCCA/SGCCA model. RGCCA/
SGCCA can be viewed as a ‘divide and conquer’ strategy that
allows incorporating prior information when defining the
blocks.
Preprocessing
In general, and especially for the covariance-based criterion, the
data might be preprocessed to ensure comparability between
variables and blocks. To make variables comparable, standard-
ization is applied (zero mean and unit variance). To make blocks
comparable, a strategy is to divide each block by the square root
of its number of variables [16]. This two-step procedure leads to
trace X>j Xj
# $
¼ n for each block (i.e. the sum of the eigenvalues
of the covariance matrix of Xj is equal to 1 whatever the block).
Such a preprocessing will be implicitly used throughout this
article.
Another way to make blocks more comparable is to divide
each block Xj by the square root of the first eigenvalue of
1
n
X>j Xj. This is exactly the normalization procedure used for
MFA [18]. The rationale of this normalization is the same as in
PCA where variables are standardized to have the same influ-
ence in the analysis; here, it can be seen as an extension to
blocks of variables where the first singular value plays the
role of the standard deviation. This second strategy may be
preferred in a situation where the numbers of uninformative
and noisy variables are unbalanced between blocks. General
guidelines for centering and scaling in component analysis
are available in [29]. Several normalization strategies used in
the context of simultaneous component analysis are dis-
cussed in [30].
Definition of the design matrix C
The between-block connections are encoded through the design
matrix C ¼ cjk
! "
; usually cjk ¼ 1 for two connected blocks and 0
otherwise. The customization of the design matrix can be
defined according to biological assumptions reflecting the biol-
ogy underlying the data blocks. For instance, multi-omics data
(transcriptomics, metabolomics, etc. . .) and other modalities
such as neuroimaging, electrophysiological data and scores of
disease severity are routinely acquired to study the complexity
of the neurodegenerative cascades. It can be roughly considered
that the path between omics data and behavioral data is medi-
ated by neuroimaging data (i.e. no direct relationship between
A strategy for multimodal data integration | 5
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omics and behavioral data is imposed). The prior information
on the between-block connections can be injected in the design
matrix.
Furthermore, from a statistical viewpoint, the design ma-
trix is a flexible way to reach one of the methods listed in
Table 1.
Determination of the shrinkage parameters
0< sj <1; j51; . . . ; J and the sparsity parameter
sj; j51; . . . ; J
The RGCCA model introduces some extra parameters, particu-
larly a shrinkage parameter. The shrinkage parameters 0 < sj
< 1; j ¼ 1; . . . ; J interpolate smoothly between maximizing the
covariance (all sj ¼ 1) and maximizing the correlation (all sj ¼ 0).
More precisely, we can define the choice of the shrinkage par-
ameters by providing interpretations on the properties of the re-
sulting block components:
• sj ¼ 1 yields the maximization of a covariance-based criterion. It
is recommended when the user wants a stable component (large
variance) while simultaneously taking into account the correl-
ations between blocks. The user must, however, be aware that
variance dominates over correlation.
• sj ¼ 0 yields the maximization of a correlation-based criterion. It
is recommended when the user wants to maximize correlations
between connected components. This option can yield unstable
solutions in case of multicollinearity and cannot be used when a
data block is rank deficient (e.g. n < pj).
• 0 < sj < 1 is a good compromise between variance and correl-
ation: the block components are simultaneously stable and as
well correlated as possible with their connected block compo-
nents. This setting can be used when the data block is rank defi-
cient. Ledoit and Wolf [31] considerMj ¼ sjIþ 1# sj
! "
ð1=nÞX>j Xj as
a shrinkage estimate of the true covariance matrix Rjj related to
block j. In case of multicollinearity within blocks or when the
number of observations is smaller than the number of variables
(Pj&n), the sample covariance matrix ð1=nÞX
>
j Xj is a poor
estimation of the true covariance matrix. The usual strategy for
finding a better estimation is to consider the class of linear com-
binations of the identity matrix and the sample covariance
matrix, fsjIþ 1# sj
! "
ð1=nÞX>j Xjg [32]. Shrinkage parameters be-
tween 0 and 1 allow stepping closer to the correlation criterion,
even in the case of high multicollinearity or when the number of
individuals is smaller than the number of variables. For each
block, the determination of the shrinkage parameter is made
fully automatic by using one of the various formulas that have
been proposed for finding an optimal shrinkage parameter [32].
Depending on the context, the shrinkage parameters should also
be determined based on V-fold cross-validation.
Barker and Rayens [33] PLS for discrimination offer a good
opportunity to illustrate the impact of the shrinkage param-
eters. They consider a block X of explanatory variables and a
block Y of dummy variables describing a categorical variable.
They are looking for a block component Xa (with a normalized)
and a standardized component Yb maximizing the following
criterion:
max
a; b
cor2 Xa; Ybð Þ ' varðXaÞ:
The rationale of the Barker and Rayens’s criterion is based on
the following idea: we are not looking for a block component Yb
that explains its own block well (as Y is a group coding matrix) but
one that correlates with Xa, hence removing from the covariance
criterion (cov2 Xa; Ybð Þ ¼ cor2 Xa; Ybð Þ ' var Xað Þ ' varðXbÞ), the
varðYbÞ part. Using the RGCCA formalism, the Barker and Rayens’s
optimization problem is recovered as follows:
max
a; b
cov2ðXa; YbÞ s:t: kak2 ¼ 1 and varðYbÞ ¼ 1;
that is for sX ¼ 1 and sY ¼ 0.
The choice to set sX ¼ 1 and more generally to set sj equals
to 1 in the optimization problem in Equation (1) is to some ex-
tent surprising. Indeed, it yields a sample covariance matrix
equal to the identity for each block. It corresponds to the
highest level of regularization that can be applied to RGCCA.
The level of regularization can be relaxed by decreasing the
value of sj. However, in high-dimensional settings, the high-
est level of regularization has proven to be necessary or even
insufficient [34, 35]. Additional penalties that promote spars-
ity are often required. The sparsity parameter sj; j ¼ 1; . . . ; J
is usually set based on cross-validation procedures (see next
section for an illustration). Alternatively, values of sj; j ¼ 1;
. . . ; J can simply be chosen to result in desired amounts of
sparsity.
Choice of the scheme function g
It is possible to choose any continuous convex function. In the
literature, classical scheme functions are g xð Þ ¼ x (horst
scheme), g xð Þ ¼ jxj (centroid scheme), g xð Þ ¼ x2 (factorial
scheme) or, more generally, for any even integer m, g xð Þ ¼ xm
(m-scheme). The horst scheme penalizes structural negative
correlation between block components, while both the centroid
scheme and the m-scheme enable two components to be nega-
tively correlated. ‘How the results of RGCCA/SGCCA depend on
the values of m?’ The answer to this question is related to the
notion of fairness. According to [22], a fair model is a model
where all blocks contribute equally to the solution in opposition
to a model dominated by only a few of the J sets. If fairness is a
major objective, the user must choose m¼1. m>1 is preferable if
the user wants to discriminate between blocks [2]. In practice, m
is equal to 1, 2 or 4. The higher the value of m, the more the
method acts as block selector [2].
Determination of the number of block components
Cross-validation is usually used to determine the number of
block components to retain. Depend on the context (supervised
or unsupervised), two types of cross-validation can be con-
sidered in the framework of RGCCA/SGCCA:
a. When the analysis is oriented toward the prediction of a
specific phenotype, then the number of components per
block can be selected based on the cross-validated predic-
tion accuracy.
b. When no external information is available, then the number
of components per block can be estimated as follows. For
each block j, some percent of the elements of Xj is removed
at random from the data matrix. The RGCCA block compo-
nents are estimated from this partially observed data set.
For each block, the missing values are imputed using the re-
construction formula. The number of components that re-
sults in the lowest sum of squared errors of the missing
values is retained.
6 | Garali et al.
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Besides, the average variance explained (AVE) by a block
component yj can also inform on the number of component to
retain. The AVE of Xj, denoted by AVE Xj
! "
, is defined as:
AVE Xj
! "
¼
1
pj
Xpj
h¼1
cor2ðxjh; yjÞ:
AVE Xj
! "
varies between 0 and 1 and reflects the proportion
of variance captured by yj. The number of block components to
retain for Xj can be determined using the ‘elbow’ criterion or al-
ternatively, the number of components that explains a prede-
fined percentage of the total variance of Xj.
Visualization of the results
As a component-based method, RGCCA/SGCCA provides the
users with graphical representations, including factor plot, cor-
relation circle and biplot. These graphical displays allow visual-
izing the sources of variability within blocks, the relationships
between variables within and between blocks and the amount
of correlation between blocks.
Assessment of the reliability of parameter estimates
It is possible to use a bootstrap resampling method [36, 37] to
assess the reliability of parameter estimates obtained using
RGCCA/SGCCA. B bootstrap samples of the same size as the
original data are repeatedly sampled with replacement from
the original data. RGCCA/SGCCA is then applied to each boot-
strap sample to obtain the RGCCA/SGCCA estimates. For
RGCCA, we calculate the mean and variance of the estimates
across the bootstrap samples, from which we derived t-ratio
and P-value (under the assumption that the parameter esti-
mates exhibited asymptotic normality) to indicate how reliably
parameters were estimated. As several P-values are con-
structed simultaneously, Bonferroni or FDR corrections can be
applied for controlling the family-wise error rate or the false
discovery rate, respectively.
For SGCCA, the percentage of times a specific variable had a
non-null weight across bootstrap sample can be derived. In add-
ition, the stability of the selected variables can be measured ac-
cording to the Fleiss’j score [38] that estimates the agreement
among the B bootstrap samples. The Fleiss’j score is always
$ 1, and the higher the value of j is, the more stable the meth-
ods are with respect to sampling. This resampling procedure,
intuitive and pragmatic, is classically used in the PLS commu-
nity. We may note that alternative resampling-based strategy
for variable and stability selection could be considered [39]. This
alternative approach has been tested for simultaneous compo-
nent analysis [40].
Case study: the SCA data set
Description of the SCA data set
Neurodegenerative disorders have become the leading cause of
disability in Western societies, e.g. SCAs that are autosomal
dominant diseases responsible for severe movement disorders.
Heterogeneous and high-dimensional sources of information
such as omics data (transcriptomics, metabolomics, etc.) and
other modalities such as neuroimaging and/or electrophysiolo-
gical data are routinely acquired to study such complex dis-
eases. Disease mathematical models are thus critically needed
to identify biomarkers that are relevant to disease mechanisms
and can be used in therapeutic trials. As gene-based therapeutic
approaches are being developed in SCA [41], it becomes increas-
ingly important to identify readouts for trials with sufficient ef-
fect sizes. Clinical scores are useful, but insufficient, and a
single biomarker is likely to fail reflecting the complexity of the
neurodegenerative cascades leading to the onset and progres-
sion of SCA. An integrated multimodal biomarkers approach is
therefore needed to (i) better understand disease pathophysi-
ology and (ii) generate composite scores with greater effect sizes
than isolated biomarkers.
SCA belongs to the group of polyglutamine repeat disorders
and is characterized by a predominant atrophy of two brain re-
gions: the cerebellum and the pons. More than 40 genetically
different SCAs have been defined. The most common—SCA1,
SCA2 and SCA3, which together affect about half of the families
with a history of SCA—are caused by abnormal CAG repeat ex-
pansions, encoding elongated polyglutamine tracts within the
proteins associated with each type [42]. Progressive cerebellar
ataxia is the prominent symptom of all SCAs. In SCA7, patients
present with additional non-neurological signs commonly seen
in patients with mitochondrial dysfunction such as pigmentary
retinopathy and cardiomyopathy. Depending on the SCA geno-
type, CAG repeat length explains about 50–70% of the variability
in age at onset, i.e. individuals with longer repeats tend to have
an earlier onset [43].
The volume of the pons has been shown to be the most sensi-
tive to change in patients with SCA [44], including at the pre-
symptomatic phase of the disease in individuals carrying
abnormal CAG repeats but who have not yet developed symp-
toms [45]. Accordingly, the pons volume is likely to closely reflect
disease progression and can also be studied longitudinally in con-
trols, unlike motor scales evaluating cerebellar dysfunctions.
Therefore, following previous work that we conducted on meta-
bolic dysfunction in polyglutamine repeat disorders [46–48], we
chose to perform multiblock analyses to discover relevant
associations between the pons volume and various metabolic
modalities—calorimetry, metabolomics and lipidomics on
plasma, and metabolic imaging by magnetic resonance
Table 2. Characteristics of the SCA cohort
Controls SCA1 SCA2 SCA3 SCA7 P-value
Number of subjects 35 18 14 22 13
Sex (M/F) 17/18 9/9 8/6 10/12 7/6
BMI (kg/m2) 2564 2466 2765 2465 2363 0.104
Age at examination (years) 48613 45615 46612 50611 46614 0.735
Age at disease onset (years) – 41612 35611 42611 38613 0.397
SARA score (/40) 0.861 1066 1467 1467 1068
Disease CAG repeats – 4867 4063 7066 4365
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spectroscopy (MRS)—in patients with SCA compared with con-
trols, to gain insight into the pathophysiology of SCA. Our ultim-
ate goal—outside the scope of these analyses—is to study
prospectively these biomarkers in longitudinal studies and gener-
ate composite scores with greater effect sizes than the pons vol-
ume alone.
Patients and controls
The SCA study (NCT 01470729) was approved by the local ethical
committee (AOM10094, CPP Ile de France VI, Ref: 105–10) and per-
formed in a unique cohort of patients with SCA—SCA1 (n¼ 18),
SCA2 (n¼ 14), SCA3 (n¼ 22) and SCA7 (n¼ 13). Healthy controls
(n¼ 35) with similar sex ratio, age and body mass index (BMI) than
patients were also recruited. All participants signed informed con-
sent to be included in the study. Their demographic characteristics
are summarized in Table 2. The scale for the assessment and rat-
ing of ataxia (SARA, score up to 40) was used to evaluate the sever-
ity of the disease [49]. The four SCA subtypes were comparable in
terms of duration of disease and SARA scores.
Application of SGCCA to the SCA data set
We collected standard clinical and brain volumetric metrics in
our cohort of SCA patients and healthy controls, and then
jointly analyzed modalities (or blocks) reflecting metabolic regu-
lations using calorimetry, metabolomics and lipidomics on
plasma, and metabolic imaging by MRS. A full description of the
methods used for the acquisition of each modality is available
as Supplemental Materials. The main objective of this integra-
tive analysis was to identify variables within each block that (i)
well explain their own block and (ii) influence the relationships
between ‘connected’ blocks. The example of the SCA data set
was well suited to illustrate the versatility and relevance of
SGCCA, as the number of variables within each block made it
difficult to identify the most important variables, so that a vari-
able selection procedure was needed. In this section, we intend
to instantiate the eight-step guideline described in ‘Practical
guidelines for using RGCCA and SGCCA’ section. Moreover,
some additional advices to set up the extra parameters accord-
ing to the nature of the data and the scientific objectives are
given. We then illustrate how relationships between the most
relevant variables can be displayed and the results interpreted
by visualizing the observations and variables in a common
space.
Construction of the multiblock data set
The SCA data set was organized into 23 blocks. A detailed de-
scription of each block, including the number of variables per
block, is reported in Table 3. Annotated metabolites were classi-
fied into metabolite sets mapping various biochemical path-
ways. Nineteen sets were proposed including 754 metabolites
classified by the confidence level of annotation and detected
using our metabolomic and lipidomic methods. These blocks
X1; . . . ; X19 were defined based on biological knowledge about
metabolic pathways from KEGG (Kyoto Encyclopedia of Genes
and Genomes), HMDB (Human Metabolome Database) and lit-
erature [50–56]. Blocks X20 and X21 contained information on
brain MRS, denoted MRS, and calorimetry information,
denoted CAL. In the framework of CPCA and HPCA methods, a
superblock defined as the concatenation of all the blocks is
also used. In the SCA data set, the superblock was defined as
X22 ¼ X1; . . . ; X21½ #, and the corresponding global components
were derived. The space spanned by the global components
was viewed as a compromise space that integrated all the
modalities. This global space was useful for visualization and
eased the interpretation of the results. Finally, X23 contained
the volume of the pons.
Preprocessing
Adjustments for confounding factors (age, gender and BMI)
were carried out by residualization (before preprocessing) for
each variable of the SCA data set. Residualization consists in re-
gressing each block by age, gender and BMI. To make blocks
more comparable, the residual variables were standardized
(zero mean and unit variance) and then divided by
ffiffiffiffi
pj
p
within
each block.
Definition of the design matrix C
In the search of biomarkers associated with the four subtypes of
SCA—SCA1, SCA2, SCA3 and SCA7—we applied SGCCA to iden-
tify variables from the 21 blocks associated with the pons vol-
ume. The between-block connections associated with this
objective of analysis are presented in Figure 1. We chose a CPCA
structure oriented toward the explanation of the volume of the
pons by imposing an additional connection between the super-
block and the pons. The ‘divide and conquer’ strategy, by incor-
porating prior knowledge in the definition of the blocks, yielded
valuable improvements and more interpretable results.
Choice of the scheme function g
In this case, it was not expected that all the blocks, especially
the metabolic pathways, contributed equivalently to the pro-
cess. The block selector behavior of SGCCA was favored by using
the scheme function g xð Þ ¼ x4.
Table 3. Description of the SCA multiblock data set
Block Xj Number of
variables
for Xj
Modalities
X1 : Arginine_Proline p1 ¼14 Metabolic
pathways
including
754 metabolites
X2 : BCAA_Threonine p2 ¼9
X3 : Carnitine_Lysine p3 ¼7
X4 : CE_sterols_bile_acids p4 ¼47
X5 : Essential_fatty_acids p5 ¼15
X6 : Fatty_acids_Ketone_bodies p6 ¼23
X7 : GABA_Glutamine_Histidine p7 ¼18
X8 : Glucose_Alanine_Pyruvate p8 ¼4
X9 : Glycerides p9 ¼177
X10 : Glycine_Serine p10 ¼16
X11 : Krebs_cycle p11 ¼5
X12 : Phenylalanine_Tyrosine p12 ¼12
X13 : Phospholipids p13 ¼292
X14 : Purines p14 ¼14
X15 : Pyrimidines p15 ¼9
X16 : Sphingolipids p16 ¼56
X17 : Tryptophan p17 ¼23
X18 : Urea_cycle p18 ¼5
X19 : Various p19 ¼8
X20 : MRS p20 ¼19 MRS of the cerebellum
X21 : CAL p21 ¼3 Calorimetry
information
X22 : Superblock p22 ¼776 X22 ¼ ½X1; . . . ; X21#
X23 : Pons p23 ¼1 The volume
of the pons
8 | Garali et al.
 149 
Determination of the sparsity parameter and the number
of block components
SGCCA requires determining the sparsity parameters. For each
block Xj, the sparsity parameter sj; j ¼ 1; . . . ; J was set using a
leave-one-out cross-validation procedure. The value of the
parameter sj was chosen in a range defined by the following
formula 1þ f0:05; 0:1; 0:15; 0:2; 0:25; 0:3; 0:35; 0:4g # ffiffiffiffiffiffipjp ,
which allowed us to impose the same degree of sparsity for all
the blocks. To select the optimal value, linear models
predicting the volume of the pons with respect to the block
components were performed, and the optimal parameter
was selected with respect to the mean squared error of
these models. The optimal values were equal to
sj ¼ 1þ 0:2#
ffiffiffiffi
pj
p
; j ¼ 1; . . . ; J.
Moreover, using a deflation strategy, four components per
block were built. We denote by yðhÞj (respectively, w
ðhÞ
j ) the hth
block component (respectively, hth block weight vector) associ-
ated with Xj.
Visualization
As the fourth global component was the most discriminant be-
tween patients and controls, the graphical display of the indi-
viduals obtained by crossing the global components yð1Þ22 and y
ð4Þ
22
and marked with their status (SCA1, SCA2, SCA3, SCA7 and con-
trols) is shown in Figure 2. It is noteworthy that, despite some
overlap, the first global component exhibited a separation
among some SCA groups, especially patients with SCA7 who
were mainly grouped at the bottom. Moreover, the fourth global
component captured the discriminative information between
patients and healthy controls as controls concentrated on the
right and patients on the left.
Figure 3 shows the variables projected on the compromise
space. The sparsity-inducing penalty of SGCCA made the inter-
pretation of the variable space easier. Indeed, only the variables
associated with non-null elements in the block weight vectorwð1Þj
and wð4Þj , j ¼ 1; . . . ; J (i.e. the ones that contribute to the con-
struction of the first and fourth dimensions) were projected on
the compromise space. A variable that is highly expressed for a
category of individuals will be projected with a high weight (far
from the origin) in the direction of that category. Likewise, the
most discriminant variables between patients and controls ap-
peared to be metabolites measured by MRS in the vermis such as
total creatine, a marker of energy metabolism and myoinositol
(myoIns), a putative glial marker (Figure 3). Interestingly, we pre-
viously identified these variables as significantly different be-
tween patients and controls [52]. We also showed that these
metabolites were associated with SARA scores, which reflect
higher disease severity [52]. Moreover, the separation among pa-
tients with SCA, and especially patients with SCA7, seemed to be
driven by certain lipid species detected in plasma by lipidomic
analyses such as sphingolipids and phospholipids (Figure 3).
Figure 3 allows visualizing relationships between variables be-
longing to the different blocks. This figure suggests relationships
between blocks that can be confirmed by a block clustering. As
the fourth dimension was the most informative axis for the ex-
planation of the pons, we considered the variables that contribute
to the construction of yð4Þj ; j ¼ 1; . . . ; 21. Let X
*
j be the block that
contains the variables associated with non-null elements in the
Figure 1. Between-block connections. X1; . . . ; X21 are connected to the superblock X22, and X22 is connected to the volume of the pons X23 . These between-block con-
nections are encoded through the design matrix C: cj;22 ¼ 1; j ¼ 1; . . . 21, c22;23 ¼ 1 and cjk ¼ 0 otherwise.
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block weight vector wð4Þj . This subsection presents the block clus-
tering of X*1; . . . ; X
*
21; X23 based on the McKeon’s measure [57].
The McKeon’s measure quantifies the homogeneity of a set of
block components and is defined by the following equation:
r1 X1w1; . . . ; XJwJð Þ ¼
1
JðJ$1Þ=2
P
j< k covðXjwj;XkwkÞ
1
J
P
j varðXjwjÞ
(3)
Equation (3) allows evaluating the homogeneity of the solu-
tion of any multiblock component methods. The computation
of the McKeon’s measure was carried out using RGCCA (full
between-block connections, sj ¼ 1 for all blocks, and g xð Þ ¼ x
for a fair analysis). Figure 4 represents the resulting block clus-
tering of X%1; . . . ; X
%
21;X23. Blocks that were the most closely
related (e.g. GABA–glutamine–histidine and Krebs cycle) con-
tained variables that were partially redundant, as they be-
longed to more than one pathway and could thus serve as an
internal validation. As previously discussed, the volume of the
pons, the most distinctive feature in this model between pa-
tients and controls, clustered with the vermis MRS profile.
Lipid species, including sphingolipids and phospholipids, also
clustered with one another providing further validation to our
model.
Assessment of the reliability of parameter estimates
To assess the reliability of parameter estimates obtained using
SGCCA, 1000 bootstrap samples were derived. SGCCA was then
applied to each bootstrap sample (with the sparsity parameters
determined at the previous step) to obtain estimates wbj , where
j denotes the block index and b the bootstrap sample index. The
percentage of times a specific variable had a non-null weight
was therefore derived. Figure 5 reports those percentages for
the blocks that contributed mostly to the construction of the
first global component.
Among the lipid species that tended to separate patients
with SCA7 from other patients, certain ceramides (Cer) were
especially represented in the sphingolipids group, as well as
certain phosphatidylcholines (PCs) in the phospholipids
group (Figure 5A and B, respectively). To our knowledge, to
date, there has been no metabolomic or lipidomic studies
conducted in SCA patients. However, one lipidomic analysis
was performed in the cerebellum of a preclinical model of
SCA2 and found significant changes in some sphingolipids
and cholesterol by-products [58]. Likewise, although conclu-
sions cannot be made without further biological validation, it
is noteworthy that both lipid classes, Cer and PC, are highly
expressed in the retina [59]. Furthermore, defects in their syn-
thesis are associated with pigmentosa retinopathy [60, 61],
which is a distinctive feature of SCA7 compared with SCA1,
SCA2 and SCA3.
Discussion and conclusion
R/SGCCA stands as a unique, general and original way for ana-
lyzing high-dimensional multiblock data sets. It allows the se-
lection of a few meaningful variables that underline the
between-block connections encoded by the design matrix C.
This design matrix is highly modular to fit any prior knowledge
the user has on the links between blocks. The variable selection
property results in models more easily interpretable than a
model based on all the variables. Being able to select variables
means that one can also study the stability of the variable selec-
tion process and possibly deduce patterns in the way the vari-
ables are selected under sampling. Moreover, the selection of a
few meaningful variables from longitudinal studies will enable
their combination into a composite score. Such a composite
score can be used as a proxy for disease severity and acts as a
basis for future therapeutic studies. Indeed, composite scores
are likely to provide both a better reflection of the disease pro-
cess pathology and a larger effect size than any biomarker
alone. This is crucial for the assessment of experimental treat-
ments in many neurodegenerative conditions, and especially in
rare diseases like SCA where patient’s recruitment is challeng-
ing. Finally, we showed that having blocks of heterogeneous
sizes and nature is taken into account routinely by SGCCA.
Figure 2. Sample space associated with the dimensions 1 and 4 of the superblock. Individuals are marked according to the status (CTRL, SCA1, SCA2, SCA3 and SCA7).
CTRL: healthy controls.
10 | Garali et al.
 151 
F
ig
u
re
3
.
V
a
ri
a
b
le
s
sp
a
ce
a
ss
o
ci
a
te
d
w
it
h
th
e
d
im
e
n
si
o
n
s
1
a
n
d
4
o
f
th
e
su
p
e
rb
lo
ck
.
O
n
ly
th
e
v
a
ri
a
b
le
s
th
a
t
co
n
tr
ib
u
te
to
th
e
co
n
st
ru
ct
io
n
o
f
co
m
p
o
n
e
n
ts
1
a
n
d
4
a
re
v
is
u
a
li
z
e
d
in
th
e
v
a
ri
a
b
le
s
sp
a
ce
.
A strategy for multimodal data integration | 11
 152 
Likewise, the application of SGCCA on our SCA data set pin-
points at a possible role of some lipid species in the pathophysi-
ology of SCA7 compared with other SCA, which merits further
metabolic explorations.
Of note, RGCCA can also be applied to longitudinal data
using the multiway formalism, which accounts for multiple
measurements (either in time or in type of acquisition) of a
given feature [62]. Multigroup structure (i.e. same sets of
Figure 4. Dendrogram for block clustering based on McKeonmeasure derived using RGCCA with a full between-block connections, sj ¼ 1 for all blocks, and g xð Þ ¼ x.
Figure 5. (A) Percentages of times the ‘Sphingolipid’ variables participate to the construction of the block component. (B) Percentages of times the ‘Phospholipids’ vari-
ables participate to the construction of the block component. We presented the most important variables, as the block contained 292 variables.
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variables observed on different groups of individuals) can also
be tackled with RGCCA: the aim is to uncover similar relation-
ships between variables across the various groups [63]. Beyond
the example data set used in this study, this framework proves
equally efficient to manage and interpret a large variety of bio-
logical data types, typically information produced by next-
generation sequencing approaches (e.g. DNA-seq, RNA-seq,
Methyl-seq, etc.) that are increasingly used to further investi-
gate normal or pathological biological processes.
Key Points
• The RGCCA-based integrative procedure requires the
setting of extra parameters that need to be carefully ad-
justed. We provide practical guidelines for the use of
RGCCA/SGCCA.
• The flexibility and usefulness of RGCCA/SGCCA was
illustrated on a unique cohort of patients with four gen-
etic subtypes of SCA, in which we obtained multiple
data sets from brain volumetry, MRS and metabolomic
and lipidomic data sets.
• We show how to graph RGCCA output.
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Chapter 8 
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Conclusion 
We have successfully taken advantage of different MR modalities in the search for 
biomarkers in view of therapeutic interventions in polyglutamine diseases. 
In HD, we validated the use of the Pi/PCr ratio as a biomarker of brain energy metabolism 
and showed that it was able to capture brain metabolic profiles before and after treatment. We 
have shown that without therapeutic intervention, abnormal brain metabolism persists over 
time. We used this biomarker and treatment on another disease characterized by primary brain 
energy deficiency – GLUT1-DS. In GLUT1-DS, we highlighted the robustness of the Pi/PCr 
ratio and affirmed the efficacy of triheptanoin on targeting brain energy deficit. These studies 
have paved the way for two ongoing therapeutic trials in HD to test the anaplerotic properties 
of triheptanoin (TRIHEP3), as well as a regulator of mitochondrial energy homeostasis, 
resveratrol (REVHD). Each of these ongoing trials benefits from a large cohort of 100 HD 
patients and uses MR related measures as primary outcome measures. As previously shown, 
we expect to confirm abnormal brain energy profiles in HD patients before treatment with an 
improvement after treatment. We also expect treated patients to have a slower rate of caudate 
atrophy than the placebo group. Likewise, microstructure alterations as measured with DTI 
should be less in treated patients than in the placebo group. 
In a rate-reaction study using MT we showed that reduced rate of CK might underlie some of 
the metabolic dysfunction in HD. We are currently using a multimodal approach to try 
identifying metabolic, functional and structural changes (HDeNERGY) that could further 
explain the pathogenic mechanism associated with energy deficiency in HD. DWS could 
complement DTI results in better probing changes in cellular and extracellular compartments 
in HD. Furthermore, the functional organization of brain networks could give an indication on 
how different areas of patients’ brain consume energy. This study will benefit from a 
multimodal integration of data to create a link between all MR measures.  
A great hindrance to MRS techniques has always been standardization. The use of different 
MR sequences and analytical techniques have yielded different reports in similar brain 
regions. Therefore, we have shown in a bi-centric study that MRS studies can be robust and 
reproducible when improved sequences with shorter TE, such as the modified semi-LASER 
sequence, and the same analytical procedures are used. We have applied this standardized 
procedure in a unique cohort of patients with SCA and we showed that several 
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neurochemicals are altered in SCAs. Furthermore, we showed that imaging markers have 
larger effect sizes than clinical scores. The use of MR markers with high effect sizes would be 
very helpful for upcoming therapeutic trials in rare diseases such as HD and SCAs.  
Integration of different modalities produces composite scores that can better characterize 
specific diseases than single biomarkers. However, modalities always differ in the type and 
number of variables they generate. That means using conventional statistical tools to analyze 
them could fail. We therefore showed how a new multiblock statistical procedure could 
overcome this challenge and generate multimodal composite scores. Another use of this 
statistical approach is the extraction of robust biomarkers.  
In the upcoming era of gene therapy for polyglutamine diseases, we believe that the MR 
biomarkers that we have identified can provide important clues in the evaluation of 
therapeutic benefits in HD and SCA patients. If gene therapies become authorized at the 
presymptomatic stages of these diseases, MR biomarkers will constitute unavoidable outcome 
measures. Furthermore, metabolic interventions such as anaplerotic approaches using 
triheptanoin, which we showed capable of improving brain energy metabolism, may also 
provide important add-on therapies as energy deficiency occurs very early in the disease 
process. 
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ABSTRACT
Objective On the basis of our previous work with
triheptanoin, which provides key substrates to the Krebs
cycle in the brain, we wished to assess its therapeutic
effect in patients with glucose transporter type 1
deﬁciency syndrome (GLUT1-DS) who objected to or did
not tolerate ketogenic diets.
Methods We performed an open-label pilot study with
three phases of 2 months each (baseline, treatment and
withdrawal) in eight patients with GLUT1-DS
(7–47 years old) with non-epileptic paroxysmal
manifestations. We used a comprehensive patient diary
to record motor and non-motor paroxysmal events.
Functional 31P-NMR spectroscopy was performed to
quantify phosphocreatine (PCr) and inorganic phosphate
(Pi) within the occipital cortex during (activation) and
after (recovery) a visual stimulus.
Results Patients with GLUT1-DS experienced a mean
of 30.8 (±27.7) paroxysmal manifestations (52% motor
events) at baseline that dropped to 2.8 (±2.9, 76%
motor events) during the treatment phase (p=0.028).
After withdrawal, paroxysmal manifestations recurred
with a mean of 24.2 (±21.9, 52% motor events;
p=0.043). Furthermore, brain energy metabolism
normalised with triheptanoin, that is, increased Pi/PCr
ratio during brain activation compared to the recovery
phase (p=0.021), and deteriorated when triheptanoin
was withdrawn.
Conclusions Treatment with triheptanoin resulted in a
90% clinical improvement in non-epileptic paroxysmal
manifestations and a normalised brain bioenergetics
proﬁle in patients with GLUT1-DS.
Trial registration number NCT02014883.
INTRODUCTION
Glucose transporter type 1 deﬁciency syndrome
(GLUT1-DS) is caused by impaired glucose trans-
port across the blood–brain barrier and into astro-
cytes, leading to cerebral energy deﬁciency.1
GLUT1-DS is caused by mutation in the SLC2A1
gene encoding the glucose transporter GLUT1. The
phenotype typically comprises psychomotor retard-
ation and permanent motor disorders, associated
with paroxysmal manifestations including seizures
and non-epileptic paroxysmal episodes.1 2 With
age, seizures tend to become less prominent,
whereas the frequency of non-epileptic paroxysmal
episodes increases.3 In patients with milder forms
of the disease, paroxysmal movement disorders,
especially dyskinesia, may be the main or the sole
manifestations of the disease and can occur at any
age.3 4 Ketogenic diets, which provide ketone
bodies to the brain and compensate for the lack of
glucose, represent the standard of care in
GLUT1-DS1 5 and are efﬁcient on seizures control
but less on movement disorders.2 Moreover, many
patients, especially adolescents and adults, have dif-
ﬁculties in complying with the difﬁcult constraints
of these long-term diets and their side effects.
Triheptanoin is an odd-chain triglyceride with
anaplerotic properties—that is, replenishing the
pool of metabolic intermediates in the Krebs cycle.
Unlike even-chain fatty acids metabolised to
acetyl-CoA only, triheptanoin can indeed provide
both acetyl-CoA and propionyl-CoA, two key
carbon sources for the Krebs cycle. We showed that
triheptanoin was able to produce C5-ketone bodies
and restore energy metabolism and neurotransmis-
sion in pyruvate carboxylase (PC) deﬁciency, a
severe metabolic disease that affects anaplerosis in
the brain.6 Recently, we demonstrated that trihepta-
noin is able to correct bioenergetics in the brain of
patients with Huntington’s disease (HD), a neuro-
degenerative disease associated with brain energy
deﬁcit.7 Here, we wished to obtain a
proof-of-concept of the therapeutic effect of trihep-
tanoin in patients with GLUT1-DS with
non-epileptic paroxysmal manifestations for whom
a ketogenic diet was not a therapeutic option.
SUBJECTS AND METHODS
Participants were enrolled in an interventional
clinical protocol (NCT02014883) at the
Pitié-Salpêtrière Hospital promoted by INSERM
and approved by the local ethical committee. All
participants and/or their legal guardians signed a
written informed consent before participating in the
study. Four children and four adults were enrolled
with GLUT1-DS as deﬁned by low cerebrospinal
ﬂuid to blood glucose ratio and a SLC2A1 missense
mutation predicted to be pathogenic by prediction
software programs. Patients had a chronic history of
non-epileptic paroxysmal motor disorders, espe-
cially paroxysmal exercise-induced dyskinesia, non-
kinesigenic dyskinesia, limb weakness, headache,
drowsiness and dysphoria. Three patients also pre-
sented a mild cognitive deﬁcit. All patients were on
a normal diet prior to their enrolment as either they
objected to or did not tolerate ketogenic diets. The
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study was divided into three phases of 2 months each (baseline,
treatment and withdrawal). A trained dietician determined the
patient’s caloric intake and adjusted their daily menus so that
their diet remained isocaloric when triheptanoin was introduced.
During the treatment phase, each patient was required to ingest
1 g/kg body-weight of triheptanoin per day, divided into 3–4
intakes during meals.
During each study phase, the patients and/or their legal guar-
dians had to ﬁll a comprehensive patient diary to record all motor
(seizure, abnormal movement, body stiffness, body weakness,
abnormal speech) and non-motor (headache, lethargy, mood
swing) paroxysmal events (see online supplementary table e1).
The approximate duration of each episode was recorded
(minutes). At each visit, recordings of all paroxysmal events were
reviewed with the evaluating physician and items were grouped
into motor and non-motor episodes. At each visit, patients were
also evaluated with a 6 min walk test (6MWT), a nine-hole peg-
board test (9HPT) and the clinical global impression-improvement
scale (CGI-I). The 6MWTwas performed in a corridor, between
two cones separated by a distance of 25 m, in order to get the
maximal distance covered during 6 min by walking. Both the dom-
inant and non-dominant hands were tested twice during the
9HPT and the best score for each hand was recorded. Blood
samples were collected after an overnight fast for standard ana-
lyses, plasma C3-carnitine and C5-ketone bodies.6
To assess the effect of triheptanoin on brain energy metabol-
ism, functional 31P-NMR spectroscopy (f-MRS) was performed
at 3 T at the end of each study phase in patients >15 years old
(n=5). We targeted the visual cortex using a surface coil as it is
easily stimulated and is close to the scalp, allowing an increased
sensitivity to the surface coil. Furthermore, visual stimulation
results in a large increase in glucose uptake and cerebral blood
ﬂow.8 Data were collected for 4 min at rest, 8 min during visual
activation, 8 min after stimulation and analysed as described.7 9
The ratio of inorganic phosphate over phosphocreatine (Pi/PCr)
was calculated to determine the brain response to cortical activa-
tion as it is directly related to the ADP levels which regulate
mitochondrial oxidative metabolism.10
Paired t tests were used for plasma analyses before and after
treatment. For clinical parameters, Friedman tests were used to
test the global hypothesis that all study phases were equal. If sig-
niﬁcant, Wilcoxon signed-rank tests were applied for pairwise
phase comparisons with an α of 0.05. For the Pi/PCr ratio,
repeated measures analysis of variance (ANOVA) were used to
test the global hypothesis that all time points (rest, activation
and recovery) were equal. If signiﬁcant, paired t tests were
applied for pairwise time comparisons with an α of 0.05.
Figure 1 (A) Number of total paroxysmal manifestations in patients
with glucose transporter type 1 deﬁciency syndrome (GLUT1-DS) during
the three phases of the study (baseline, treatment and withdrawal) of
2 months each. A signiﬁcant reduction of non-epileptic paroxysmal
manifestations was observed when patients were treated with
triheptanoin for 2 months (*p<0.05). Of note, the total number of
events was comparable between the baseline and withdrawal phases.
Error bars represent SEM. (B) Changes in the inorganic phosphate and
phosphocreatine (Pi/PCr) ratio from 31P-NMR spectroscopy (f-MRS)
studies during the three phases of the study (baseline, treatment and
withdrawal). During baseline, f-MRS showed an abnormal brain energy
proﬁle in patients with GLUT1-DS with no change in the Pi/PCr ratio
during visual stimulation. After 2 months of treatment with
triheptanoin, the proﬁle was corrected and we observed an increase in
the Pi/PCr ratio during visual stimulation followed by a decrease during
recovery (*p=0.021). Error bars represent SEM of within-subject
differences using the method of Morey.
Table 1 Main characteristics of patients with GLUT1-DS during
the baseline, treatment and withdrawal phases
Patients
MeanP1 P2 P3 P4 P5 P6
Sex F F M M M M
Age 23 20 7 14 16 47 21.2
Baseline
Total events 10 20 13 26 31 85 30.8
Motor events 6 16 10 1 12 54 16.5
6MWT (m) 502 558 458 514 471 504 501
9HPT(D/ND) (s) 17/18 18/23 19/21 15/17 18/22 14/16 17/19
Treatment
Total events 4 7 5 0 1 0 2.8
Motor events 2 7 3 0 1 0 2.2
6MWT (m) 453 580 425 484 496 500 490
9HPT(D/ND) (s) 17/19 17/20 19/19 17/21 17/18 15/18 17/19
Withdrawal
Total events 10 11 5 20 36 63 24.2
Motor events 9 9 1 1 15 40 12.5
6MWT (m) 532 528 461 496 475 510 500
9HPT(D/ND) (s) 15/22 14/20 17/17 17/19 18/20 15/15 16/19
Total events: all motor and non-motor paroxysmal manifestations during each
2-month-phase. Motor events: all motor paroxysmal episodes during each
2-month-phase. 6MWT: Total distance walked (metres). 9HPT-D: the best score
(seconds) obtained with the dominant hand. 9HPT-ND: best score (seconds) with the
non-dominant hand.
GLUT1-DS, glucose transporter type 1 deficiency syndrome; 6MWT, 6 min walk test;
9HPT, nine-hole pegboard test
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RESULTS
Triheptanoin was well tolerated in all patients and none experi-
enced gastrointestinal symptoms. Two patients were considered
not compliant with the study as they consumed less than 50%
of the recommended dose of triheptanoin and they (or their
legal guardians) regularly omitted to ﬁll the patient diary: a
13-year-old patient with mild cognitive delay who experienced
only a few paroxysmal manifestations prior to the study, and a
23-year-old patient who was in denial of his disease. Owing to
the small sample size, a per-protocol analysis was performed in
the six patients who completed the study (see online supplemen-
tary table e2).
During the baseline phase, patients with GLUT1-DS experi-
enced a mean of 30.8 (±27.7, 10–85) paroxysmal manifesta-
tions over 2 months, including 16.5 (±19.1, 1–54) motor
episodes. When treated with triheptanoin for 2 months, parox-
ysmal manifestations dropped to a mean of 2.8 (±2.9, 0–7),
including 2.2 (±2.6, 0–7) motor episodes (p=0.028, ﬁgure 1A),
representing overall a 90% symptoms reduction. Two patients
became free from paroxysmal manifestations (table 1). Although
not signiﬁcant, triheptanoin tended to also reduce the mean
duration of the remaining motor episodes—59±44 min at base-
line compared to 10±10 min with triheptanoin, p=0.224. On
the patient-rated CGI-I scale, all patients reported a clear
improvement when treated (‘much improved’). Conversely,
during the 2-month withdrawal phase, patients experienced a
mean of 24.2 (±21.9, 5–63) paroxysmal manifestations, includ-
ing 12.5 (±14.5, 1–40) motor episodes (p=0.043, ﬁgure 1A).
On the patient-rated CGI-I scale, ﬁve out of six patients
reported a clear worsening during withdrawal (‘much worse’).
The patients’ performance on the 6WMT and 9HPT was
unchanged along the different phases of the study (table 1). On
study completion, all patients wished to continue treatment
with triheptanoin.
Compared to baseline, we observed a signiﬁcant increase in
plasma C3-carnitine (p=0.026) and C5-ketone bodies
(p=0.008) on triheptanoin, reﬂecting its proper metabolism in
the six compliant patients with GLUT1-DS. Conversely, the
levels of triheptanoin metabolites were unchanged in the two
non-compliant patients. During baseline, f-MRS showed an
abnormal proﬁle with no change in the Pi/PCr ratio during
brain activation in patients with GLUT1-DS (ﬁgure 1B), unlike
what we reported in healthy individuals.7 9 After 2 months on
triheptanoin, the bioenergetics proﬁle normalised and repeated
measures ANOVA were signiﬁcant for the Pi/PCr ratio
(p=0.014). We observed an increase in the Pi/PCr ratio during
visual stimulation and a decrease during recovery using paired t
tests (p=0.021). The increased Pi/PCr ratio during brain activa-
tion reﬂected a proportional elevation of ADP, allowing
increased mitochondrial ATP production with triheptanoin.
After treatment withdrawal, the f-MRS proﬁle returned to its
preintervention abnormal state (ﬁgure 1B).
DISCUSSION
Treatment with triheptanoin promptly reduced the number of
non-epileptic paroxysmal manifestations in children and adults
with GLUT1-DS. This marked clinical response was associated
with a signiﬁcant production of C5-ketone bodies and the nor-
malisation of the f-MRS bioenergetics proﬁle during brain acti-
vation. Despite the absence of a control group, the magnitude
of the intervention effect (90% reduction) combined with the
metabolic responses argues against a placebo effect. The lack of
change in effort-based outcome measures tests such as the
6MWT and 9HPT during treatment further argues against a
generalised placebo effect in this study.
Our current observation in GLUT1-DS is supported by previ-
ous preclinical and clinical studies. In animal models of diseases
associated with brain energy deﬁciency, triheptanoin improved
energy metabolism and motor deﬁcits.11–14 The ﬁrst clinical
response on neurological deﬁcits with triheptanoin was reported
in PC deﬁciency.6 Triheptanoin was also able to correct the bio-
energetics proﬁle in the brain of early affected patients with
HD.7 Recently, a study in epileptic patients with GLUT1-DS
showed a reduction in spike-waves on EEG about 90 min after
taking antiepileptic drugs and triheptanoin.15 Despite the small
sample size, our study provides strong evidence for a sustainable
clinical improvement with triheptanoin in GLUT1-DS together
with a robust metabolic response using a validated biomarker of
brain energy metabolism.7 The conﬁrmation of our data in a
larger controlled study would hold promise for an alternative
therapeutic approach in GLUT1-DS, especially for patients who
cannot comply with the constraints of ketogenic diets.
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